<!DOCTYPE html>
<html lang="en" class="scroll-smooth">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Communicable Diseases - Brain And Scalpel</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  background: url("assets/background.jpg") center center / cover no-repeat fixed;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
}

body::before {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
  
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
  
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* Responsive utilities */
@media (max-width: 768px) {
  .glass-card {
    border-radius: 16px;
  }
  
  .glass {
    border-radius: 12px;
  }
}

    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        Cerebellum / qBank / PSM
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">60</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="flex container mx-auto px-6 gap-8">
        <!-- Question Navigation Sidebar -->
        <div class="w-80 glass p-6 h-fit sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="flex-1 max-w-4xl">
            <div class="glass-card p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <!-- Explanation Video -->
                    <div id="solutionVideo" class="hidden">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls>
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd" />
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z" />
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

    <script>
        let questionsData = [
  {
    "id": 1544,
    "choices": [
      {
        "id": 6171,
        "text": "<p><span style=\"font-size:12pt;\">May 1975</span></p>"
      },
      {
        "id": 6172,
        "text": "<p><span style=\"font-size:12pt;\">April 1977</span></p>"
      },
      {
        "id": 6173,
        "text": "<p><span style=\"font-size:12pt;\">August 1979</span></p>"
      },
      {
        "id": 6174,
        "text": "<p><span style=\"font-size:12pt;\">May 1980</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">In a global health lecture, the topic of smallpox eradication is discussed, highlighting one of the major public health achievements of the 20th century. The eradication of smallpox was declared at different times in various countries. A medical student interested in the history of infectious diseases asks about the year in which India, a country with a large population and diverse geographic regions, was declared smallpox-free. In which year was India officially declared free of smallpox?</span></p><p>&nbsp;</p>",
    "unique_key": "Q3502600",
    "question_audio": null,
    "question_video": null,
    "map_id": 34150,
    "difficulty_level": "difficult",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. B. April 1977</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The <strong>last known case of smallpox</strong> in India occurred on <strong>24th May 1975</strong>. <strong>India </strong>was declared <strong>smallpox free on 5th July 1975</strong>.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><i><strong>Epidemiological reasons/basis for Smallpox eradication:</strong></i></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>No</strong> known <strong>animal reservoir</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>No long term carrier state</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Infection </strong>provides <strong>lifelong immunity</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Case detection simple</strong> due to characteristic <strong>rash</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Subclinical cases</strong> did <strong>not transmit</strong> the <strong>disease</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">A <strong>highly effective vaccine</strong> was available</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">International cooperation</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Important Pointers about Small Pox -&nbsp;</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>Last indigenous</strong> case of <strong>Small pox</strong> in India: <strong>17th May 1975</strong></span></li><li><span style=\"font-size:12pt;\"><strong>Last</strong> [importation] <strong>case of Small pox</strong> in India: <strong>24th May 1975</strong></span></li><li><span style=\"font-size:12pt;\"><strong>India</strong> declared <strong>Small pox-free</strong>: <strong>23 April, 1977</strong></span></li><li><span style=\"font-size:12pt;\"><strong>Last case</strong> of <strong>Small pox</strong> <strong>globally</strong>: <strong>26th October 1977</strong> (<strong>Somalia</strong>)</span></li><li><span style=\"font-size:12pt;\">Actual <strong>last case</strong> of small pox [<strong>Laboratory accident</strong>]: <strong>1978</strong></span></li><li><span style=\"font-size:12pt;\"><strong>Global eradication of Small pox: 8th May 1980&nbsp;</strong></span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>India </strong>was <strong>declared small pox free</strong> on -&nbsp;<strong>23 April, 1977</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Global eradication</strong> of <strong>Small pox</strong>: <strong>8th May 1980&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Park 26<sup>th</sup> edition (page 158)</strong></span></p>",
    "correct_choice_id": 6172,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 1552,
    "choices": [
      {
        "id": 6203,
        "text": "<p><span style=\"font-size:12pt;\">60%</span></p>"
      },
      {
        "id": 6204,
        "text": "<p><span style=\"font-size:12pt;\">45%</span></p>"
      },
      {
        "id": 6205,
        "text": "<p><span style=\"font-size:12pt;\">25%</span></p>"
      },
      {
        "id": 6206,
        "text": "<p><span style=\"font-size:12pt;\">90%</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">During an infectious disease rotation, a medical resident is learning about varicella (chickenpox), a highly contagious infection caused by the varicella-zoster virus. The resident is tasked with assessing the risk of transmission within households and communities. A key concept in understanding the spread of chickenpox is the secondary attack rate, which measures the likelihood of the disease spreading to susceptible individuals after exposure to a primary case. What is the secondary attack rate typically associated with chickenpox?</span></p>",
    "unique_key": "Q4664464",
    "question_audio": null,
    "question_video": null,
    "map_id": 34151,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. D. 90%</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>SAR</strong> is approximately <strong>90 %</strong> in <strong>susceptible household contacts</strong> of <strong>chicken pox case</strong>.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Secondary Attack Rate (SAR): </strong>Is <strong>no. of exposed persons</strong> developing the <strong>disease</strong> within range of <strong>incubation period</strong>, following <strong>exposure </strong>to the <strong>primary case</strong>. The <strong>denominator</strong>&nbsp;includes only those <strong>susceptible to disease</strong>. The <strong>primary </strong>case is always <strong>excluded</strong> both from <strong>numerator and denominator</strong> for <strong>SAR calculation.</strong></span></p><p><span style=\"font-size:12pt;\">&nbsp;</span></p><p><span style=\"font-size:12pt;\"><strong>Secondary attack rate of some important diseases are -&nbsp;</strong></span></p><p><span style=\"font-size:16px;\">\u200b\u200b\u200b\u200b\u200b&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\u200b\u200b\u200b\u200b\u200b<img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-161226.png\" alt=\"\" width=\"1000\" height=\"456\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Chickenpox -&nbsp;</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Period of <strong>Communicability/ infectivity</strong> - <strong>1\u20132 days before</strong> to <strong>4\u20135 days after</strong> appearance of <strong>rash</strong>.&nbsp;</span></li><li><span style=\"font-size:12pt;\"><strong>Incubation Period</strong> - <strong>14-16</strong> days</span></li><li><span style=\"font-size:12pt;\">Rash -<strong>&nbsp;Chickenpox rash</strong> -&nbsp;<strong>Dew drop</strong> on <strong>rose petal</strong> appearance <strong>Centripetal </strong>distribution, <strong>Pleomorphic</strong> rash</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The <strong>secondary attack rate</strong> of <strong>Chickenpox</strong> is - <strong>90%</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Park 26<sup>th</sup> edition (page 159)</strong></span></p>",
    "correct_choice_id": 6206,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InvestigationBased"
    ]
  },
  {
    "id": 1556,
    "choices": [
      {
        "id": 6219,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">20-40%</span></span></p>"
      },
      {
        "id": 6220,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">0.4-2%</span></span></p>"
      },
      {
        "id": 6221,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">2-10%</span></span></p>"
      },
      {
        "id": 6222,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">14-25%</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">During an obstetrics and gynecology rotation, a medical resident is learning about the complications associated with viral infections during pregnancy. A topic of particular interest is the risk of congenital varicella syndrome (CVS) in the fetus when a pregnant woman contracts the Varicella Zoster virus, especially during the first 20 weeks of gestation. The resident is asked about the likelihood of developing CVS in children born to mothers who become infected with Varicella Zoster virus during this critical period. What is the percentage risk of congenital varicella syndrome in these cases?</span></span></p>",
    "unique_key": "Q8070388",
    "question_audio": null,
    "question_video": null,
    "map_id": 34153,
    "difficulty_level": "difficult",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. B. 0.4-2%</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Infection</strong> during <strong>pregnancy </strong>presents a <strong>risk</strong> for the <strong>foetus</strong> leading to <strong>congenital varicella syndrome</strong>. It occurs in <strong>0.4-2.0 percent</strong> of <strong>children born to mothers</strong> who become <strong>infected with VZV</strong> during the <strong>first 20 weeks of gestation.</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Congenital Varicella</strong>: Most <strong>threatening</strong> if transmitted in <strong>Ist trimester</strong> of <strong>pregnancy.</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Common Gestational Periods for Vertical Transmission of Diseases -&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Congenital Varicella: First trimester</strong></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Congenital Rubella: First trimester</strong></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Congenital Parvovirus: Second Trimester</span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Congenital Syphilis: Third trimester</span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Congenital Toxoplasmosis: Third trimester</span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Congenital Hepatitis B: Third trimester</strong></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Congenital CMV: Third trimester</span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Congenital HIV: During delivery</strong></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Congenital Hepatitis C: During delivery</span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Congenital Herpes: During delivery</strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>0.4 - 2% of children</strong> who <strong>acquire</strong> this condition <strong>born to mothers</strong> who become <strong>infected</strong> with <strong>Varicella Zoster virus</strong> during <strong>first 20 weeks of gestation.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 158)</strong></span></span></p>",
    "correct_choice_id": 6220,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 1559,
    "choices": [
      {
        "id": 6231,
        "text": "<p><span style=\"font-size:12pt;\">1 to 2 days before rash and 4 to 5 days thereafter</span></p>"
      },
      {
        "id": 6232,
        "text": "<p><span style=\"font-size:12pt;\">4 to 5 days before rash and 1 to 2 days thereafter</span></p>"
      },
      {
        "id": 6233,
        "text": "<p><span style=\"font-size:12pt;\">3 to 4 days before rash and 4 to 5 days thereafter</span></p>"
      },
      {
        "id": 6234,
        "text": "<p><span style=\"font-size:12pt;\">1 day before rash and 2 days thereafter</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A medical resident treating a patient with chickenpox is discussing the case with a senior colleague. They talk about the infectious period of chickenpox, which is important for implementing appropriate isolation measures and preventing the spread of the infection. The resident is asked to identify the typical period during which a patient with chickenpox is infectious to others. When is the period of infectivity in a case of chickenpox?</span></p><p>&nbsp;</p>",
    "unique_key": "Q5435931",
    "question_audio": null,
    "question_video": null,
    "map_id": 34154,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A. 1 to 2 days before rash and 4 to 5 days thereafter</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">&nbsp;<strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">The <strong>period of communicability</strong> of patients with <strong>varicella </strong>is estimated to range from <strong>1 to 2 days</strong> <strong>before</strong> the appearance of <strong>rash</strong>, and <strong>4 to 5 days</strong> thereafter. The <strong>virus</strong> tends to <strong>die</strong> out <strong>before</strong> the <strong>pustular stage</strong>. The <strong>patient ceases</strong> to be <strong>infectious</strong> once the <strong>lesions</strong> have <strong>crusted.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Some important Pointers -&nbsp;</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Chicken pox rash -&nbsp;<strong>Dew drop</strong> on <strong>rose petal</strong> appearance;&nbsp;<strong>Centripetal distribution</strong>;&nbsp;<strong>Pleomorphic rash</strong></span></li><li><span style=\"font-size:12pt;\"><strong>False</strong> about chickenpox is - <strong>Crusts</strong> contain <strong>live virus</strong></span></li><li><span style=\"font-size:12pt;\">Chickenpox<strong> Synonym</strong>: <strong>\u2018Varicella\u2019</strong></span></li><li><span style=\"font-size:12pt;\">Causative agent: <strong>Varicella zoster virus</strong> [Human (alpha) <strong>Herpes Virus\u20133</strong>]</span></li><li><span style=\"font-size:12pt;\">Incubation period: <strong>14\u201316 days</strong></span></li><li><span style=\"font-size:12pt;\">Source of infection: Case (<strong>person-to-person contact</strong>)</span></li><li><span style=\"font-size:12pt;\"><strong>Mode</strong> of <strong>transmission</strong>: <strong>Air droplets</strong> (respiratory)</span></li><li><span style=\"font-size:12pt;\"><strong>Secondary Attack rate</strong>: <strong>90%MC</strong> late complication of <strong>chickenpox</strong>: <strong>Shingles</strong> (caused by <strong>reactivation</strong> of the <strong>virus decades</strong> after the <strong>initial episode of chickenpox</strong>)</span></li><li><span style=\"font-size:12pt;\">Most<strong> rapid and sensitive</strong> means of diagnosis: Examination of <strong>vesicle fluid</strong> under <strong>electron microscope</strong> (shows round particles)</span></li><li><span style=\"font-size:12pt;\">&nbsp;Congenital Varicella: <strong>Most threatening</strong> if transmitted in <strong>1<sup>st</sup></strong> <strong>trimester</strong> of <strong>pregnancy</strong></span></li><li><span style=\"font-size:12pt;\"><strong>Live attenuated Chickenpox Monovalent Vaccine Strain</strong> -&nbsp;<strong>OKA</strong> strain</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The <strong>period of infectivity</strong> in a case of <strong>Chickenpox</strong> -&nbsp;<strong>1 to 2 days before</strong> <strong>rash</strong> and <strong>4 to 5 days thereafter.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Park 26<sup>th</sup> edition (page 159)</strong></span></p>",
    "correct_choice_id": 6231,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 1561,
    "choices": [
      {
        "id": 6239,
        "text": "<p><span style=\"font-size:12pt;\">Small pox</span></p>"
      },
      {
        "id": 6240,
        "text": "<p><span style=\"font-size:12pt;\">Measles</span></p>"
      },
      {
        "id": 6241,
        "text": "<p><span style=\"font-size:12pt;\">Dengue</span></p>"
      },
      {
        "id": 6242,
        "text": "<p><span style=\"font-size:12pt;\">Chickenpox</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A pediatric resident is evaluating a child at a Community Health Center (CHC) who presents with fever and a distinctive rash. Upon examination, the resident notes the simultaneous presence of papules, vesicles, and crusts all in the same area of the skin. This combination of lesions at different stages of development in the same area is characteristic of a specific viral infection. What is the most probable diagnosis for this child?</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/18/image_4PQz4JP.png\" width=\"300\" height=\"170\"></span></p>",
    "unique_key": "Q3911264",
    "question_audio": null,
    "question_video": null,
    "map_id": 34155,
    "difficulty_level": "beginner",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. D. Chickenpox</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">A <strong>characteristic feature</strong> of the <strong>rash in chickenpox</strong> is its <strong>pleomorphism</strong>, that is, <strong>all stages</strong> of the <strong>rash (papules, vesicles and crusts)</strong> may be seen <strong>simultaneously at one time</strong>, in the <strong>same area</strong>. This is <strong>due</strong> to the <strong>rash</strong> appearing in <strong>successive crops </strong>for<strong> 4 to 5 days</strong> in the <strong>same area.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option</strong>&nbsp;<strong>A. Small pox:</strong>&nbsp;<strong>smallpox lesions</strong> appear in the <strong>same stage of development</strong> at the <strong>same time</strong> all over the body (<strong>non pleomorphic</strong>), <strong>unlike chickenpox</strong> where <strong>different stages</strong> are <strong>seen </strong>in the <strong>same area.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><img src=\"https://my.clevelandclinic.org/-/scassets/images/org/health/articles/10855-smallpox\" alt=\"Smallpox: Causes, Symptoms, Treatment &amp; Prevention\" width=\"350\" height=\"202\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option&nbsp;B. Measles:</strong> &nbsp;<strong>Maculopapular rash</strong> that typically <strong>begins</strong> on the <strong>face and spreads downward</strong>. It does <strong>not </strong>present with <strong>lesions at different stages</strong> (papules, vesicles, crusts) in the <strong>same area.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/28/image-20231128145356-1.jpeg\" width=\"350\" height=\"210\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option&nbsp;C. Dengue:</strong> <strong>Dengue fever</strong> can present with a <strong>rash,</strong> but it is usually a <strong>diffuse erythematous rash</strong>, <strong>not</strong> one with <strong>papules, vesicles, and crusts</strong> in the <strong>same area.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><img src=\"https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcRj7uaO9jM9z0k4dHy9_lFnLS9eMRr-Nksglw&amp;usqp=CAU\" alt=\"Exanthematic dengue fever mimicking rubella - ScienceDirect\" width=\"350\" height=\"204\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Chickenpox rash</strong> -&nbsp;<strong>Dew drop</strong> on <strong>rose</strong> <strong>petal appearance</strong>;&nbsp;<strong>Centripetal distribution;&nbsp;Pleomorphic rash.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Difference between Chicken Pox and Small Pox rash</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/12/picture11_HrNvuDK.jpg\" alt=\"\" width=\"1000\" height=\"963\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Park 26<sup>th</sup> edition (page 159)</strong></span></p>",
    "correct_choice_id": 6242,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 1565,
    "choices": [
      {
        "id": 6255,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">March</span></span></p>"
      },
      {
        "id": 6256,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">August</span></span></p>"
      },
      {
        "id": 6257,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">October&nbsp;</span></span></p>"
      },
      {
        "id": 6258,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">November&nbsp;</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">During a clinical discussion on the epidemiology of common viral infections, a medical resident asks about the seasonality of varicella-zoster virus (VZV) infections. Understanding the seasonal trends of infectious diseases is crucial for planning public health interventions and anticipating healthcare needs. Based on epidemiological patterns, in which of the following months is a varicella-zoster virus infection (chickenpox) more likely to occur?</span></span></p>",
    "unique_key": "Q8246186",
    "question_audio": null,
    "question_video": null,
    "map_id": 34156,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A. March </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A:</strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Infection</strong> with <strong>varicella</strong> occurs <strong>year-round</strong>, although the incidence is found to <strong>peak in March, April and May</strong> in <strong>temperate climates.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>CHICKENPOX:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Also known as &lsquo;<strong>Varicella</strong>&rsquo;</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Causative agent: <strong>Varicella zoster virus</strong> [Human (alpha) <strong>Herpes Virus &ndash; 3</strong>]</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Secondary attack rate: <strong>90%</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Incubation period: <strong>14&ndash;16 days</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Rash:&nbsp;<strong>Dew drop</strong> on <strong>rose petal appearance</strong>;&nbsp;<strong>Centripetal distribution;&nbsp;Pleomorphic rash</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>MC late complication</strong> of <strong>Chickenpox</strong>: <strong>Shingles </strong>(caused by <strong>reactivation of</strong> the <strong>virus decades</strong> <strong>after </strong>the <strong>initial episode</strong> of <strong>chickenpox</strong>)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Aspirin </strong>must <strong>not</strong> be given to children with chickenpox: <strong>Risk of Reye&rsquo;s</strong> <strong>Syndrome</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Strain</strong> of <strong>Live attenuated Chickenpox Vaccine</strong>: <strong>OKA strain</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Congenital Varicella</strong>: <strong>Most threatening</strong> if transmitted in <strong>1<sup>st</sup> trimester</strong> of <strong>pregnancy</strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Varicella-zoster virus</strong> infections (<strong>chickenpox</strong>) are more likely to occur in <strong>March,</strong> <strong>late winter and early spring</strong>, which is important for <strong>healthcare planning</strong> and <strong>public health interventions</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>:&nbsp;Clinical Maternal-Fetal Medicine by Winn, 1/e p263&nbsp;</strong></span></span></p>",
    "correct_choice_id": 6255,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InvestigationBased"
    ]
  },
  {
    "id": 1568,
    "choices": [
      {
        "id": 6267,
        "text": "<p><span style=\"font-size:12pt;\">0.15 ml per kg body weight</span></p>"
      },
      {
        "id": 6268,
        "text": "<p><span style=\"font-size:12pt;\">0.25 ml per kg body weight</span></p>"
      },
      {
        "id": 6269,
        "text": "<p><span style=\"font-size:12pt;\">0.35 ml per kg body weight</span></p>"
      },
      {
        "id": 6270,
        "text": "<p><span style=\"font-size:12pt;\">0.45 ml per kg body weight</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">During a clinical discussion on the management of measles, particularly in high-risk patients or those with contraindications to the measles vaccine, the topic of passive immunization arises. A medical resident is asked about the appropriate dosing of human immunoglobulin for providing passive immunity against measles. Understanding the correct dosage is crucial for effective post-exposure prophylaxis in susceptible individuals. What is the recommended dose of human immunoglobulin for passive immunization against measles?</span></p>",
    "unique_key": "Q1411244",
    "question_audio": null,
    "question_video": null,
    "map_id": 34157,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. B. 0.25 ml per kg body weight</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Measles</strong> may be <strong>prevented</strong> by administration of <strong>immunoglobulin (human)</strong> early in the <strong>incubation period</strong>. The <strong>dose</strong> recommended by <strong>WHO</strong> is <strong>0.25 ml</strong> per kg of <strong>body weight</strong> should be given <strong>within 4 days</strong> of <strong>exposure.</strong>&nbsp;</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">The person<strong> passively immunized</strong> should be given <strong>live vaccine, 8-12 weeks</strong> later.&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Dose</strong> of <strong>human immunoglobulin</strong> for providing <strong>passive immunity</strong> <strong>against</strong> <strong>measles</strong> -&nbsp;<strong>0.25 ml</strong> per <strong>kg of body weight.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Park 26<sup>th</sup> edition (page 165)</strong></span></p>",
    "correct_choice_id": 6268,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "InvestigationBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 1570,
    "choices": [
      {
        "id": 6275,
        "text": "<p><span style=\"font-size:12pt;\">5 years</span></p>"
      },
      {
        "id": 6276,
        "text": "<p><span style=\"font-size:12pt;\">Lifelong</span></p>"
      },
      {
        "id": 6277,
        "text": "<p><span style=\"font-size:12pt;\">10 years</span></p>"
      },
      {
        "id": 6278,
        "text": "<p><span style=\"font-size:12pt;\">No immunity</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt;\">During a pediatric infectious disease rotation, a medical student learns about the natural immunity conferred by viral infections. One topic of interest is the immunity that follows an infection with the measles virus. Understanding the duration of immunity after natural infection is important for patient counseling and future vaccination planning. After a patient recovers from an attack of measles, how long does the immunity typically last?</span></p>",
    "unique_key": "Q3867676",
    "question_audio": null,
    "question_video": null,
    "map_id": 34158,
    "difficulty_level": "beginner",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. B. lifelong</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>No age</strong> is <strong>immune</strong> if there was <strong>no previous immunity</strong>. <strong>One</strong> attack of <strong>measles</strong> generally confers <strong>life-long immunity.</strong> <strong>Second attacks</strong> are <strong>rare</strong>.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Other diseases</strong> provide <strong>lifelong immunity</strong> with a <strong>single attack</strong> - <strong>Mumps, Rubella, Yellow fever.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">In <strong>measles disease</strong>, <strong>both</strong> <strong>natural infection and vaccination</strong> confer <strong>lifelong immunity/protection</strong> from infection of <strong>measles.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Park 26<sup>th</sup> edition (page 162)</strong></span></p>",
    "correct_choice_id": 6276,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 1571,
    "choices": [
      {
        "id": 6279,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">10 days</span></span></p>"
      },
      {
        "id": 6280,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">5 days</span></span></p>"
      },
      {
        "id": 6281,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">18 days</span></span></p>"
      },
      {
        "id": 6282,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">28 days</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A medical resident is preparing for a public health campaign focused on maternal and child health, which includes educating about vaccine-preventable diseases such as rubella. During a team meeting, the topic of rubella&#39;s clinical course and its implications for public health is discussed. The resident is asked to explain the incubation period of rubella, also known as German measles, to help the team develop appropriate educational materials and strategies. What is the average incubation period of rubella?</span></span></p>",
    "unique_key": "Q7800867",
    "question_audio": null,
    "question_video": null,
    "map_id": 34159,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. 18 days</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation: </u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Rubella</strong> has <strong>got</strong> an <strong>average incubation period</strong> of <strong>18 days (14-21 days).</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Rubella (German Measles)</strong> - Some Important Pointers -&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Causative agent: <strong>RNA virus</strong> of <strong>Togavirus family</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Source of infection: <strong>Cases or subclinical cases</strong> &ndash; &lsquo;<strong>No known carrier state&rsquo;</strong> for <strong>postnatally</strong> <strong>acquired rubella</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Mode of transmission: <strong>Air droplets</strong> (respiratory)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Period of communicability: <strong>One week prior to onset of symptoms</strong> to <strong>one</strong> <strong>week after rash appears.</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Immunity for Rubella: &ndash; <strong>Single attack confers life long immunity</strong> (Second attacks rare)</span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>40%</strong> of reproductive age group <strong>females are susceptible</strong> in India</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Infants</strong> <strong>protected</strong> till <strong>4-6 months of age</strong></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Most <strong>widely used test</strong> for diagnosis: <strong>Heme-agglutination Inhibition test</strong> (HAI) </span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Rubella Vaccine -&nbsp;</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Type of vaccine</strong>: <strong>Live attenuated, &lsquo;strain RA 27/3&rsquo;</strong>&nbsp;[Vaccine virus non-communicable]</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Dose and route: <strong>0.5 ml, subcutaneous</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Rubella vaccine</strong> is <strong>contraindicated </strong>in <strong>pregnancy</strong> and <strong>not </strong>given to infants&nbsp;&ndash; If <strong>female vaccinated</strong> for <strong>rubella</strong>: Advice <strong>against pregnancy</strong> for <strong>next 3 months</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Priority groups for rubella vaccination in India:</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>1st PRIORITY: 15&ndash;49 years reproductive age</strong> group <strong>females</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>2nd priority</strong>: All children <strong>1&ndash;14 years age</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>3rd priority</strong>: <strong>Routine universal immunization</strong> of <strong>all children aged 1</strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Average<strong> incubation period</strong> for <strong>German measles (Rubella)</strong> - <strong>18 days (14-21</strong> <strong>days)</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Incubation period of some important diseases -&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:16px\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/12/picture12.jpg\" style=\"height:1009px; width:1000px\" /></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 166)</strong></span></span></p>",
    "correct_choice_id": 6281,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InvestigationBased"
    ]
  },
  {
    "id": 1572,
    "choices": [
      {
        "id": 6283,
        "text": "<p><span style=\"font-size:12pt;\">RA 27/3 strain</span></p>"
      },
      {
        "id": 6284,
        "text": "<p><span style=\"font-size:12pt;\">Jeryll lynn strain</span></p>"
      },
      {
        "id": 6285,
        "text": "<p><span style=\"font-size:12pt;\">Edmonston Zagreb strain&nbsp;</span></p>"
      },
      {
        "id": 6286,
        "text": "<p><span style=\"font-size:12pt;\">17 D strain</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">During a public health campaign aimed at increasing vaccination rates, a 30-year-old pediatrician is discussing the rubella vaccine with his interns. He emphasizes the importance of understanding the components of vaccines, including the specific viral strains used, to effectively communicate with the community and address any concerns. He poses a question to his interns about the strain of the virus used in the current rubella vaccines. Which strain of the virus is used in the current rubella vaccines?</span></p>",
    "unique_key": "Q1199618",
    "question_audio": null,
    "question_video": null,
    "map_id": 34160,
    "difficulty_level": "beginner",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A. RA 27/3 strain</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The currently used <strong>rubella vaccines</strong> are based on the <strong>live attenuated RA 27/3 strain.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Some <strong>important</strong> Pointers related to <strong>Rubella Vaccine</strong> -&nbsp;</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>Type</strong> of vaccine: <strong>Live attenuated</strong>, \u2018<strong>strain RA 27/3\u2019</strong> [Vaccine virus non-communicable]&nbsp;.</span></li><li><span style=\"font-size:12pt;\"><strong>Rubella vaccine</strong> is <strong>contraindicated</strong> in <strong>pregnancy</strong> and <strong>not </strong>given <strong>to infants</strong>&nbsp; If <strong>female vaccinated</strong> for <strong>rubella</strong>: Advice <strong>against pregnancy</strong> for <strong>next 3</strong> <strong>months.</strong></span></li><li><span style=\"font-size:12pt;\"><strong>Priority</strong> groups for <strong>rubella vaccination</strong> in <strong>India:</strong></span><ul><li><span style=\"font-size:12pt;\"><strong>1st PRIORITY</strong>: <strong>15\u201349</strong> years <strong>reproductive age</strong> group females</span></li><li><span style=\"font-size:12pt;\"><strong>2nd priority</strong>: All <strong>children 1\u201314 years age</strong></span></li><li><span style=\"font-size:12pt;\"><strong>3rd priority</strong>: Routine <strong>universal immunization</strong> of all children <strong>aged 1</strong></span></li></ul></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option&nbsp;B. Jeryll lynn strain</strong> - Mumps vaccine&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option&nbsp;C. Edmonston Zagreb strain</strong> - Measles vaccine</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option&nbsp;D. 17 D strain</strong> - Yellow Fever Vaccine&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Rubella</strong> vaccine <strong>strain -</strong> <strong>RA 27/3</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Vaccines and different strains :</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/12/picture13.jpg\" alt=\"\" width=\"1000\" height=\"697\"></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Ref: Park 26<sup>th</sup> edition (page 167)</strong></span></p>",
    "correct_choice_id": 6283,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 1573,
    "choices": [
      {
        "id": 6287,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Pancreatitis</span></span></p>"
      },
      {
        "id": 6288,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Orchitis</span></span></p>"
      },
      {
        "id": 6289,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Sensorineural deafness</span></span></p>"
      },
      {
        "id": 6290,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Cholecystitis</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 5-year-old child presents to the outpatient department (OPD) with a 2-day history of bilateral tender neck swelling, accompanied by low-grade fever, myalgia, and headache. Based on the presentation, a likely diagnosis is a viral infection typically causing parotitis. The medical resident is considering potential complications of the disease and discusses this with a colleague. Which of the following is NOT a recognized complication of this disease, the condition likely affecting this child?</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:16px\"><img alt=\"Mumps | Photos | CDC\" src=\"https://www.cdc.gov/mumps/images/people_mumps.jpg?_=95438\" /></span></p>",
    "unique_key": "Q2623204",
    "question_audio": null,
    "question_video": null,
    "map_id": 34161,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. D. Cholecystitis</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>complications</strong> for <strong>mumps</strong> include <strong>orchitis, ovaritis, pancreatitis, meningoencephalitis, thyroiditis, neuritis, hepatitis</strong> and <strong>myocarditis</strong>.&nbsp; <strong>Rarer</strong> complications include <strong>nerve deafness, polyarthritis, hydrocephalus, encephalitis, cerebellar ataxia, facial palsy</strong> and <strong>transverse myelitis</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Mumps</strong> is one of the main <strong>infectious causes of sensorineural deafness</strong>, which affects approximately<strong> 5 per 100,000 mumps cases</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Some Important Pointers related to MUMPS </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Causative agent: <strong>Myxovirus parotiditis</strong> (<strong>RNA paramyxovirus)</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Incubation Period:<strong> 14-21</strong> days</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Source of Infection: Clinical &amp; subclinical cases</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Mode of transmission</strong>: <strong>Air droplets (respiratory)</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Period of Communicability:</strong> <strong>4-6 days</strong> <strong>before </strong>to <strong>7 days after</strong> <strong>onset</strong> of <strong>symptoms</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Mumps</strong> show <strong>lifelong immunity</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Secondary attack</strong> rate of Mumps: <strong>86%</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Clinical features:</span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Salivary (esp. Parotid) glands</strong> involvement</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>MC complication: Aseptic meningitis</strong></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>MC </strong>complication in <strong>adolescents: Orchitis, Oophoritis</strong></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Mumps is <strong>prevented</strong> by: <strong>Active</strong> immunization by <strong>Mumps vaccine</strong> &ndash; Type: <strong>Live attenuated vaccine</strong> (Strain: <strong>Jeryll Lynn strain</strong>)</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>complications of Mumps</strong> include <strong>Orchitis, Pancreatitis, Sensorineural deafness</strong> but <strong>not</strong> <strong>Cholecystitis.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 168)</strong></span></span></p>",
    "correct_choice_id": 6290,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual",
      "ImageBased"
    ]
  },
  {
    "id": 1574,
    "choices": [
      {
        "id": 6291,
        "text": "<p><span style=\"font-size:12pt;\">26%</span></p>"
      },
      {
        "id": 6292,
        "text": "<p><span style=\"font-size:12pt;\">66%</span></p>"
      },
      {
        "id": 6293,
        "text": "<p><span style=\"font-size:12pt;\">86%</span></p>"
      },
      {
        "id": 6294,
        "text": "<p><span style=\"font-size:12pt;\">100%</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">During an epidemiology lecture at a medical school, the professor discusses the transmission dynamics of various viral infections. Mumps, a contagious viral infection, is highlighted for its notable secondary attack rate, particularly in settings where close contact occurs, such as schools and family households. A medical student is asked about the secondary attack rate of mumps to understand its transmissibility. What is the secondary attack rate of mumps?</span></p>",
    "unique_key": "Q5007617",
    "question_audio": null,
    "question_video": null,
    "map_id": 34162,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. C. 86%</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The Secondary attack rate for mumps is estimated to be about 86 percent.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Secondary Attack Rate (SAR)</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Is no. of exposed persons developing the disease within the range of incubation period (IP), following exposure to the primary case</span></li><li><span style=\"font-size:12pt;\">Denominator includes only those susceptible in close contact</span></li><li><span style=\"font-size:12pt;\">Primary case is always excluded both from numerator and denominator for SAR calculation</span></li></ul><p>&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:20px;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;<img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/12/picture14.jpg\" alt=\"\" width=\"1000\" height=\"690\"></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Secondary Attack Rate of some diseases&nbsp;</span></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Secondary attack rate of Mumps - 86% (&gt;85%)</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Infectivity is also termed as Secondary attack rate</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Park 26<sup>th</sup> edition (page 168)</strong></span></p>",
    "correct_choice_id": 6293,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InvestigationBased"
    ]
  },
  {
    "id": 1575,
    "choices": [
      {
        "id": 6295,
        "text": "<p><span style=\"font-size:12pt;\">45 mg OD of Oseltamivir</span></p>"
      },
      {
        "id": 6296,
        "text": "<p><span style=\"font-size:12pt;\">75 mg OD of Oseltamivir</span></p>"
      },
      {
        "id": 6297,
        "text": "<p><span style=\"font-size:12pt;\">45 mg OD of Zanamivir</span></p>"
      },
      {
        "id": 6298,
        "text": "<p><span style=\"font-size:12pt;\">70 mg OD of Zanamivir</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">During an infectious disease rotation, a medical resident is tasked with developing a protocol for managing potential outbreaks of Influenza H1N1 in a hospital setting. As part of the protocol, the resident must consider options for chemoprophylaxis, especially for high-risk patients and healthcare workers who may be exposed to the virus. The resident discusses with the supervising physician about the appropriate medication for chemoprophylaxis against Influenza H1N1.&nbsp; Which medication is recommended for chemoprophylaxis against Influenza H1N1?</span></p>",
    "unique_key": "Q2579267",
    "question_audio": null,
    "question_video": null,
    "map_id": 34163,
    "difficulty_level": "beginner",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. B. 75 mg of Oseltamivir</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Oseltamivir (Tamiflu)</strong> is the drug of choice for<strong> chemoprophylaxis to health care personnel and close contacts</strong> of suspected, <strong>probable or confirmed</strong> case of <strong>pandemic influenza A (H1N1)</strong> 2009. It should be given till <strong>10 days after last exposure</strong>.&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>For adults</strong> above <strong>40 kg</strong> the dose is <strong>75 mg OD.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>H1N1 (Type A)</strong> \u2013 Cause of <strong>Swine flu</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Antiviral</strong> therapy for <strong>H1N1</strong>:</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>Severe/progressive</strong> clinical illness: <strong>Oseltamivir</strong> (if <strong>not available</strong> or <strong>resistant</strong>, use <strong>Zanamivir</strong>)</span></li><li><span style=\"font-size:12pt;\"><strong>High risk</strong> of <strong>severe/complicated</strong> illness<strong>: Oseltamivir OR Zanamivir</strong></span></li><li><span style=\"font-size:12pt;\"><strong>Not</strong> high risk OR <strong>Uncomplicated</strong> confirmed/suspected illness: <strong>No</strong> need of <strong>treatment</strong></span></li><li><span style=\"font-size:12pt;\">Dosage:</span><ul><li><span style=\"font-size:12pt;\"><strong>Oseltamivir</strong> - <strong>75 mg BD</strong> \u00d7 <strong>5 days</strong> (DOC)</span></li><li><span style=\"font-size:12pt;\"><strong>Zanamivir</strong> - <strong>2 inhalations</strong> (<strong>2 \u00d7 5</strong> mg) <strong>BD</strong> \u00d7 <strong>5 days</strong></span></li></ul></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Chemoprophylaxis</strong>&nbsp;against&nbsp;<strong>H1N1 - Oseltamivir 75 mg OD</strong> till <strong>10 days</strong> after <strong>last exposure.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Reference: Park 26<sup>th</sup> edition (page 175)</strong></span></p>",
    "correct_choice_id": 6296,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 1580,
    "choices": [
      {
        "id": 6315,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Carriers are more common sources of infection than cases</span></span></p>"
      },
      {
        "id": 6316,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Incubation period is 2-6 days</span></span></p>"
      },
      {
        "id": 6317,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">25 Lf of diphtheria toxoid are present per ml in DPT vaccine</span></span></p>"
      },
      {
        "id": 6318,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Diphtheria is an endemic disease in India</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A medical resident working in a community health center is reviewing the epidemiology and clinical aspects of diphtheria as part of a public health initiative. The resident is presented with a series of statements about diphtheria and is asked to identify which one is NOT true. This exercise is important for ensuring accurate understanding and effective communication about the disease to the public. Which of the following statements about diphtheria is NOT true?</span></span></p>",
    "unique_key": "Q2669764",
    "question_audio": null,
    "question_video": null,
    "map_id": 34164,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. 25 Lf of diphtheria toxoid are present per ml in DPT vaccine</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>DPT VACCINE:-</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Composition -&nbsp;</span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/26/screenshot-2024-08-26-093455.png\" style=\"height:734px; width:1000px\" /></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">DPT vaccine contains <strong>Thiomersal </strong>(<strong>Preservative</strong>)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">DPT contains <strong>Aluminum hydroxide/ aluminium phosphate</strong> (<strong>Adjuvant</strong>).&nbsp;It <strong>increases immunogenicity</strong> of vaccine</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Absolute Contraindications</strong> to <strong>DPT vaccine</strong>:</span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Severe hypersensitivity reaction</strong> to <strong>previous dose </strong></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Progressive neurological disease</strong> (e.g. ACTIVE Epilepsy) [Cerebral palsy &amp; seizures controlled on anti-epileptics do not preclude the use of DPT; DPT should be given under these circumstances]</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Cold Chain Temperature</strong> of <strong>DPT</strong>: <strong>+2&deg; to +8&deg;C</strong>&nbsp; (If DPT vaccine gets frozen accidentally, then have to&nbsp;discard the vaccine)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Adult</strong> type of <strong>Diphtheria &ndash; tetanus vaccine</strong> (dT): contains up to <strong>2 Lf</strong> of <strong>diphtheria toxoid</strong> per dose; given <strong>2 doses</strong> <strong>4-6 weeks apart</strong>, followed by a <strong>booster</strong> after <strong>6&ndash;12 months</strong>; is useful for <strong>immunizing</strong> children over <strong>12 yrs of age</strong> &amp; <strong>adults</strong> (Incl. <strong>Pregnant women</strong>)</span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option&nbsp;A</strong>. <strong>Carriers are more common sources of infection than cases</strong>: &nbsp;<strong>TRUE</strong>.&nbsp;<strong>95%</strong> of total disease <strong>transmission</strong> is due to <strong>carriers</strong>&nbsp;</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Nasal carriers</strong> are <strong>more dangerous</strong> than <strong>throat carriers</strong></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Incidence of carriers</strong> in a community: <strong>0.5-1%</strong></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Immunization <strong>does not</strong> prevent <strong>carrier state</strong></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Note -&nbsp;<strong>Source of infection</strong>: <strong>Case or carrier</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option&nbsp;B. Incubation period is 2-6 days</strong>: &nbsp;<strong>TRUE</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Mode</strong> of <strong>transmission</strong>: <strong>droplet infection</strong> (main mode), directly from <strong>cutaneous lesions and fomites</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Period of Infectivity</strong>: <strong>14-28 days</strong> from <strong>onset of disease</strong>; longer for carriers.</span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A <strong>case/carrier</strong> may be considered <strong>non-communicable</strong> when at least <strong>2 cultures</strong> from <strong>nose and throat</strong>, <strong>24 hrs apart</strong>, are <strong>negative.</strong></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>MC</strong> Subtype: <strong>Faucial</strong> (<strong>Tonsillar + Pharyngeal</strong>)</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option&nbsp;D. Diphtheria is an endemic disease in India</strong>: &nbsp;<strong>TRUE</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>DPT</strong> vaccine - <strong>25 Lf</strong> of <strong>diphtheria toxoid</strong> are present per <strong>0.5 ml</strong> i.e. <strong>per dose.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>DT&nbsp;</strong>Vaccine - Contains up to <strong>2 Lf</strong> of <strong>diphtheria toxoid</strong> per <strong>dose.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 27<sup>th</sup> edition (page 180)&nbsp;</strong></span></span></p>",
    "correct_choice_id": 6317,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 1584,
    "choices": [
      {
        "id": 6331,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">MR vaccine</span></span></p>"
      },
      {
        "id": 6332,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">MMR vaccine</span></span></p>"
      },
      {
        "id": 6333,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">MMRV vaccine</span></span></p>"
      },
      {
        "id": 6334,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Hexavalent vaccine</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A medical resident working in a pediatric clinic is reviewing the National Immunization Schedule as part of a public health initiative to improve vaccination rates in the community. Recently, there have been updates to the schedule, particularly regarding the measles vaccine. The resident is discussing these changes with a senior pediatrician to ensure accurate information is provided to patients and their families. In the National Immunization Schedule, the measles vaccine has been replaced by which of the following vaccines?</span></span></p>",
    "unique_key": "Q6284347",
    "question_audio": null,
    "question_video": null,
    "map_id": 34165,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A. MR vaccine</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">In <strong>National Immunisation Schedule</strong>, <strong>Measles</strong> vaccine has been <strong>replaced</strong> by <strong>Measles Rubella (MR) vaccine.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. &nbsp;MMR</strong>: &nbsp;Is a type of <strong>live attenuated vaccine</strong>, recommended at the age of <strong>15&ndash;18 months.&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">NOTE - In <strong>Delhi&rsquo;s Immunization Schedule</strong>, there are <strong>2 additional vaccines</strong> &ndash; <strong>MMR</strong> (<strong>single</strong> dose at <strong>15 months</strong> of age) and&nbsp;<strong>Typhoid </strong>(<strong>single dose</strong> between <strong>2-5</strong> <strong>years</strong> of age)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. &nbsp;MMRV Combination Vaccine:&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Given </strong>at age group of <strong>9 months&ndash;12 years</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Minimum</strong> interval between <strong>2 doses</strong>: <strong>4 weeks</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Preferable schedule: <strong>2nd dose</strong> <strong>6 weeks-3 months later</strong> or at <strong>4-6 years age.</strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>The maximum</strong> age for administration of <strong>MMRV</strong> is&nbsp;<strong>12 years</strong>. It should <strong>not </strong>be administered to <strong>anyone 13 years of age or older</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. &nbsp;Hexavalent Vaccine:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">There is <strong>no hexavalent vaccine</strong> available in <strong>India</strong> that contains <strong>MMR </strong>in combination.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">In <strong>National Immunisation Schedule</strong>, <strong>Measles vaccine</strong> has been <strong>replaced by</strong> <strong>Measles Rubella (MR) vaccine</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">NEW <strong>National Immunization Schedule</strong> (NIS) <strong>2023-24</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-125017_KHN9A8u.png\" style=\"height:1129px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">NOTE -&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>JE vaccine</strong> only in <strong>Endemic districts</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>HiB Vaccine</strong> introduced as <strong>Pentavalent vaccine</strong> &ndash; <strong>DPT + HepB + HiB</strong> vaccine in <strong>16 states.</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>fIPV</strong> is fractionated <strong>intradermal at 6 weeks</strong> &amp; <strong>14 weeks</strong> or <strong>IPV Intramuscular </strong>only at <strong>14 weeks</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Rotaviral vaccine</strong> introduced in <strong>9 States</strong> &ndash; Andhra Pradesh, Haryana, Himachal Pradesh, Odisha, Madhya Pradesh, Assam, Rajasthan, Tamil Nadu and Tripura.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Measles-Rubella/ MR vaccine</strong> started from <strong>5 States/UTs</strong> - Karnataka, Tamil Nadu, Goa, Lakshadweep and Puducherry.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Pneumococcal conjugate</strong> PCV vaccine introduced in all 12 districts of Himachal Pradesh, 6 districts of Uttar Pradesh and 17 districts of Bihar</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Adult JE Vaccine</strong> introduced in <strong>31 high burden districts</strong> from <strong>Assam</strong>, <strong>Uttar Pradesh and West Bengal</strong> for <strong>adult</strong>. <strong>JE vaccination</strong> in the age-group of <strong>15-65 years.&nbsp;</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>MoHFW-GOI</strong> (<strong>August 2018</strong>) - <strong>TT </strong>be <strong>replaced</strong> by <strong>Td</strong>; Replacement for <strong>TT booster </strong>doses given <strong>at 10 years, 16 years</strong> age and <strong>Pregnant women</strong> (incl<strong>. booster dose</strong>).</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Textbook of Community Medicine- Rajvir Bhalwar- 4<sup>th</sup> edition (page 732)</strong></span></span></p>",
    "correct_choice_id": 6331,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 1586,
    "choices": [
      {
        "id": 6339,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Catch up</span></span></p>"
      },
      {
        "id": 6340,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Follow up</span></span></p>"
      },
      {
        "id": 6341,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Outreach vaccination</span></span></p>"
      },
      {
        "id": 6342,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">High risk immunisation</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A medical resident working in a community health center is involved in planning a measles immunization program. As part of the program, various strategies are being considered to effectively increase measles immunity in the community. The resident is tasked with identifying key components of the immunization strategy, particularly activities that are unique and not regularly repeated. In the context of a measles immunization program, which of the following activities is considered a &lsquo;one-time activity&rsquo; aimed at rapidly increasing community immunity levels?</span></span></p>",
    "unique_key": "Q3248567",
    "question_audio": null,
    "question_video": null,
    "map_id": 34166,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A. Catch up</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Measles Catch-up campaigns</strong> -&nbsp;Catch up is a <strong>onetime event</strong>. During the <strong>measles</strong> <strong>catch up</strong> campaign all the children in <strong>target age group</strong> (<strong>9 months to 14</strong> years) will receive a <strong>supplementary dose of Measles vaccine</strong> regardless of <strong>previous vaccination history</strong> or <strong>history</strong> of <strong>measles disease</strong>.</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>WHO Measles Elimination</strong> Strategy: &lsquo;<strong>Catch up, keep up, Follow up&rsquo;</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Catch up</strong>: <strong>One time Nationwide</strong>, <strong>vaccination</strong> campaign targeting all children <strong>9 months to 14 years of age</strong>, irrespective of history of Measles disease or vaccination status</span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Keep up</strong>: <strong>Routine services</strong> aimed at <strong>vaccinating</strong> more than <strong>95%</strong> of each <strong>successive birth cohort.</strong></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Follow up</strong>: <strong>Subsequent nationwide vaccination</strong> campaigns conducted every <strong>2&ndash;4 years</strong> targeting usually <strong>all children born</strong> <strong>after</strong> the <strong>catch-up campaign</strong>.</span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Accelerated Measles Mortality Reduction Strategy</strong> (WHO/UNICEF):<strong>&nbsp;Two doses</strong> of <strong>Measles containing vaccine</strong> (MCV) to <strong>all children</strong> through <strong>routine</strong> and <strong>supplementary immunization activities.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option&nbsp;B. Follow up: </strong>&nbsp;<strong>Subsequent nationwide vaccination campaigns</strong> conducted every<strong> 2&ndash;4 years</strong>&nbsp;(not one-time event) targeting usually all <strong>children born</strong> <strong>after</strong> the <strong>catch-up campaign</strong>. (Part of WHO Measles Elimination Strategy: &lsquo;Catch up, keep up, Follow up&rsquo;)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option&nbsp;C.&nbsp;Outreach vaccination</strong>: &nbsp;While outreach vaccination is important for <strong>reaching underserved</strong> or <strong>hard-to-reach populations</strong>, it is generally an <strong>ongoing activity</strong> rather than a one-time event.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option&nbsp;D. High risk immunization: </strong>&nbsp;Immunization of high-risk groups is an important <strong>part</strong> of <strong>any immunization strategy</strong> but is typically an <strong>ongoing effort</strong> rather than a one-time activity.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Measles Catch-up campaigns </strong>-&nbsp; <strong>One time Nationwide</strong>, <strong>vaccination campaign</strong> targeting all children <strong>9 months to 14 years of age</strong>, <strong>irrespective</strong> of history of <strong>Measles disease or vaccination status.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Textbook of Community Medicine- Rajvir Bhalwar- 4<sup>th</sup> edition (page 730)</strong></span></span></p>",
    "correct_choice_id": 6339,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 1588,
    "choices": [
      {
        "id": 6347,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Penicillin</span></span></p>"
      },
      {
        "id": 6348,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Erythromycin</span></span></p>"
      },
      {
        "id": 6349,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Doxycycline</span></span></p>"
      },
      {
        "id": 6350,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Rifampicin</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">During an infectious disease rotation, a medical resident is consulted about a patient who is identified as a carrier of Corynebacterium diphtheriae, the bacterium responsible for diphtheria. While the patient is asymptomatic, the resident understands the importance of treating carriers to prevent the spread of the infection. The resident discusses with the supervising physician about the appropriate pharmacological intervention for carriers of diphtheria. What is the recommended drug for treating carriers of<strong> </strong>diphtheria?</span></span></p>",
    "unique_key": "Q8437868",
    "question_audio": null,
    "question_video": null,
    "map_id": 34167,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. B. Erythromycin</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>carriers of Diphtheria </strong>should be <strong>treated</strong> with <strong>10 days</strong> course of <strong>oral erythromycin</strong>, which is the <strong>most effective</strong> drug for the <strong>treatment of carriers</strong>.&nbsp;This <strong>antibiotic</strong> is <strong>effective</strong> in <strong>eliminating</strong> the <strong>bacterium</strong> from the <strong>nasopharynx</strong>, thereby <strong>reducing</strong> the <strong>risk of transmission.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option&nbsp;A. Penicillin: </strong>&nbsp;can be used as <strong>DOC</strong> for treating <strong>Diphtheria</strong> <strong>Cases</strong> not carriers.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option&nbsp;C. Doxycycline: </strong>&nbsp;<strong>Drug of choice</strong> for <strong>chemoprophylaxis</strong> for <strong>Malaria</strong>, if needed for<strong> &lt;6 weeks</strong> (not for diphtheria)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option&nbsp;D. Rifampicin: </strong>&nbsp;<strong>Drug of choice</strong> for <strong>chemoprophylaxis</strong> for <strong>Meningococcal</strong> <strong>meningitis</strong> (not for diphtheria)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Drug of Choice</strong> in <strong>Diphtheria:-</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:16px\">&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-155339.png\" style=\"height:463px; width:1000px\" /></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Drugs for Chemoprophylaxis:</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:16px\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-155111.png\" style=\"height:642px; width:1000px\" /></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 177)</strong></span></span></p>",
    "correct_choice_id": 6348,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "InvestigationBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 1590,
    "choices": [
      {
        "id": 6355,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Human and animals are the reservoirs of infection</span></span></p>"
      },
      {
        "id": 6356,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">There are no subclinical cases.</span></span></p>"
      },
      {
        "id": 6357,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The incubation period is fairly fixed at ten days.</span></span></p>"
      },
      {
        "id": 6358,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Effective vaccine is available.</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">During a public health seminar focusing on vaccine-preventable diseases, a discussion arises about the global efforts to eliminate measles. A medical resident is reviewing various factors that support the potential elimination of measles in the near future. The resident considers the key elements that contribute to the successful control and eventual elimination of measles but also recognizes challenges that might impede these efforts. Which of the following points is NOT in favor of the elimination of measles in the near future?</span></span></p>",
    "unique_key": "Q7531549",
    "question_audio": null,
    "question_video": null,
    "map_id": 34168,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A. Human and animals are the reservoirs of infection</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Human beings</strong> are the <strong>only reservoir</strong> of infection. <strong>Man</strong> is <strong>Obligate Host</strong>. This is one of the reason for <strong>elimination of measles</strong> in the <strong>future.&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option&nbsp;B. There are no subclinical cases: </strong>&nbsp;Correct.&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option&nbsp;C. The incubation period is fairly fixed at ten days: </strong>&nbsp;Correct</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option&nbsp;D. Effective vaccine is available: </strong>&nbsp;Correct.&nbsp;Very effective vaccine is available.&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Eradication </strong>of <strong>Measles</strong>: Requires a <strong>vaccination coverage &gt;96%.</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Epidemic </strong>of <strong>measles</strong> occur: If the proportion of <strong>susceptible children is &gt;40%.</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">If <strong>Measles </strong>is <strong>introduced </strong>in a <strong>virgin community</strong>: it <strong>infects &gt;90%</strong> children.</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The experience of <strong>eradicating polio</strong> and <strong>small pox</strong> using <strong>similar strategies</strong> of <strong>vaccination</strong> combined with <strong>surveillance and contamination</strong> already exist.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Other reasons</strong> for the <strong>elimination of measles</strong> in the <strong>future:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Source </strong>of Infection are&nbsp;<strong>only cases</strong>&nbsp;(carriers are not known to occur)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Measles </strong>has <strong>no second attacks</strong> (<strong>lifelong immunity</strong> seen)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Manifestations</strong> of disease are <strong>well known</strong> to the <strong>community</strong>.</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Reasons</strong> for the <strong>elimination of measles</strong> in the <strong>future:</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Human beings</strong> are the <strong>only reservoir</strong> of infection. <strong>Man</strong> is <strong>Obligate Host.</strong></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Source of Infection</strong> are&nbsp;<strong>ONLY CASES</strong>&nbsp;(carriers are not known to occur).</span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">There are <strong>no subclinical cases.</strong></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Manifestations</strong> of disease are <strong>well known</strong> to the community.</span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Measles has <strong>no second attacks</strong> (lifelong immunity seen).</span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>incubation period</strong> is <strong>fairly fixed at ten days</strong>.</span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Very effective</strong> vaccine is <strong>available.</strong>&nbsp;</span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Textbook of Community Medicine- Rajvir Bhalwar- 4<sup>th</sup> edition (page 731)</strong></span></span></p>",
    "correct_choice_id": 6355,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased",
      "Factual"
    ]
  },
  {
    "id": 1591,
    "choices": [
      {
        "id": 6359,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Pertussis</span></span></p>"
      },
      {
        "id": 6360,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Tuberculosis</span></span></p>"
      },
      {
        "id": 6361,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Plague</span></span></p>"
      },
      {
        "id": 6362,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Diphtheria</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">While attending a lecture on respiratory illnesses in children, a medical student learns about various infectious diseases that present with prolonged coughing. The lecturer emphasizes the importance of recognizing specific clinical patterns in diagnosis. One disease, known for its characteristic and protracted cough, is highlighted for being notoriously referred to as the &quot;Hundred-day cough.&quot; The student is asked to identify this disease based on its distinctive clinical presentation. Which respiratory illness is commonly known as the &quot;Hundred-day cough&quot; due to its prolonged and characteristic coughing episodes?</span></span></p>",
    "unique_key": "Q3471435",
    "question_audio": null,
    "question_video": null,
    "map_id": 34169,
    "difficulty_level": "beginner",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A. Pertussis</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">An <strong>acute infectious disease</strong>, usually of <strong>young children</strong>, caused by <strong>B. pertussis</strong>. It is clinically characterized by an <strong>insidious onset</strong> with <strong>mild fever</strong> and an <strong>irritating cough</strong>, gradually becoming <strong>paroxysmal</strong> with the characteristic &ldquo;<strong>whoop</strong>&rdquo; (loud crowing inspiration) often with <strong>cyanosis and vomiting</strong>. The <strong>spectrum of disease</strong> varies from <strong>severe illness to atypical and mild illness</strong> <strong>without whoop</strong>. The Chinese call it a &ldquo;<strong>Hundred Day Cough</strong>&rdquo;.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. &nbsp;Tuberculosis: Incorrect.</strong> Serious <strong>respiratory illness</strong> caused by <strong>Mycobacterium tuberculosis</strong>. TB symptoms include a <strong>persistent cough</strong>, but the disease is known for <strong>its systemic symptoms</strong> and potential for <strong>severe lung damage</strong> rather than the <strong>duration of coughing episodes</strong>.</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. Plague:</strong> <strong>Incorrect.</strong> Caused by <strong>Yersinia pestis</strong>, can have a respiratory form known as <strong>pneumonic plague</strong>.&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Diphtheria: Incorrect</strong>. Bacterial infection caused by <strong>Corynebacterium diphtheriae</strong>. While it affects the respiratory system, it is <strong>not</strong> associated with the <strong>prolonged cough</strong>, as characteristic of <strong>pertussis</strong>.</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Some Important Pointers related to&nbsp;Pertussis/Whooping Cough -&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">&bull; Causative agent: <strong>Bordetella pertussis</strong> (<strong>5%</strong> cases by <strong>B. parapertussis</strong>)<br />\r\n&bull; Also known as &lsquo;<strong>Whooping Cough&rsquo;</strong> or &lsquo;<strong>100 Day Cough&rsquo;</strong> &ndash; <strong>Paroxysms</strong> of cough are followed by an <strong>inspiratory whoop</strong> (high pitch)<br />\r\n&bull; Incubation period<strong>: 7&ndash;14 days</strong><br />\r\n&bull; Source of Infection: <strong>Case</strong><br />\r\nThere is <strong>no subclinical or chronic carrier state.</strong><br />\r\n<strong>Neither</strong> <strong>vaccination nor infection</strong> <strong>confers long-term immunity.</strong><br />\r\n&bull;<strong> Secondary Attack rate: &gt; 90%</strong><br />\r\n&bull; Incidence and fatality: Females &gt; Males.<br />\r\n&bull; <strong>Leukocytosis</strong> does <strong>not</strong> correlates with the <strong>severity of cough.</strong><br />\r\n&bull; Chief complications: Bronchitis, <strong>bronchopneumonia,</strong> bronchiectasis, <strong>subconjunctival hemorrhages</strong>, epistaxis, <strong>hemoptysis</strong>, punctuate cerebral hemorrhages, <strong>convulsions and coma</strong>.<br />\r\n&bull; Laboratory diagnosis: Culturing of <strong>nasopharyngeal swabs</strong> on <strong>Bordet-Gengou medium,</strong> polymerase chain reaction (<strong>PCR</strong>), <strong>immunofluorescence (DFA),</strong> and <strong>serological methods</strong><br />\r\n&bull; Drug of choice:<strong> Erythromycin (40 mg/kg QID &times; 10 days)</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Hundred Day Cough</strong> is - <strong>Pertussis (Whooping Cough</strong>) - caused by<strong> Bordetella</strong> <strong>pertussis).</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 179)</strong></span></span></p>",
    "correct_choice_id": 6359,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 1595,
    "choices": [
      {
        "id": 6375,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">More in Males</span></span></p>"
      },
      {
        "id": 6376,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">More in Females</span></span></p>"
      },
      {
        "id": 6377,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Equal in Males and females</span></span></p>"
      },
      {
        "id": 6378,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Differs in Males and Females in different states</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A medical resident in a pediatric clinic is reviewing epidemiological data on pertussis (whooping cough) as part of his research project. Pertussis, caused by Bordetella pertussis, is a highly contagious respiratory disease. While vaccination has significantly reduced its incidence, there are concerns about increasing cases in certain populations. The resident is analyzing trends in the incidence and fatality of pertussis, particularly in vulnerable groups, to better understand the current challenges in managing and preventing this disease. Which statement accurately reflects the current trends in the incidence and fatality of pertussis?</span></span></p>",
    "unique_key": "Q6664301",
    "question_audio": null,
    "question_video": null,
    "map_id": 34170,
    "difficulty_level": "difficult",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. B. More in females</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Incidence and fatality</strong> of <strong>Pertussis</strong> are observed to be <strong>more</strong> among <strong>female </strong>than male children.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Some <strong>Important</strong> Pointers related to&nbsp;<strong>Pertussis/Whooping Cough</strong> -&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Causative agent: <strong>Bordetella pertussis</strong> (5% cases by B. parapertussis)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Also known as &lsquo;<strong>Whooping Cough&rsquo; or &lsquo;100 Day Cough&rsquo;</strong> &ndash; <strong>Paroxysms </strong>of <strong>cough</strong> are followed by an <strong>inspiratory whoop (high pitch)</strong>.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Incubation period: <strong>7&ndash;14 days</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Source of Infection</strong>: <strong>Case</strong></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">There is <strong>no subclinical or chronic carrier state</strong></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Neither vaccination nor infection </strong>confers<strong> long-term immunity.</strong></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Secondary</strong> Attack rate: &gt; <strong>90%</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Incidence and fatality: <strong>Females </strong>&gt; Males</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Leukocytosis </strong>does <strong>not</strong> correlates with the <strong>severity of cough</strong>.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Chief complications: Bronchitis, <strong>bronchopneumonia</strong>, bronchiectasis, <strong>subconjunctival hemorrhages</strong>, epistaxis, <strong>hemoptysis,</strong> <strong>punctuate cerebral </strong>hemorrhages, convulsions and coma.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Laboratory diagnosis: <strong>Culturing</strong> of <strong>nasopharyngeal swabs</strong> on <strong>Bordet-Gengou</strong> <strong>medium</strong>, polymerase chain reaction (<strong>PCR)</strong>, immunofluorescence (<strong>DFA</strong>), and <strong>serological methods</strong>.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Drug of choice: <strong>Erythromycin (40 mg/kg QID &times; 10 days)</strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Incidence and fatality of Pertussis</strong> are observed to be <strong>more </strong>among <strong>female than</strong> <strong>male</strong> children.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 179)</strong></span></span></p>",
    "correct_choice_id": 6376,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InvestigationBased"
    ]
  },
  {
    "id": 1607,
    "choices": [
      {
        "id": 6423,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Cotrimoxazole</span></span></p>"
      },
      {
        "id": 6424,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Doxycycline</span></span></p>"
      },
      {
        "id": 6425,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Erythromycin</span></span></p>"
      },
      {
        "id": 6426,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Ciprofloxacin</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">In a primary care setting, a family medicine physician encounters a family where one child has been diagnosed with pertussis. Recognizing the contagious nature of the disease, the physician considers the appropriate treatment protocol not only for the affected child but also for the family members who have been in close contact. The physician reviews the latest treatment guidelines to ensure the recommended first-line therapy is provided to both the patient and the contacts to effectively control the spread of the disease.&nbsp; What is the recommended first-line therapy for treating individuals diagnosed with pertussis and their close contacts?</span></span></p>",
    "unique_key": "Q8964566",
    "question_audio": null,
    "question_video": null,
    "map_id": 34171,
    "difficulty_level": "beginner",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. Erythromycin</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Cases:</strong> Although <strong>several antibiotics</strong> are <strong>effective</strong> against <strong>B. pertussis,</strong> <strong>erythromycin</strong> is probably the <strong>drug of choice.</strong> A dose of <strong>30-50 mg/kg</strong> of body weight in <strong>4 divided doses</strong> for <strong>10 days</strong> has been recommended.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Contacts:</strong> Those <strong>known </strong>to have been in <strong>contact with whooping cough</strong> may be given <strong>prophylactic antibiotic</strong> (<strong>erythromycin or azithromycin</strong>) treatment for <strong>10 days</strong> to prevent the <strong>infecting bacteria</strong> to become <strong>established.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Cotrimoxazole: </strong>Incorrect. <strong>Not </strong>the <strong>first-line</strong> treatment for <strong>pertussis.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. &nbsp;Doxycycline: </strong>Incorrect. Doxycycline can be <strong>used</strong> in <strong>certain cases,</strong> especially in <strong>older children and adults</strong>, but it is <strong>not</strong> typically the <strong>first-line</strong> treatment for <strong>pertussis.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Ciprofloxacin</strong>: Incorrect. <strong>Not</strong> used as the <strong>first-line treatment</strong> for <strong>pertussis.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Drug of choice</strong> for <strong>Pertussis Case</strong> and <strong>Contact</strong>: <strong>Erythromycin (40 mg/kg QID X 10 days)</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref:</u></strong><strong> Park 26<sup>th</sup> edition (page 180)</strong></span></span></p>",
    "correct_choice_id": 6425,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "InvestigationBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 1611,
    "choices": [
      {
        "id": 6439,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Whooping cough is more infectious during catarrhal stage</span></span></p>"
      },
      {
        "id": 6440,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Infective period may extend from a week after exposure to about 3 weeks after the onset of paroxysmal stage</span></span></p>"
      },
      {
        "id": 6441,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Asymptomatic chronic carriers of B. pertussis are common</span></span></p>"
      },
      {
        "id": 6442,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Secondary attack rate is 90%</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A medical resident in a public health clinic is advising parents about pertussis (whooping cough) as part of an educational initiative. Bordetella pertussis, the bacterium responsible for pertussis, has a specific period during which it is infectious. The resident needs to be well-informed about this infective period to provide accurate advice on prevention and control measures, such as isolation and treatment. However, there are some misconceptions about the infective period of B. pertussis. Which of the following statements is NOT true regarding the infective period of Bordetella pertussis?</span></span></p>",
    "unique_key": "Q3735188",
    "question_audio": null,
    "question_video": null,
    "map_id": 34172,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. Asymptomatic chronic carriers of B. pertussis are common</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Asymptomatic</strong> <strong>chronic carriers</strong> of <strong>B. pertussis</strong> are <strong>uncommon.</strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">In <strong>Pertussis</strong> -&nbsp;<strong>Subclinical cases</strong> do <strong>not</strong> <strong>exist</strong>.&nbsp; (Source of Infection: <strong>ONLY Cases</strong>)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Whooping cough is more infectious during the catarrhal stage:</strong> <strong>True</strong>. The <strong>catarrhal stage</strong>, which is the <strong>early</strong> phase of <strong>whooping cough</strong>, is characterized by<strong> symptoms</strong> similar to a <strong>common cold</strong>. During this stage, the <strong>disease</strong> is <strong>highly infectious.</strong> <strong>Catarrhal stage</strong> (<strong>1 week after exposure </strong>to <strong>3 weeks after</strong> <strong>onset of paroxysmal stage</strong>, although communicability <strong>diminishes</strong> <strong>rapidly after the catarrhal stage</strong>).</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Infective period may extend from a week after exposure to about 3 weeks after the onset of paroxysmal stage:</strong> <strong>True</strong>.&nbsp;The <strong>infective period</strong> for <strong>whooping</strong> cough can <strong>last</strong> from the <strong>initial exposure </strong>through the <strong>paroxysmal stage</strong>, during which <strong>severe coughing</strong> fits occur.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Secondary attack rate is 90%: True</strong>. The secondary attack rate for <strong>whooping cough</strong> is <strong>very high</strong>, meaning that the disease is <strong>highly contagious</strong> within <strong>households or close-contact settings.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Some Important Pointers related to PERTUSSIS -&nbsp;&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Drug of choice</strong>:<strong> Erythromycin (40 mg/kg in 4 divided doses X 10 days)</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Complications: Bronchitis, <strong>bronchopneumonia</strong>, bronchiectasis, convulsions, coma</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">While <strong>whooping</strong> cough is <strong>highly contagious</strong> during the <strong>catarrhal stage</strong> and has a <strong>high secondary attack</strong> rate,&nbsp;the <strong>asymptomatic chronic carriers</strong> of <strong>B. pertussis</strong> are <strong>uncommon</strong>.&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">SAR of some diseases are: </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:14px\"><span style=\"font-family:Georgia,serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/12/picture17.jpg\" style=\"height:833px; width:1000px\" /></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 179)</strong></span></span></p>",
    "correct_choice_id": 6441,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 1613,
    "choices": [
      {
        "id": 6447,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">DPT</span></span></p>"
      },
      {
        "id": 6448,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">BCG</span></span></p>"
      },
      {
        "id": 6449,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Meningococcal vaccine</span></span></p>"
      },
      {
        "id": 6450,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Measles Rubella (MR)</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An intern, as part of their pediatric clinic rotation, is focusing on the safety profiles of childhood vaccines. This review is crucial to enhance their understanding of vaccine safety and to better counsel parents effectively. In particular, the intern is examining the rare but serious side effects that can occur post-vaccination. The topic of discussion shifts to convulsions, a serious complication that can be associated with certain vaccines, albeit rarely. The intern is tasked with identifying the specific vaccine linked to this adverse effect. Which vaccine is known to have a rare association with convulsions as a serious post-immunization complication?</span></span></p>",
    "unique_key": "Q5466872",
    "question_audio": null,
    "question_video": null,
    "map_id": 34173,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A. DPT</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Following <strong>DPT vaccine,</strong> the <strong>rare</strong> vaccine reactions are <strong>persistent</strong> (more than <strong>3 hours</strong>) inconsolable screaming, <strong>seizures</strong>, <strong>hypotonic hypo-responsive episodes</strong>, <strong>anaphylactic reaction</strong>, and very rarely <strong>encephalopathy.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. BCG (Bacillus Calmette&ndash;Gu&eacute;rin):</strong> <strong>Incorrect</strong>. The complications associated with BCG vaccine are <strong>Prolonged severe ulceration</strong> at <strong>site</strong> of <strong>vaccination</strong>, Suppurative <strong>lymphadenitis</strong>,&nbsp;<strong>Osteomyelitis</strong>,&nbsp;<strong>Disseminated BCG infection</strong> and&nbsp;<strong>Death</strong>.</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. Meningococcal vaccine:</strong> <strong>Incorrect</strong>.&nbsp;In rare cases, a meningococcal vaccine may cause a&nbsp;<strong>severe allergic reaction</strong> (Hypersensitivity).</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. MR (Measles and Rubella):</strong> <strong>Incorrect</strong>. Although <strong>febrile convulsions</strong> can occur following the<strong> MR vaccine</strong> due to <strong>fever</strong>, the association is <strong>less prominent</strong> compared to the <strong>DPT vaccine</strong>.&nbsp;<strong>Measles (&amp; MMR)</strong> vaccine can lead to <strong>Toxic Shock Syndrome.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Some <strong>Specific side effects</strong> of important vaccines are:</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">&bull; <strong><em>Guillian Barre Syndrome: </em>Killed influenza vaccine</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>&bull; <em>Vaccine associated paralysis: </em>OPV (Sabin)</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">&bull; <em>Shock: </em>DPT, Pertussis vaccine</span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">&bull; <em>Hypersensitivity: </em>Hep-B, Meningococcal vaccine, DPT, dT </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>rare</strong> vaccine reactions <strong>post DPT vaccination</strong> are <strong>persistent</strong> (more than <strong>3 hours</strong>) inconsolable <strong>screaming, seizures, hypotonic hypo-responsive episodes, anaphylactic reaction,</strong> and very rarely <strong>encephalopathy.</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Some important Rare vaccine reactions:</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-154619.png\" style=\"height:850px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 180)</strong></span></span></p>",
    "correct_choice_id": 6447,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 1620,
    "choices": [
      {
        "id": 6475,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">X</span></span></p>"
      },
      {
        "id": 6476,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Y</span></span></span></p>"
      },
      {
        "id": 6477,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Z</span></span></p>"
      },
      {
        "id": 6478,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">W135</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">During an epidemiology lecture at a medical school, the topic of Neisseria meningitidis (the causative agent of meningococcal meningitis) is being discussed. The professor explains that various serotypes of N. meningitidis are responsible for the disease&#39;s epidemiology, including both endemic cases and outbreaks. A medical student, interested in infectious diseases, is asked to identify the serotype of N. meningitidis that is less commonly associated with causing both endemic disease and outbreaks. Which serotype of Neisseria meningitidis is typically NOT associated with causing both endemic disease and outbreaks?</span></span></p>",
    "unique_key": "Q4510582",
    "question_audio": null,
    "question_video": null,
    "map_id": 34174,
    "difficulty_level": "difficult",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. Z</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>12 serotypes</strong> have been<strong> identified</strong>, viz. <strong>Groups</strong> <strong>A, B, C, 29E, H, I, K, L, W135, X, Y, Z</strong> based on the structure of the <strong>polysaccharide capsule.</strong>&nbsp;</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The majority of invasive<strong> meningococcal infections</strong> are caused by organisms of <strong>serogroups A, B, C, X, W135</strong> and <strong>Y</strong>. <strong>Meningococci</strong> of these <strong>serogroups</strong> have the potential to cause <strong>both endemic disease and outbreaks</strong>. </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Most <strong>lethal</strong> form is <strong>B</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Epidemics - A, C &gt; B &gt; W-135, Y</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">In <strong>African meningitis belt</strong>, <strong>subgroup A</strong> has been the most <strong>important</strong> cause of <strong>disease</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Neisseria meningitides</strong> Serotype <strong>not</strong> associated with <strong>endemics and outbreaks - Serotype Z.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>MC serotype</strong> of <strong>Meningococcus</strong> causing <strong>epidemics</strong> <strong>worldwide</strong> is <strong>A</strong> and the most <strong>lethal form</strong> is <strong>B.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 181)</strong></span></span></p>",
    "correct_choice_id": 6477,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 1628,
    "choices": [
      {
        "id": 6507,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">15 year</span></span></p>"
      },
      {
        "id": 6508,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">2 years</span></span></p>"
      },
      {
        "id": 6509,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">5 years</span></span></p>"
      },
      {
        "id": 6510,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">10 years</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">In a paediatric immunization clinic, a nurse practitioner is educating a group of new parents about the vaccination schedule for their infants. One of the vaccines discussed is the quadrivalent meningococcal vaccine, which offers protection against four strains of Neisseria meningitidis. A parent inquires about the appropriate age to start this vaccination for their child. The nurse practitioner knows that the vaccine&#39;s efficacy and safety are age-dependent and prepares to explain the age guidelines.&nbsp;At what minimum age is the quadrivalent meningococcal vaccine typically not recommended in children?</span></span></p>",
    "unique_key": "Q6202962",
    "question_audio": null,
    "question_video": null,
    "map_id": 34175,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. B. 2 years</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Quadrivalent vaccines</strong> are administered as a <strong>single dose</strong> to individuals aged <strong>&gt; 2 years</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Important pointers regarding <strong>Meningococcal Vaccine</strong> -</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Type of Vaccine: <strong>killed vaccine, cellular fraction</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Dose: 0.5 ml</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Route: <strong>Subcutaneous</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Site: Antero-lateral thigh (Middle one-third)</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Booster every <strong>3 years</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Available for <strong>group A, C, W135 and Y meningococci</strong></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Vaccine is <strong>not </strong>available for <strong>Group B meningococcus</strong>: Group B polysaccharide is <strong>non-immunogenic.</strong></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Contraindications:</span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Pregnancy</strong></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Infants and children &lt; 2 years</strong> of age (due to development of <strong>immunologic tolerance</strong>)</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Meningococcal Vaccine</strong> - <strong>Contraindications</strong> - <strong>Pregnant women, Infants</strong> and children <strong>&lt;2 years</strong> of age.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 182)</strong></span></span></p>",
    "correct_choice_id": 6508,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 1631,
    "choices": [
      {
        "id": 6519,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Mass vaccination</span></span></p>"
      },
      {
        "id": 6520,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Health education</span></span></p>"
      },
      {
        "id": 6521,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Isolation of cases</span></span></p>"
      },
      {
        "id": 6522,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Mass chemoprophylaxis</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">During a public health department meeting, a medical officer is discussing strategies for controlling an outbreak of meningococcal meningitis in a community. Various measures are considered, including vaccination and antibiotic prophylaxis. However, certain interventions are not recommended in the control of meningococcal meningitis epidemics. The medical officer is reviewing these strategies to ensure that the response is evidence-based and effective. In the control of an epidemic of meningococcal meningitis, which of the following interventions is NOT recommended?</span></span></p>",
    "unique_key": "Q1856961",
    "question_audio": null,
    "question_video": null,
    "map_id": 34176,
    "difficulty_level": "difficult",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. Isolation of Cases</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Isolation</strong> of cases is <strong>not</strong> useful in <strong>epidemics of meningococcal meningitis</strong> as <strong>carriers outnumber cases</strong>.&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Mass vaccination:</strong> &nbsp;This is a recommended intervention in the control of a <strong>meningococcal meningitis epidemic</strong>. Vaccination is <strong>effective</strong> in <strong>preventing </strong>the <strong>spread </strong>of the <strong>disease</strong>, especially in <strong>areas </strong>with <strong>high incidence rates</strong>.</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Health education: &nbsp;HE</strong> is an important <strong>component</strong> of <strong>epidemic control</strong>. Educating the public about the<strong> symptoms</strong> of <strong>meningococcal meningitis</strong> and the importance of seeking timely <strong>medical care</strong> can help in <strong>early detection</strong> and <strong>treatment of cases</strong>.</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Mass chemoprophylaxis: </strong>&nbsp;Mass chemoprophylaxis, using <strong>antibiotics</strong> like <strong>rifampicin, ciprofloxacin, or ceftriaxone</strong>, can be recommended in certain situations during a <strong>meningococcal meningitis epidemic</strong>. It is particularly used for <strong>close contacts of infected individuals</strong> to <strong>prevent</strong> the <strong>spread</strong> of the <strong>disease</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Some Important Pointers</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>DOC</strong> for <strong>Chemoprophylaxis</strong> of <strong>Meningococcal Meningitis</strong> - <strong>Rifampicin (600 mg BD &times; 2 days).</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Meningococcal disease</strong> is <strong>endemic</strong> in India.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Treatment with <strong>Penicillin doesn&rsquo;t eradicate</strong> the <strong>carrier state</strong> in <strong>meningococcal meningitis.</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Meningococcal Meningitis Prevention &amp; Control</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Treatment of cases: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Antibiotics</strong> <strong>started &lt; 48 hours</strong> of illness save <strong>95% lives.</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Drug of choice: <strong>Penicillin</strong> (Ceftriaxone if allergic to Penicillin)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Epidemics</strong>: <strong>Single dose</strong> Long-acting <strong>Chloramphenicol or Ceftriaxone</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Treatment of carriers: Rifampici</strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Treatment of contacts:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Start treatment &lt; 24 hours</strong> of identification of <strong>index case</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Drugs used: Rifampicin, Ciprofloxacin, Ceftriaxone, Azithromycin</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">In the control of a <strong>meningococcal meningitis epidemic</strong>, <strong>isolation</strong> of individual cases is <strong>not</strong> a typically recommended intervention. <strong>Mass vaccination</strong> and <strong>chemoprophylaxis</strong>, along with <strong>health education</strong>, are key strategies in <strong>controlling and preventing</strong> the <strong>spread of the disease.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Textbook of Community Medicine- Rajvir Bhalwar (4<sup>th</sup> edition) (page 757)</strong></span></span></p>",
    "correct_choice_id": 6521,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 1639,
    "choices": [
      {
        "id": 6551,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Outpatient treatment</span></span></p>"
      },
      {
        "id": 6552,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Give injection/ oral drops</span></span></p>"
      },
      {
        "id": 6553,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Home management</span></span></p>"
      },
      {
        "id": 6554,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Urgent referral</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A pediatric resident is evaluating a 6-month-old infant in a community health center. The infant presents with high fever, rapid breathing, and a convulsion. The resident refers to the IMNCI (Integrated Management of Neonatal and Childhood Illnesses) chart for guidance on management. According to the IMNCI chart, what does the pink color indicate regarding the necessary action for this patient?</span></span></p>",
    "unique_key": "Q5618463",
    "question_audio": null,
    "question_video": null,
    "map_id": 34177,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. D. Urgent referral</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Under <strong>IMNCI,</strong> <strong>pink color</strong> in <strong>chart</strong> refers to <strong>urgent referral.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>IMNCI</strong> classifications are <strong>colour coded</strong> :</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">&ldquo;<strong>pin</strong>k&rdquo; suggests <strong>hospital referral or admission</strong>, </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">&ldquo;<strong>yellow</strong>&rdquo; indicates <strong>initiation of treatment</strong>, and </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">&ldquo;<strong>green</strong>&rdquo; calls for <strong>home treatment</strong>.&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Outpatient treatment: </strong>Yellow color</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B.&nbsp;Give injection/ oral drops - </strong>yellow color<strong>&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. Home management - </strong>green color</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Integrated Management of Neonatal and Childness illness (IMNCI)</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>IMNCI </strong>is a strategy for <strong>reducing morbidity and mortality</strong> associated with <strong>major</strong> causes of <strong>childhood illness.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Curative component</strong> includes management of:</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">1. Diarrhoea</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">2. Measles</span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">3. Pneumonia</span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">4. Malaria</span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">5. Severe malnutrition and nutritional counseling</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Case management process</strong>: Is presented in a series of charts (Mnemonic: <strong>A Case Is Treated &amp; Care Given</strong>).</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Assess the young infant or child</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Classify the illness</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Identify the treatment</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Treat the infant or child</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Counsel the mother</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Give follow-up care</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Example - <strong>IMNCI</strong> guidelines for <strong>Pneumonia</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Textbook of Community Medicine- Rajvir Bhalwar (4<sup>th</sup> edition) (page 428)</strong></span></span></p>",
    "correct_choice_id": 6554,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 1641,
    "choices": [
      {
        "id": 6559,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Very severe disease</span></span></p>"
      },
      {
        "id": 6560,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Severe pneumonia</span></span></p>"
      },
      {
        "id": 6561,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Pneumonia</span></span></p>"
      },
      {
        "id": 6562,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">No pneumonia- cough or cold</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">In a pediatric clinic, a medical resident is evaluating a series of infants under 2 months old as part of an initiative to enhance early disease detection and management. The resident is utilizing the Integrated Management of Neonatal and Childhood Illnesses (IMNCI) guidelines to classify the severity of illnesses in these young patients. While discussing the cases with a senior pediatrician, the resident is asked to identify which classification is not typically used in the IMNCI guidelines for infants less than 2 months old.</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Which of the following is NOT a classification under the IMNCI for this age group?</span></span></p>",
    "unique_key": "Q2945086",
    "question_audio": null,
    "question_video": null,
    "map_id": 34178,
    "difficulty_level": "difficult",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. Pneumonia</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C: </strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">In the <strong>IMNCI classification</strong> for <strong>infants less than 2 months old</strong>, the specific category of <strong>&#39;Pneumonia&#39; is not used</strong>. <strong>Instead,</strong> respiratory conditions are classified as <strong>&#39;Severe pneumonia&#39; or &#39;Very severe disease.&#39;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Very severe disease</strong>: <strong>Incorrect</strong>. This includes <strong>critical signs</strong> like&nbsp;<strong>Stopped feeding well</strong>, <strong>convulsions</strong>, abnormally sleepy or<strong> difficult</strong> to <strong>wake</strong>, <strong>stridor</strong> in <strong>calm</strong> <strong>child, wheezing</strong> </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Severe pneumonia: Incorrect</strong>. &#39;Severe pneumonia&#39; characterized by symptoms like <strong>chest indrawing</strong> and <strong>fast breathing</strong> (<strong>60 per minute or more</strong>)</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. No pneumonia-cough or cold:</strong> <strong>Incorrect</strong>. This term is <strong>used</strong> when an <strong>infant </strong>presents with a <strong>cough or cold</strong> but <strong>does not</strong> show <strong>signs of pneumonia</strong> or <strong>very severe disease</strong> i.e.&nbsp;<strong>No </strong>severe <strong>chest indrawing</strong> and <strong>no fast breathing.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>IMNCI</strong> guidelines for <strong>pneumonia</strong> (NEW, 2017 Guideline)</span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">If <strong>0-2 months</strong> old <strong>Young Infant</strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">&bull; Count the <strong>breaths </strong>(recount, if <strong>&gt;60/min</strong>)<br />\r\n&bull; Look for <strong>severe</strong> <strong>chest indrawing</strong>.&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:14px\"><span style=\"font-family:Georgia,serif\">&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:14px\"><span style=\"font-family:Georgia,serif\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/28/image_bI6qll7.png\" style=\"height:142px; width:540px\" /></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">2 month - 5 year child</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-154152.png\" style=\"height:1246px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">In the <strong>IMNCI </strong>classification for <strong>infants less than 2 months</strong> old, the specific category of &#39;<strong>Pneumonia</strong>&#39; is <strong>not used.</strong> Instead, <strong>respiratory conditions</strong> are <strong>classified</strong> as <strong>&#39;Severe pneumonia&#39; or &#39;Very severe disease.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 187)</strong></span></span></p>",
    "correct_choice_id": 6561,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 1670,
    "choices": [
      {
        "id": 6675,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Pneumonia</span></span></p>"
      },
      {
        "id": 6676,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Diarrhoea</span></span></p>"
      },
      {
        "id": 6677,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Dengue</span></span></p>"
      },
      {
        "id": 6678,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Meningitis</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">During a public health policy meeting, a medical resident reviewed various initiatives and campaigns launched to combat significant health issues in children. One of the initiatives discussed is the SAANS campaign, launched in November 2019. The resident is tasked with identifying the specific disease targeted by the SAANS initiative, as understanding these campaigns is crucial for effective public health planning and patient education. The SAANS initiative, launched in November 2019, was aimed at combating which disease?</span></span></p>",
    "unique_key": "Q8744650",
    "question_audio": null,
    "question_video": null,
    "map_id": 34152,
    "difficulty_level": "beginner",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A. Pneumonia</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>SAANS</strong> Campaign <strong>2019</strong> (Launched on <strong>16th November 2019</strong>)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>SAANS</strong>: <strong>Social Awareness and Action plan to Neutralise pneumonia Successfully&nbsp;</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Target: To <strong>reduce Childhood mortality</strong> due to <strong>Pneumonia</strong> to <strong>less</strong> than <strong>3 per</strong> <strong>1000 Live Birth by 2025</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Objectives:</span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Awareness in community</strong></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Awareness of care</strong> gives to <strong>identify early</strong></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Dispels myths</strong> and <strong>notions and trigger</strong> behaviour change</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Target beneficiaries:</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Primary beneficiaries: All care givers, Mothers, Fathers</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Secondary beneficiaries: Key Opinion Leaders (Gram Panchayat Leaders, Local Administration, Religious Leaders, Village Health Sanitation and Nutrition Committee Members, ICDS, Private practitioners)</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:14px\"><span style=\"font-family:Georgia,serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/12/picture22.jpg\" style=\"height:164px; width:300px\" />&nbsp;<img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/19/image_4j10Igd.png\" style=\"height:174px; width:404px\" /></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>SAANS</strong> Campaign <strong>2019</strong> - for <strong>Childhood Pneumonia.&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u>:https://nhm.gov.in/index1.php?lang=1&amp;level=4&amp;sublinkid=1336&amp;lid=716</strong></span></span></p>",
    "correct_choice_id": 6675,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 1577,
    "choices": [
      {
        "id": 6303,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">5 days before onset of symptoms</span></span></p>"
      },
      {
        "id": 6304,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">3 days before onset of symptoms</span></span></p>"
      },
      {
        "id": 6305,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">1 day before onset of symptoms</span></span></p>"
      },
      {
        "id": 6306,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">From the day of onset of symptoms</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A medical resident in an internal medicine ward is managing a patient suspected of having Influenza H1N1. As part of the management plan, the resident needs to advise the patient and their family about isolation practices to prevent the spread of the virus. Understanding the communicability period of Influenza H1N1 is crucial for implementing effective infection control measures. When does a case of Influenza H1N1 typically become communicable with others?</span></span></p>",
    "unique_key": "Q4471074",
    "question_audio": null,
    "question_video": null,
    "map_id": 34179,
    "difficulty_level": "difficult",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. 1 day before onset of symptoms</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Virus</strong> is present in the <strong>nasopharynx </strong>from <strong>1 to 2 days before</strong> and <strong>1 to 2 days after onset of symptoms.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Period of Communicability</strong>: Is the <strong>time during</strong> which an <strong>infectious agent</strong> may be <strong>transferred</strong> directly/indirectly from an <strong>infected </strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>person to another person</strong>, from <strong>infected animal to man</strong> or from an <strong>infected person to animal</strong>, including <strong>arthropods</strong>.&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">An important <strong>measure of communicability</strong> is <strong>secondary attack rate.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Period of <strong>Communicability/ Infectivity</strong> of some<strong> important diseases</strong> -&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Chickenpox</strong>:<strong> 1&ndash;2 days before</strong> to <strong>4&ndash;5 days after</strong> appearance of <strong>rash</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Measles</strong>: <strong>4 days before</strong> to <strong>5 days after</strong> appearance of <strong>rash</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Rubella: 7 days before symptoms to 7 days after appearance of rash</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Mumps: 4&ndash;6 days before symptoms to 7 days thereafter</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Influenza</strong>: <strong>1&ndash;2 days before</strong> to <strong>1&ndash;2 days</strong> after <strong>onset of symptoms</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Diphtheria</strong>: <strong>14&ndash;28 days</strong> from <strong>disease onset</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Pertussis: 7 days after exposure to 3 weeks after paroxysmal stage</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Meningococccus: Until absent from nasal and throat discharges</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Tuberculosis: As long as not treated</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Poliomyelitis: 7&ndash;10 days before and after onset of symptoms</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Hepatitis A: 2 weeks before to 1 week after onset of jaundice</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Hepatitis B: Till disappearance of HBsAg &amp; appearance of anti-HBs</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Tetanus: None</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Influenza</strong> Period of <strong>Communicability/ Infectivity</strong> -&nbsp;<strong>1&ndash;2 days before</strong> to <strong>1&ndash;2 days after</strong> onset of symptoms.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 170)</strong></span></span></p>",
    "correct_choice_id": 6305,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InvestigationBased"
    ]
  },
  {
    "id": 1578,
    "choices": [
      {
        "id": 6307,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Endotoxin</span></span></p>"
      },
      {
        "id": 6308,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">O antigens</span></span></p>"
      },
      {
        "id": 6309,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Exotoxin</span></span></p>"
      },
      {
        "id": 6310,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">K antigen</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">In an infectious disease lecture, a medical resident is learning about Corynebacterium diphtheriae, the bacterium responsible for diphtheria. The discussion focuses on the factors that contribute to the virulence of this pathogen. Understanding the virulence factors of Corynebacterium diphtheriae is crucial for comprehending the pathogenesis of diphtheria and for developing effective treatment and prevention strategies.</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Which is the most important factor for determining the virulence of Corynebacterium diphtheriae?</span></span></p>",
    "unique_key": "Q1881650",
    "question_audio": null,
    "question_video": null,
    "map_id": 34180,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. Exotoxin</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The important factor <strong>determining virulence</strong> of <strong>C.diphtheria</strong> is the <strong>exotoxin.</strong> The <strong>production of exotoxin </strong>depends on a <strong>lysogenic beta phage</strong>. The <strong>diphtheria toxin</strong> <strong>inhibits protein synthesis</strong> in <strong>host cells</strong>, leading to <strong>cell death.</strong> This <strong>toxin</strong> is responsible for the <strong>major effects</strong> seen in <strong>diphtheria</strong>, including <strong>local tissue damage</strong> and <strong>systemic effects.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Note -&nbsp;<strong>Toxoids</strong> are <strong>prepared </strong>from - <strong>Exotoxins</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Some important Pointers related to&nbsp;<strong>Diphtheria</strong> -&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Causative agent: <strong>Corynebacterium diphtheriae</strong>, a <strong>gram positive non-motile </strong>organism</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Diphtheria </strong>is an <strong>endemic disease</strong> in India</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Source</strong> of infection: <strong>Case or carrier</strong></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Carriers</strong> are more important as <strong>source of infection</strong>: <strong>95%</strong> of total <strong>disease transmission.</strong></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Nasal carriers</strong> are more <strong>dangerous</strong> than throat carriers</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Incidence of carriers</strong> in a community: <strong>0.5-1%</strong></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Immunization</strong> does <strong>not</strong> prevent <strong>carrier state</strong></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Incubation Period: <strong>2-6 days</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Mode of transmission: <strong>droplet infection</strong> (main mode), <strong>directly</strong> from <strong>cutaneous lesions</strong> and <strong>fomites</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Period of Infectivity: <strong>14-28 days</strong> from <strong>onset of disease</strong>; <strong>longer</strong> for <strong>carriers&nbsp;</strong>&ndash; A case/carrier may be considered <strong>non-communicable</strong> when at least <strong>2 cultures</strong> from <strong>nose and throat</strong>, <strong>24 hrs apart, </strong>are <strong>negative</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">MC Subtype<strong>: Faucial </strong>(Tonsillar + Pharyngeal)</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option&nbsp;A. Endotoxin: </strong>Endotoxins are associated with the <strong>outer membrane</strong> of <strong>Gram-negative bacteria</strong>. <strong>Corynebacterium diphtheriae</strong> is a <strong>Gram-positive</strong> <strong>bacterium </strong>and does <strong>not</strong> produce <strong>endotoxin.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option&nbsp;B. O Antigen: </strong>&nbsp;It is a <strong>cell-wall component</strong> and important in the <strong>pathogenesis</strong> of the <strong>disease </strong>but <strong>not</strong> responsible for the <strong>major disease signs</strong> and <strong>symptoms.</strong>&nbsp;&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option&nbsp;D. K Antigen: </strong>&nbsp;It is a <strong>cell-wall component</strong> (capsular polysaccharides) and important in the <strong>pathogenesis</strong> of the<strong> disease</strong> but <strong>not </strong>responsible for the <strong>major disease signs</strong> and <strong>symptoms.&nbsp;&nbsp;</strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Most <strong>important factor</strong> for <strong>determining virulence</strong> of <strong>Corynebacterium diphtheria &ndash; Exotoxin.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Textbook of Community Medicine- Rajvir Bhalwar- 4<sup>th</sup> edition (page 749) and WHO Health topics - Diphtheria&nbsp;</strong></span></span></p>",
    "correct_choice_id": 6309,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InvestigationBased"
    ]
  },
  {
    "id": 1587,
    "choices": [
      {
        "id": 6343,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">60%</span></span></p>"
      },
      {
        "id": 6344,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">70%</span></span></p>"
      },
      {
        "id": 6345,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">80%</span></span></p>"
      },
      {
        "id": 6346,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">90%</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A medical resident in a family practice clinic is discussing influenza vaccination with patients as part of an annual public health campaign. One of the patients, a 45-year-old woman, asks about the effectiveness of the inactivated influenza vaccine. The resident recalls recent studies and guidelines to provide an informed answer, emphasizing the importance of vaccination in preventing influenza and its complications, especially in adults younger than 65 years of age. What is the effectiveness of the inactivated influenza vaccine in adults younger than 65 years of age?</span></span></p>",
    "unique_key": "Q2381585",
    "question_audio": null,
    "question_video": null,
    "map_id": 34200,
    "difficulty_level": "difficult",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A. 60%</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Inactivated influenza vaccine</strong>:&nbsp;The vaccine is about <strong>60 percent effective</strong> among <strong>healthy</strong> persons <strong>younger than 65 years</strong> of age. On vaccination, the <strong>vaccine </strong>becomes <strong>effective</strong> after <strong>14 days</strong>. The <strong>immunity lasts</strong> from <strong>6-12 months</strong>. The vaccine is <strong>50-60 percent effective</strong> in <strong>preventing hospitalization</strong> and <strong>80 percent</strong> <strong>effective </strong>in <strong>preventing death</strong> among elderly persons.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Inactivated Influenza vaccine</strong> - <strong>Trivalent Flu Vaccine</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">&bull; Protection: &ndash; <strong>Two</strong> <strong>influenza A viruses</strong> (an <strong>H1N1</strong> and an <strong>H3N2</strong>)<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ndash; An <strong>influenza B virus</strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">&bull; Types of <strong>Trivalent vaccine</strong>:<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ndash; <strong>Standard-dose</strong> trivalent shots: Approved for people of <strong>different ages.</strong><br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ndash; <strong>High-dose trivalent shot</strong>: Approved for people <strong>65 and older.</strong><br />\r\n&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &ndash; <strong>Trivalent shot</strong>: Approved for people <strong>18 and older.</strong><br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ndash; <strong>Recombinant trivalent shot</strong>: Approved for people <strong>18 years</strong> <strong>and older.</strong></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Contraindications</strong> to <strong>Inactivated Influenza vaccines -&nbsp;</strong></span></span>\r\n\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Severe <strong>allergy</strong> to <strong>chicken eggs.</strong></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">History of <strong>hypersensitivity/anaphylactic reactions</strong> previously.</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Development of <strong>Guillain-Barr&eacute; Syndrome</strong> (GBS) within <strong>6 weeks</strong> of vaccine.</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Infants less</strong> than <strong>6 month&rsquo;s age.</strong></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Moderate-to-severe illness</strong> with <strong>fever</strong>.</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>effectiveness</strong> of the <strong>inactivated influenza vaccine</strong> in <strong>adults younger</strong> than <strong>65 years of age</strong> is typically around <strong>- 50-60%.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 173)</strong></span></span></p>",
    "correct_choice_id": 6343,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "InvestigationBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 1655,
    "choices": [
      {
        "id": 6615,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Covishield vaccine</span></span></p>"
      },
      {
        "id": 6616,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Covaxin vaccine</span></span></p>"
      },
      {
        "id": 6617,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Pfizer BioNtech vaccine</span></span></p>"
      },
      {
        "id": 6618,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Moderna COVID 19 vaccine</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a seminar on the recent advancements in COVID-19 vaccine technology. One of the topics discussed is the variety of vaccine platforms used to combat the pandemic. A particular focus is given to a vaccine developed using a recombinant chimpanzee adenovirus vector. Which COVID-19 vaccine is developed using a recombinant chimpanzee adenovirus vector?</span></span></p>",
    "unique_key": "Q5596132",
    "question_audio": null,
    "question_video": null,
    "map_id": 34201,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A. Covishield vaccine</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Covishield vaccine</strong> (<strong>Oxford-AstraZeneca</strong>) is a <strong>recombinant</strong> chimpanzee adenovirus vector vaccine, administered <strong>intramuscularly</strong> in <strong>deltoid muscle</strong>. Given in <strong>two doses</strong>, <strong>28 days apart</strong>. The protective level of<strong> antibodies</strong> are generally developed <strong>two weeks after the 2nd dose</strong> of the vaccine. The vaccine has been approved for individuals <strong>18 years of age and above.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Covaxin vaccine: </strong>&nbsp;Whole <strong>Virion</strong> Inactivated vaccine, strain is &quot;<strong>Niv-2020-770</strong>&quot;.&nbsp; Manufactured by <strong>Bharat Biotech BSL-3 facility</strong> &amp; <strong>ICMR</strong> &amp; <strong>NIV</strong> (<strong>100</strong>% Indigenous vaccine of India). This is for Individuals <strong>&ge;18</strong> years old, given in <strong>2 doses</strong> (<strong>0.5</strong> mL each) <strong>4-6</strong> weeks apart (Route - ONLY Intramuscular, at <strong>Deltoid muscle</strong>).&nbsp;Protective efficacy is <strong>86-96%.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. Pfizer BioNTech vaccine:</strong>&nbsp;<strong>mRNA</strong> vaccine. It uses <strong>messenger RNA</strong> to instruct cells to produce the <strong>spike protein</strong> of the virus, <strong>triggering</strong> an <strong>immune response</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Moderna COVID-19 vaccine:</strong> Similar to the <strong>Pfizer BioNTech vaccine,</strong> this is also an <strong>mRNA vaccine</strong> and <strong>operates</strong> on the <strong>same principle.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Covishield vaccine</strong> is a <strong>recombinant</strong> chimpanzee <strong>adenovirus</strong> vector vaccine</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Comparison of some important COVID vaccines </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-125437.png\" style=\"height:825px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 203)</strong></span></span></p>",
    "correct_choice_id": 6615,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InvestigationBased"
    ]
  },
  {
    "id": 1714,
    "choices": [
      {
        "id": 6849,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">5 days</span></span></p>"
      },
      {
        "id": 6850,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">15 days</span></span></p>"
      },
      {
        "id": 6851,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">10 days</span></span></p>"
      },
      {
        "id": 6852,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">28 days</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A public health officer is working on a cholera outbreak response in a region. One of the key aspects of managing the outbreak is determining when the area can be declared free of cholera. This involves understanding the criteria based on the time elapsed since the last confirmed case. The officer is reviewing these criteria to ensure that the declaration of cholera freedom in the area is based on sound epidemiological principles and to plan for post-outbreak surveillance. When can an area be declared free of cholera after the death or isolation of the last confirmed case?</span></span></p>",
    "unique_key": "Q9740370",
    "question_audio": null,
    "question_video": null,
    "map_id": 34199,
    "difficulty_level": "difficult",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. &nbsp;C. 10 days</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>An area</strong> is declared <strong>free of cholera</strong> when <strong>twice</strong> the <strong>incubation period</strong> (i.e., <strong>10 days</strong>) has <strong>elapsed</strong> since the <strong>death, recovery or isolation</strong> of the <strong>last case</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Incubation period</strong> of <strong>Cholera</strong> - <strong>1&ndash;2 days</strong> (Few hours&ndash;5 days)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Guidelines for Cholera Control (WHO)</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Verification of diagnosis</strong>:</span></span>\r\n\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Identifying <strong>Vibrio cholerae 01 in stools</strong> of <strong>few patients</strong> is <strong>sufficient</strong></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">It is <strong>&lsquo;not</strong> necessary to <strong>culture stools</strong> of <strong>all cases or contacts&rsquo;</strong></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Notification:</strong></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Cholera</strong> is a notifiable disease <strong>locally, nationally and internationally</strong></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Under <strong>International Health Regulations, Cholera</strong> is notifiable to <strong>WHO </strong>by <strong>national govt</strong> within <strong>24 hours</strong> (<strong>no. of cases &amp; deaths</strong> to be reported <strong>daily and weekly)</strong></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">An <strong>area</strong> is <strong>declared free of Cholera</strong> when <strong>twice</strong> the <strong>IP </strong>has <strong>elapsed since last case.</strong></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Early case</strong> finding: through <strong>aggressive case</strong> search&nbsp;</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Establishment</strong> of <strong>treatment centres</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Rehydration</strong> therapy: through <strong>ORS</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Adjuncts</strong> to therapy: Only <strong>antibiotics</strong> may be used when <strong>vomiting stops</strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-114333.png\" style=\"height:464px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Epidemiological investigations</strong>: General <strong>sanitation</strong> measures, epidemiological studies </span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Sanitation measures: <strong>Water control, excreta disposal, food sanitation, disinfection</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Chemoprophylaxis:</strong></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Mass</strong> chemoprophylaxis is <strong>not advised</strong> for <strong>total community</strong>; is only advisable for <strong>household contacts</strong> or a<strong>&nbsp;closed community</strong>.</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Drug of choice</strong> for chemoprophylaxis: <strong>Tetracycline</strong></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>To prevent</strong> one case of cholera, <strong>10,000</strong> persons need to be given <strong>chemoprophylaxis.</strong></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Vaccination</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Health education</strong>: <strong>Most effective</strong> prophylactic measure</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">An area is <strong>declared free of Cholera</strong> when <strong>twice</strong> the <strong>IP </strong>has <strong>elapsed since last</strong> <strong>case </strong>(i.e<strong>. 10 days</strong>)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 270)</strong></span></span></p>",
    "correct_choice_id": 6851,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 1992,
    "choices": [
      {
        "id": 7961,
        "text": "<p><span style=\"font-size:12pt;\">Food safety</span></p>"
      },
      {
        "id": 7962,
        "text": "<p><span style=\"font-size:12pt;\">Immunisation with whole cell killed parenteral vaccine</span></p>"
      },
      {
        "id": 7963,
        "text": "<p><span style=\"font-size:12pt;\">Proper excreta disposal</span></p>"
      },
      {
        "id": 7964,
        "text": "<p><span style=\"font-size:12pt;\">Super chlorination of water</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">An epidemiologist working with a global health organization is developing a training module on outbreak response strategies for various infectious diseases. One of the diseases being focused on is cholera, known for its potential to cause rapid and severe outbreaks, especially in areas with poor water and sanitation facilities. The training module aims to outline the key steps and interventions necessary for an effective response to a cholera outbreak. However, it is also important to clarify common misconceptions about what should not be included in these response strategies. The epidemiologist is preparing a question to test the trainees' understanding of these concepts. In the context of an effective response strategy for a cholera outbreak, which of the following steps is NOT typically recommended?</span></p><p>&nbsp;</p>",
    "unique_key": "Q6727905",
    "question_audio": null,
    "question_video": null,
    "map_id": 34189,
    "difficulty_level": "beginner",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. &nbsp;B. Immunisation with whole cell killed parenteral vaccine</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Mass vaccination</strong> is <strong>not</strong> recommended in an <strong>outbreak of cholera.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Guidelines for <strong>Cholera Control (WHO):</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Verification of diagnosis:</span><ul><li><span style=\"font-size:12pt;\">Identifying <strong>Vibrio cholerae 01</strong> in <strong>stools</strong> of <strong>few patients</strong> is sufficient.</span></li><li><span style=\"font-size:12pt;\">It is \u2018<strong>not necessary</strong> to <strong>culture</strong> stools of <strong>all cases or contacts\u2019.</strong></span></li></ul></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Notification:</span></p><ul><li><p style=\"text-align:justify;\"><strong>Cholera</strong> is a notifiable <strong>disease locally, nationally and internationally.</strong></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Under <strong>International Health Regulations</strong>, <strong>Cholera</strong> is notifiable to WHO by <strong>National Govt</strong> within <strong>24 hours</strong> (no. of cases &amp; deaths&nbsp;to be reported daily and weekly).</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">An area is declared <strong>free of Cholera</strong> when <strong>twice</strong> the <strong>IP</strong> has <strong>elapsed</strong> since <strong>last case.</strong></span></p></li></ul></li><li><span style=\"font-size:12pt;\">Early case finding: through aggressive case search&nbsp;</span></li><li><span style=\"font-size:12pt;\">Establishment of treatment centres</span></li><li><span style=\"font-size:12pt;\">Rehydration therapy: through <strong>ORS</strong></span></li><li><span style=\"font-size:12pt;\">Adjuncts to therapy: Only <strong>antibiotics</strong> may be used when <strong>vomiting stops.</strong></span></li></ul><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-114613.png\" alt=\"\" width=\"1000\" height=\"803\"></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>Epidemiological investigations</strong>: <strong>General sanitation</strong> measures, <strong>epidemiological studies</strong>.</span></li><li><span style=\"font-size:12pt;\"><strong>Sanitation</strong> measures: <strong>Water control, excreta disposal</strong>, food sanitation, disinfection</span><ul><li><span style=\"font-size:12pt;\"><strong>Chemoprophylaxis:</strong></span></li><li><span style=\"font-size:12pt;\">Mass chemoprophylaxis is <strong>not advised</strong> for <strong>total community</strong>; is only advisable for <strong>household contacts</strong> or a&nbsp;<strong>closed community.</strong></span></li><li><span style=\"font-size:12pt;\"><strong>Drug of choice</strong> for chemoprophylaxis: <strong>Tetracycline</strong></span></li></ul></li><li><span style=\"font-size:12pt;\">To <strong>prevent one case of cholera</strong>, <strong>10,000 persons</strong> need to be given <strong>chemoprophylaxis.</strong></span></li><li><span style=\"font-size:12pt;\"><strong>Health education</strong>: <strong>most effective</strong> prophylactic measure</span></li><li><span style=\"font-size:12pt;\">Vaccination -&nbsp;<strong>Mass vaccination</strong> is <strong>not </strong>recommended</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\">CHOLERA ORAL VACCINES</span></p><p>&nbsp;</p><ol><li><span style=\"font-size:12pt;\"><strong>Dukoral</strong>*&nbsp;(WC-rBS): <strong>Monovalent</strong>, <strong>V cholera O1</strong> plus Recombinant <strong>toxin B</strong> subunit</span></li><li><span style=\"font-size:12pt;\"><strong>Sanchol</strong>: <strong>Bivalent,</strong> <strong>Serogroups O1 &amp; O139</strong>, No toxin B subunit, No buffer required</span></li><li><span style=\"font-size:12pt;\"><strong>mORCVAX</strong>: <strong>Bivalent, Serogroups O1 &amp; O139</strong>, No toxin B subunit, No buffer required</span></li><li><span style=\"font-size:12pt;\"><strong>CVD103-HgR</strong>: <strong>Live attenuated, single dose</strong>, <strong>not</strong> produced now</span></li></ol><p>&nbsp;</p><p><span style=\"font-size:12pt;\">*<strong>Dukoral</strong>\u00ae&nbsp;is mainly used for <strong>travellers</strong>. <strong>Two doses</strong> of Dukoral\u00ae provide <strong>protection </strong>against <strong>cholera</strong> <strong>for 2 years.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Steps</strong> taken during an <strong>outbreak of cholera</strong> - <strong>Verification</strong> of <strong>diagnosis</strong>, <strong>Notification</strong>, <strong>early case</strong> finding, <strong>treatment &amp; chemoprophylaxis</strong> for <strong>household contacts,</strong> <strong>sanitation</strong> measures and <strong>health education.</strong>&nbsp;</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Mass vaccination</strong> is <strong>not</strong> recommended.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Textbook of Community Medicine- Rajvir Bhalwar- 4<sup>th</sup> edition (page 680)</strong></span></p>",
    "correct_choice_id": 7962,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "InvestigationBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 1994,
    "choices": [
      {
        "id": 7969,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Dukoral</span></span></p>"
      },
      {
        "id": 7970,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Euvichol</span></span></p>"
      },
      {
        "id": 7971,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Lakichol</span></span></p>"
      },
      {
        "id": 7972,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Sanchol</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A nurse educator is conducting a training session for a group of nursing students who are about to start their clinical rotations in a travel medicine clinic. The focus of the session is on vaccines, particularly those administered orally, as travellers often seek advice on preventive measures against diseases like cholera. The educator wants to ensure that the students can correctly identify which oral vaccines are specifically for cholera and which are not, as this knowledge is crucial for providing accurate travel health advice. In the context of travel medicine, which of the following oral vaccines is NOT used for the prevention of cholera?</span></span></p>",
    "unique_key": "Q3520123",
    "question_audio": null,
    "question_video": null,
    "map_id": 34191,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. Lakichol</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>CHOLERA ORAL VACCINES</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Dukoral (WC-rBS):</strong> <strong>Monovalent, V cholera O1 plus</strong> <strong>Recombinant toxin B subunit.</strong>&nbsp;Dukoral&reg;&nbsp;is mainly used for <strong>travellers</strong>.<strong> Two doses of Dukoral</strong>&reg; provide <strong>protection</strong> against <strong>cholera for 2 years</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B.&nbsp; Euvichol and&nbsp;Option D. Sanchol: Bivalent</strong>, <strong>Serogroups O1 &amp; O139</strong>, <strong>No toxin B subunit</strong>, <strong>No buffer</strong> required Shanchol&trade; and Euvichol&reg; are&nbsp;essentially the <strong>same vaccine</strong> produced by <strong>two different manufacturers</strong>. They <strong>do not</strong> require a <strong>buffer solution</strong> for <strong>administration.</strong> They are given to <strong>all individuals</strong> <strong>over </strong>the age of <strong>one year</strong>.&nbsp;<strong>Shanchol&trade; and&nbsp;<em>Euvichol</em>&reg;</strong> provide protection against <strong>cholera</strong> for <strong>3 years</strong>, while a <strong>single dose</strong> provides <strong>short term</strong> <strong>protection</strong>.&nbsp;Shanchol&trade; and Euvichol&reg; are the vaccines currently available for <strong>mass vaccination</strong> campaigns through the <strong>Global OCV Stockpile</strong>, which is <strong>supported </strong>by <strong>Gavi,</strong> the Vaccine Alliance.&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Other Vaccines: </strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Morcvax</strong>: <strong>Bivalent,</strong> Serogroups <strong>O1 &amp; O139</strong>, <strong>No toxin B subunit</strong>, <strong>No buffer</strong> required</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>CVD103-HgR</strong>: <strong>Live attenuated, single dose</strong>, NOT produced now</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Three types of <strong>oral cholera vaccines</strong> are available: (A) Dukoral (WC-rBS). (D) Sanchol and mORCVAX and (B) Euvichol. The live attenuated single-dose vaccine (CVD103-HgR) is no longer produced.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 267)</strong></span></span></p>",
    "correct_choice_id": 7971,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 1997,
    "choices": [
      {
        "id": 7981,
        "text": "<p><span style=\"font-size:12pt;\">Blood culture</span></p>"
      },
      {
        "id": 7982,
        "text": "<p><span style=\"font-size:12pt;\">Gastric aspirate</span></p>"
      },
      {
        "id": 7983,
        "text": "<p><span style=\"font-size:12pt;\">Stool culture</span></p>"
      },
      {
        "id": 7984,
        "text": "<p><span style=\"font-size:12pt;\">Widal test</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">A medical researcher is reviewing diagnostic protocols for various bacterial infections. One of the conditions under discussion is typhoid fever, caused by Salmonella typhi. Accurate and timely diagnosis is crucial for the effective management of typhoid fever. The researcher is learning about the various methods used to diagnose this condition and is asked to identify the mainstay of diagnosis for typhoid fever.&nbsp;What is the mainstay of diagnosis for typhoid fever?</span></p>",
    "unique_key": "Q8109176",
    "question_audio": null,
    "question_video": null,
    "map_id": 34194,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A. Blood culture</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Blood culture</strong> is the <strong>mainstay</strong> of <strong>diagnosis of Typhoid culture</strong>.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Blood culture</strong> is the <strong>gold standard</strong> for diagnosing <strong>typhoid fever</strong>, especially in the <strong>early stages&nbsp;(first week)</strong> of the illness. It has <strong>high specificity and sensitivity,</strong> although the yield can <strong>decrease</strong> as the <strong>disease progresses</strong> or if the patient has <strong>taken antibiotics</strong>.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u>&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Gastric aspirate:&nbsp;</strong> Not used due to low yield</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. Stool Culture</strong>: &nbsp;Stool cultures can be used for the <strong>diagnosis</strong> of <strong>typhoid fever,</strong> particularly in the <strong>later stages (3rd week)</strong> of the disease.&nbsp;</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option D. Widal test: </strong>The Widal test, which measures <strong>agglutinating antibody levels</strong> against <strong>Salmonella antigens</strong>, It has&nbsp;<strong>Moderate sensitivity &amp; specificity</strong>.&nbsp; It is used in settings where <strong>blood culture</strong> facilities are <strong>not</strong> available.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Mainstay of diagnosis of Typhoid fever - Blood Culture</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Laboratory Diagnosis: <strong>\u2018BASU\u2019</strong> Mnemonic</span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-124354.png\" alt=\"\" width=\"1000\" height=\"814\"></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Park 26<sup>th</sup> edition (page 273)</strong></span></p>",
    "correct_choice_id": 7981,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "InvestigationBased"
    ]
  },
  {
    "id": 1998,
    "choices": [
      {
        "id": 7985,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Heat killed whole cell vaccine</span></span></p>"
      },
      {
        "id": 7986,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Live oral vaccine</span></span></p>"
      },
      {
        "id": 7987,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Typhoid conjugate vaccine</span></span></p>"
      },
      {
        "id": 7988,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">None of the above</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">During a session on vaccine-preventable diseases in a medical school, a professor is discussing various vaccines used for the prevention of typhoid fever. Typhoid fever, caused by Salmonella typhi, can be effectively prevented with vaccination. However, not all types of vaccines are used for this purpose. The professor presents a question to the medical students to identify which of the listed vaccines is not typically used for the prevention of typhoid fever. Which of the following vaccines is NOT used for the prevention of typhoid fever?</span></span></p>",
    "unique_key": "Q6463757",
    "question_audio": null,
    "question_video": null,
    "map_id": 34195,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A. Heat killed whole cell vaccine</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>old parenteral killed whole-cell vaccine</strong> was <strong>effective</strong> but produced <strong>strong</strong> <strong>side-effects</strong>. <strong>Two safe and effective vaccines</strong> are now <strong>licensed and available.</strong> One is <strong>based</strong> on <strong>defined subunit antigens</strong>, the <strong>other</strong> on <strong>whole-cell live attenuated bacteria</strong>. <strong>Vi polysaccharide vaccine</strong> and <strong>Ty21a vaccine</strong> are used now.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. &nbsp;Live Oral Vaccine</strong>: &nbsp;<strong>Typhoral Ty21a vaccine</strong>.&nbsp;Contains <strong>&gt;109</strong> viable organism of <strong>attenuated S. typhi</strong>.&nbsp;Schedule: One capsule each on <strong>days 1, 3, 5</strong> (<strong>booster</strong> of <strong>3 doses</strong>, <strong>once</strong> every <strong>3 years</strong>).</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. &nbsp;Typhoid conjugate vaccine</strong> -&nbsp;<strong>TYPHIM Vi</strong> Vaccine.&nbsp;<strong>Vi- Polysaccharide</strong> containing <strong>single</strong> dose <strong>I/m or subcutaneous.</strong>&nbsp;<strong>Not</strong> given in age <strong>&lt; 2 years.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Two safe and effective</strong> vaccines are now <strong>licensed</strong> and <strong>available</strong> against <strong>typhoid - Vi polysaccharide vaccine</strong> and <strong>Ty21a vaccine</strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Immunization for Typhoid Fever -</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-123808.png\" style=\"height:608px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 275)</strong></span></span></p>",
    "correct_choice_id": 7985,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 1999,
    "choices": [
      {
        "id": 7989,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Is orally administered.</span></span></p>"
      },
      {
        "id": 7990,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Given for individuals aged more than 2 years.</span></span></p>"
      },
      {
        "id": 7991,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">3 dose regimen is recommended on alternate days.</span></span></p>"
      },
      {
        "id": 7992,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Protective immunity is achieved 7 days after last dose.</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An infectious disease specialist is giving a lecture to medical students about various vaccination strategies for preventing globally prevalent diseases. The discussion includes vaccines that are not routinely administered in all countries but are crucial for specific diseases in endemic areas or for travelers. A focus of the lecture is on the Ty21a vaccine for typhoid fever. The specialist aims to test the students&#39; understanding of the unique attributes of the Ty21a vaccine, particularly how it differs from other common vaccines in terms of administration and scheduling. In a lecture about vaccination strategies against typhoid fever, which point should the infectious disease specialist emphasize to highlight a unique characteristic of the Ty21a vaccine?</span></span></p>",
    "unique_key": "Q5466553",
    "question_audio": null,
    "question_video": null,
    "map_id": 34196,
    "difficulty_level": "difficult",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. B. Given for individuals aged more than 2 years.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The vaccine is <strong>licensed</strong> for use in <strong>individual aged &gt; 5 years.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Other 3 options</strong> are <strong>correct</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ty21a vaccine:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Orally administered (Option A)</strong> <strong>live attenuated</strong>, <strong>lyophilized </strong>vaccine for Typhoid.&nbsp; Contains <strong>&gt;10<sup>9 </sup>viable organism</strong> of <strong>attenuated S. typhi.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>capsules</strong> are <strong>licensed</strong> for use in individuals <strong>aged &gt;5 years. </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>vaccine</strong> is <strong>administered</strong> every other day; on <strong>1, 3, and 5th day</strong>; a <strong>3-dose</strong> <strong>regimen </strong>is recommended<strong>. (Option C)</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">With the <strong>3-dose regimen</strong>, protective <strong>immunity</strong> is achieved <strong>7 days after</strong> the <strong>last dose</strong>. <strong>(Option D)</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>recommendation</strong> is to repeat this series every <strong>3 years</strong> for people living in <strong>endemic areas</strong>, and <strong>every year</strong> for <strong>individuals travelling</strong>; from <strong>non-endemic</strong> to <strong>endemic countries</strong>. </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>Ty21a vaccine</strong> may be given <strong>simultaneously</strong> with <strong>other vaccines</strong>, including <strong>live vaccines</strong> against <strong>polio, cholera, and yellow fever</strong>, or the <strong>measles, mumps</strong> and <strong>rubella (MMR)</strong> combination.</span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Note - <strong>Stop Proguanil</strong> and <strong>antibacterial drugs 3 days before</strong> and until <strong>3 days</strong> <strong>later of administration.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Immunization for Typhoid Fever</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/24/screenshot-2024-08-24-155851.png\" style=\"height:606px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ty21a vaccine</strong> -&nbsp;<strong>Orally</strong> administered, <strong>live attenuated, lyophilized vaccine</strong>, for individuals aged <strong>&gt;5 years</strong>,&nbsp;<strong>3-dose regimen</strong> (administered every other day </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">on <strong>1, 3, and 5th day</strong>),&nbsp;<strong>protective immunity</strong> is achieved <strong>7 days after the last dose</strong>. &nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 275)</strong></span></span></p>",
    "correct_choice_id": 7990,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 2000,
    "choices": [
      {
        "id": 7993,
        "text": "<p><span style=\"font-size:12pt;\">Campylobacter</span></p>"
      },
      {
        "id": 7994,
        "text": "<p><span style=\"font-size:12pt;\">Clostridium</span></p>"
      },
      {
        "id": 7995,
        "text": "<p><span style=\"font-size:12pt;\">Salmonella</span></p>"
      },
      {
        "id": 7996,
        "text": "<p><span style=\"font-size:12pt;\">Staphylococcus</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">A group of individuals presented to a clinic with symptoms of abdominal cramps, diarrhea, and vomiting approximately 2 hours after consuming a milkshake from a local eatery. As a medical resident in gastroenterology, you are tasked with determining the most likely etiological agent responsible for these symptoms. Given the rapid onset of symptoms and the nature of the consumed product, you consider various foodborne pathogens that could be involved. Based on the symptoms and their rapid onset following the consumption of a milkshake, what is the most likely etiological agent responsible for the illness in these individuals?</span></p>",
    "unique_key": "Q6563939",
    "question_audio": null,
    "question_video": null,
    "map_id": 34197,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. D. Staphylococcus</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Staphylococcal </strong>food poisoning: (<strong>MC Food Poisoning</strong>)</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Agent: <strong>Enterotoxins</strong> of Staphylococcus aureus</span><br>&nbsp;</p><p><span style=\"font-size:12pt;\">Toxins formed at <strong>35\u00b0\u201337\u00b0 C&nbsp;</strong></span><br>&nbsp;</p><p><span style=\"font-size:12pt;\">Toxins are relatively <strong>heat stable</strong> and <strong>resist</strong> <strong>boiling</strong> for <strong>30 min</strong> or more</span><br>&nbsp;</p><p><span style=\"font-size:12pt;\">Incubation period: <strong>1\u20136 hours</strong>.</span><br>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>IP</strong> is <strong>short</strong> because of \u2018<strong>preformed toxin\u2019</strong></span><br>&nbsp;</p><p><span style=\"font-size:12pt;\">Mechanism of food poisoning: <strong>Intra-dietetic toxins</strong> (ingestion of toxins <strong>pre-formed</strong> in <strong>food</strong>, in which <strong>bacteria</strong> have <strong>grown</strong>)</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The foods involved are <strong>salads, custards, milk and milk products</strong> which get contaminated by <strong>staphylococci.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u>&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. Campylobacter:&nbsp;</strong> An infection caused by <strong>gram negative bacteria</strong> usually from<strong> contaminated food and water.</strong> &nbsp;Infections are often associated with international travel, <strong>undercooked poultry, unpasteurized milk, untreated</strong> <strong>water, and contact</strong> with <strong>farm animals</strong>. It causes <strong>diarrhea</strong>&nbsp;which may be <strong>bloody,</strong> <strong>cramping, abdominal pain, and fever</strong>&nbsp;within <strong>two to five days</strong> after exposure to the bacteria<strong>. Nausea</strong> (a feeling of sickness in the stomach) and <strong>vomiting</strong> may also occur. The illness typically <strong>lasts</strong> about <strong>one week.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option</strong> <strong>B. Clostridium 2 types: &nbsp;Botulism food poisoning</strong> by <strong>Clostridium botulinum</strong> type <strong>A, B, E</strong>;&nbsp;<strong>IP 12\u201336 hours</strong>;&nbsp;food poisoning is due to&nbsp;<strong>Intra-dietetic</strong> <strong>toxins</strong>; prominent symptoms are&nbsp;<strong>Dysphagia,&nbsp;Diplopia and&nbsp;Dysarthria</strong>&nbsp;(GIT SYMPOTOMS ARE SLIGHT).</span></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Clostridium perfringens food poisoning</strong> by&nbsp;<strong>Clostridium perfringens</strong> (welchii);&nbsp;<strong>IP&nbsp;6\u201324 hours</strong>, found&nbsp;on <strong>raw meat and poultry</strong>, in the <strong>soil</strong>, <strong>excreta</strong>.&nbsp;Symptoms are <strong>watery diarrhea and abdominal cramps</strong>.<strong>&nbsp;Rapid recovery</strong> with <strong>no deaths.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option C. Salmonella:</strong> Salmonella bacteria spread by&nbsp;<strong>improper handling</strong> and <strong>cooking of food</strong>. Occurs by <strong>eating contaminated food</strong> such as <strong>undercooked pork</strong> and <strong>poultry meat, dairy products</strong> made from <strong>unpasteurized milk</strong>, <strong>chocolate</strong> or <strong>raw fruit and vegetables</strong>. IP <strong>12-24 hr</strong>.&nbsp;<strong>Some people</strong> with salmonella infection have <strong>no symptoms</strong>. Most people <strong>develop diarrhea</strong>, <strong>fever and stomach</strong> (abdominal) <strong>cramps</strong> within <strong>12 to 72 hours</strong> after exposure. Most<strong> healthy</strong> people <strong>recover within a few days</strong> to a <strong>week</strong> without specific treatment.</span></p><p><span style=\"font-size:12pt;\"><strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong></span></p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Incubation period of food poisoning:&nbsp;</strong></span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-123108_XcxG8VU.png\" alt=\"\" width=\"1000\" height=\"537\"></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Some food poisoning causing organisms</strong></span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-123453.png\" alt=\"\" width=\"1000\" height=\"546\"></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Park 26<sup>th</sup> edition (page 276)</strong></span></p>",
    "correct_choice_id": 7996,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 2010,
    "choices": [
      {
        "id": 8033,
        "text": "<p><span style=\"font-size:12pt;\">i- c, ii- b, iii- a, iv-d</span></p>"
      },
      {
        "id": 8034,
        "text": "<p><span style=\"font-size:12pt;\">i- c, ii- a, iii- b, iv-d</span></p>"
      },
      {
        "id": 8035,
        "text": "<p><span style=\"font-size:12pt;\">i- d, ii- b, iii- a, iv-c</span></p>"
      },
      {
        "id": 8036,
        "text": "<p><span style=\"font-size:12pt;\">i- d, ii- a, iii- b, iv-c</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">As part of an epidemiology class focusing on foodborne illnesses, medical students are learning about various pathogens and their associated incubation periods. Understanding these incubation periods is crucial for diagnosing foodborne illnesses and identifying the likely causative agents. The professor has provided a list of common foodborne pathogens and a separate list of their typical incubation periods. The students are asked to match each pathogen with its corresponding incubation period. Task: Match the following pathogens with their respective incubation periods for food poisoning.</span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-120803.png\" alt=\"\" width=\"1000\" height=\"320\"></p>",
    "unique_key": "Q1354522",
    "question_audio": null,
    "question_video": null,
    "map_id": 34202,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A. i- c, ii- b, iii- a, iv-d</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Incubation Period of Food Poisonings&nbsp;</span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-123108.png\" alt=\"\" width=\"1000\" height=\"537\"></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Some Important Pointers on Food Poisoning -&nbsp;</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>MC food poisoning</strong> - <strong>Staphylococcus</strong></span></li><li><span style=\"font-size:12pt;\">Food poisoning in <strong>less than 6 hours</strong> - <strong>Staphylococcal FP</strong></span></li><li><span style=\"font-size:12pt;\">Prominent symptoms in <strong>Botulism FP:</strong> <strong>Dysphagia,&nbsp;Diplopia,&nbsp;Dysarthria</strong> (GIT sympotoms are slight)</span></li><li><span style=\"font-size:12pt;\"><strong>Food poisoning</strong> is an example of: <strong>Common source, single exposure epidemic.</strong></span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Incubation period</strong> of <strong>food poisoning</strong>: <strong>Salmonella 12\u201324 hours</strong>, <strong>Staphylococcal 1\u20136 hours, Botulism 12\u201336 hours, Cl. perfirengens 6\u201324 hours, B. cereus</strong> (emetic form) <strong>1\u20136 hours</strong>, <strong>B. cereus</strong> (diarrhoel form) <strong>12\u201324 hours</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref:</u> Park 26<sup>th</sup> edition (page 277)</strong></span></p>",
    "correct_choice_id": 8033,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "ImageBased",
      "InvestigationBased"
    ]
  },
  {
    "id": 2013,
    "choices": [
      {
        "id": 8045,
        "text": "<p><span style=\"font-size:12pt;\">Both affected and not affected persons are interviewed</span></p>"
      },
      {
        "id": 8046,
        "text": "<p><span style=\"font-size:12pt;\">Hospitalized persons are interviewed</span></p>"
      },
      {
        "id": 8047,
        "text": "<p><span style=\"font-size:12pt;\">Only affected persons are interviewed</span></p>"
      },
      {
        "id": 8048,
        "text": "<p><span style=\"font-size:12pt;\">Only not affected persons are interviewed</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">A medical resident is participating in an epidemiology training focused on the investigation of food poisoning outbreaks. Understanding the investigative process is crucial for identifying the source of the outbreak, implementing control measures, and preventing future occurrences. The training covers various aspects of outbreak investigation, including the identification of the pathogen, interviewing affected individuals, and inspecting food handling facilities. The resident is asked to identify a true statement regarding the investigation of a food poisoning outbreak. Which of the following statements is true regarding the investigation of a food poisoning outbreak?</span></p>",
    "unique_key": "Q2748316",
    "question_audio": null,
    "question_video": null,
    "map_id": 34203,
    "difficulty_level": "beginner",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A. Both affected and not affected persons are interviewed</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u>&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Getting <strong>food history</strong> about <strong>suspected meal in a food poisoning</strong> outbreak:</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>List of each and every dish</strong> which was <strong>served</strong> during that <strong>meal </strong>is <strong>made.</strong></span></li><li><span style=\"font-size:12pt;\"><strong>Each </strong>and <strong>every person</strong> who <strong>attended the meal</strong> is <strong>interviewed.</strong></span></li><li><span style=\"font-size:12pt;\"><strong>History of consumption</strong> of each and every <strong>food item</strong> that was <strong>served </strong>during that <strong>meal is noted.</strong></span></li><li><span style=\"font-size:12pt;\"><strong>Information</strong> is <strong>recorded.</strong></span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>During the Investigation</strong> of <strong>food poisoning outbreak</strong> -&nbsp;<strong>Both affected and not affected</strong> persons <strong>must </strong>be<strong> interviewed</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Textbook of Community Medicine- Rajvir Bhalwar- 4<sup>th</sup> edition (page 672)</strong></span></p>",
    "correct_choice_id": 8045,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "InvestigationBased"
    ]
  },
  {
    "id": 2016,
    "choices": [
      {
        "id": 8057,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">To eliminate viral hepatitis as a public health problem.</span></span></p>"
      },
      {
        "id": 8058,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">To ensure universal access to hepatitis C vaccines</span></span></p>"
      },
      {
        "id": 8059,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">To provide accessible and affordable treatment for hepatitis B and C.</span></span></p>"
      },
      {
        "id": 8060,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">To promote awareness and screening for viral hepatitis</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A health policy analyst is evaluating various national health initiatives to provide recommendations for resource allocation. One of the programs under review is the National Viral Hepatitis Control Program, which aims to address the public health challenge of viral hepatitis. The analyst is assessing the program&#39;s objectives to determine how well they align with broader public health goals. Understanding the specific aims of the program is crucial for this evaluation, and the analyst needs to identify a goal that is not a part of the program&rsquo;s objectives. In the context of evaluating the National Viral Hepatitis Control Program, which of the following is NOT an objective of the program?</span></span></p>",
    "unique_key": "Q2665991",
    "question_audio": null,
    "question_video": null,
    "map_id": 34187,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. B. To ensure universal access to hepatitis C vaccines</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B:</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Universal</strong> access to <strong>hepatitis C vaccines</strong> - is <strong>not</strong> an objective of the <strong>National Viral Hepatitis Control Program</strong>.&nbsp;Primarily because as of now, there is <strong>no commercially</strong> available <strong>vaccine for hepatitis C</strong>. Hence, ensuring <strong>universal access</strong> to such a vaccine is <strong>not</strong> a <strong>feasible objective.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. To eliminate viral hepatitis as a public health problem:</strong> &nbsp;This is typically a <strong>primary objective of national viral hepatitis programs</strong>, aiming to <strong>reduce </strong>the <strong>incidence and impact</strong> of the <strong>disease</strong> to <strong>non-threatening levels</strong>.</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong> <strong>To provide accessible and affordable treatment for hepatitis B and C</strong>:&nbsp;</span></span><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">One of the key objectives of program is to ensure that <strong>treatment</strong> for <strong>Hepatitis B and Hepatitis C</strong> is <strong>accessible and affordable</strong>, aiming to&nbsp;<strong>ending Viral Hepatitis</strong> by <strong>2030 (SDG 3.3).</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. To promote awareness and screening for viral hepatitis: </strong><strong>Raising awareness</strong> and <strong>promoting screening</strong> are common objectives, as <strong>early detection</strong> and <strong>public knowledge</strong> are crucial for <strong>control and prevention.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Some important Pointers </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:14px\"><span style=\"font-family:Georgia,serif\"><img src=\"https://nvhcp.mohfw.gov.in/assets/images/mainlogo.png\" /></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>National Viral Hepatitis Control Program</strong> has been launched by <strong>Ministry of</strong> <strong>Health and Family Welfare</strong>, Government of <strong>India</strong> on the occasion of the <strong>World Hepatitis Day, 28th July 2018.</strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Aim:</span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Combat hepatitis</strong> and achieve <strong>country-wide elimination of Hepatitis C</strong> by <strong>2030;</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Achieve significant <strong>reduction </strong>in the <strong>infected population</strong>, <strong>morbidity</strong>, and <strong>mortality</strong> associated with <strong>Hepatitis B and C</strong> Viz. <strong>Cirrhosis and Hepatocellular carcinoma (liver cancer);</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Reduce </strong>the <strong>risk, morbidity and mortality</strong> due to <strong>Hepatitis A and E.</strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The key components include:</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">1. <strong>Preventive component</strong>: This remains the cornerstone of the <strong>NVHCP</strong>. It will include</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Awareness generation</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Immunization of <strong>Hepatitis B</strong> (birth dose, high risk groups, health care workers)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Safety of blood and blood products</strong> </span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;<strong>Injection safety</strong>, safe socio-cultural practices</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Safe drinking water, hygiene and sanitary toilets</strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">2<strong>. Diagnosis and Treatment</strong>:</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Screening</strong> of <strong>pregnant women</strong> for <strong>HBsAg</strong> to be done in areas where institutional deliveries are <strong>&lt; 80%</strong> to ensure their <strong>referral</strong> for <strong>institutional delivery for birth</strong> dose <strong>Hepatitis B vaccination.</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Free screening, diagnosis and treatment</strong> for <strong>both hepatitis B and C</strong> would be made available <strong>at all levels</strong> of <strong>health care</strong> in a phased manner.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Provision of <strong>linkages</strong>, including with <strong>private sector</strong> and <strong>not-for-profit</strong> <strong>institutions</strong>, for <strong>diagnosis and treatment.</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Engagement</strong> with <strong>community/peer support</strong> to enhance and ensure adherence to <strong>treatment and demand generation</strong>.</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">3. <strong>Monitoring and Evaluation, Surveillance</strong> and <strong>Research Effective</strong> linkages to the <strong>surveillance system</strong> would be <strong>established</strong> and <strong>operational research</strong> would be undertaken through <strong>Department of Health Research (DHR).</strong> <strong>Standardised M&amp;E</strong> framework would be <strong>developed </strong>and an <strong>online web</strong> based system <strong>established.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">4. <strong>Training and Capacity Building:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">This would be a <strong>continuous process</strong> and will be supported by <strong>NCDC, ILBS </strong>and <strong>state tertiary care institutes</strong> and <strong>coordinated by NVHCP</strong>. The <strong>hepatitis induction </strong>and <strong>update programs</strong> for <strong>all level of health care workers</strong> would be made available using both, the <strong>traditional cascade</strong> model of <strong>training</strong> through <strong>master trainers</strong> and various platforms available for <strong>enabling electronic</strong>, <strong>e-learning and e-courses.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>National viral hepatitis</strong> control programs <strong>aim</strong> to <strong>eliminate</strong> the <strong>disease</strong> as a <strong>public health problem</strong>, <strong>provide treatment,</strong> and <strong>promote awareness</strong> and <strong>screening</strong>, they <strong>do not</strong> typically include the <strong>objective</strong> of <strong>ensuring universal access to hepatitis C vaccines</strong>, mainly <strong>due</strong> to the current <strong>unavailability</strong> of such <strong>vaccines.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref:</u></strong><strong> https://www.nhp.gov.in/national-viral-hepatitis-control-program-(nvhcp)_pg</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>",
    "correct_choice_id": 8058,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 2021,
    "choices": [
      {
        "id": 8077,
        "text": "<p><span style=\"font-size:12pt;\">Rapid and feeble pulse</span></p>"
      },
      {
        "id": 8078,
        "text": "<p><span style=\"font-size:12pt;\">Skin pinch retracts on 4 seconds</span></p>"
      },
      {
        "id": 8079,
        "text": "<p><span style=\"font-size:12pt;\">Thirsty and restless</span></p>"
      },
      {
        "id": 8080,
        "text": "<p><span style=\"font-size:12pt;\">Very dry tongue</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">A two-year-old child is brought to the emergency department by his parents with symptoms of diarrhea and vomiting for the past 24 hours. The child appears lethargic, and the parents report that he has not had a wet diaper in over 6 hours. The medical team is assessing the child for dehydration, a common complication of gastrointestinal illness in young children. One of the residents is tasked with evaluating the severity of the child's dehydration to determine the appropriate treatment plan.&nbsp; In assessing the severity of dehydration in this two-year-old child, which of the following is NOT a clinical findings would most likely indicate SEVERE dehydration?</span></p>",
    "unique_key": "Q7665429",
    "question_audio": null,
    "question_video": null,
    "map_id": 34188,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. C. Thirsty and restless</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Thirsty and restless</strong> is symptom of <strong>Some Dehydration</strong>, <strong>NOT</strong> Severe&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other 3 options</strong> are <strong>sign/ symptoms</strong> of <strong>Severe Dehydration.&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Sign/ symptom</strong> of <strong>Severe dehydration</strong>:</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Patient appearance- <strong>Drowsy, limp, cold, sweaty,</strong> maybe <strong>comatose.</strong></span></li><li><span style=\"font-size:12pt;\">Radial pulse- <strong>Rapid, feeble</strong>, sometimes <strong>impalpable</strong></span></li><li><span style=\"font-size:12pt;\">Blood pressure- <strong>Less than 80 mmHg</strong>, may be <strong>unrecordable</strong></span></li><li><span style=\"font-size:12pt;\"><strong>Skin elasticity</strong>- <strong>Pinch retracts very slowly</strong> (more than 2 seconds)</span></li><li><span style=\"font-size:12pt;\"><strong>Tongue- Very dry</strong></span></li><li><span style=\"font-size:12pt;\"><strong>Anterior fontanelle</strong>- <strong>Very sunken</strong></span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">IMNCI guidelines for dehydration and diarrhoea</span></p><p>&nbsp;</p><p><span style=\"color:black;font-size:14px;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/12/picture33.jpg\" alt=\"\" width=\"700\" height=\"578\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Reference: Park 26<sup>th</sup> edition (page 262)</strong></span></p>",
    "correct_choice_id": 8079,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 2025,
    "choices": [
      {
        "id": 8093,
        "text": "<p><span style=\"font-size:12pt;\">Campylobacter jejuni</span></p>"
      },
      {
        "id": 8094,
        "text": "<p><span style=\"font-size:12pt;\">Entamoeba histolytica</span></p>"
      },
      {
        "id": 8095,
        "text": "<p><span style=\"font-size:12pt;\">Rotavirus</span></p>"
      },
      {
        "id": 8096,
        "text": "<p><span style=\"font-size:12pt;\">Shigella</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt;\">A 3-year-old child presents to the pediatric clinic with a 2-day history of diarrhea. The mother reports that the child has had several episodes of loose stools, some of which contained blood. The child does not have a fever and appears otherwise healthy. The pediatric resident examining the child is considering various infectious causes of bloody diarrhea (dysentery) and recalls that certain pathogens are more commonly associated with this presentation than others. The resident needs to identify which pathogen is least likely to be the cause of this child's bloody diarrhea. Based on the clinical presentation, which of the following pathogens is the least likely cause of bloody diarrhea in this child?</span></p>",
    "unique_key": "Q8674213",
    "question_audio": null,
    "question_video": null,
    "map_id": 34190,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. C. Rotavirus</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">The <strong>most</strong> common <strong>symptoms</strong> of <strong>rotavirus</strong> are <strong>severe watery diarrhea</strong>, <strong>vomiting</strong>, <strong>fever</strong>, and/or <strong>abdominal pain</strong>. Symptoms usually <strong>start</strong> about <strong>two days</strong> <strong>after</strong> a person is <strong>exposed to rotavirus</strong>. <strong>Vomiting and watery diarrhea</strong> can <strong>last&nbsp;three to eight days</strong>.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u>&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. Campylobacter jejuni</strong> -&nbsp;<strong>Campylobacter infection</strong> usually have <strong>diarrhea</strong> (often <strong>bloody)</strong>, <strong>fever</strong>, and <strong>stomach cramps</strong>. <strong>Nausea and vomiting</strong> may <strong>accompany</strong> the <strong>diarrhea</strong>. Symptoms usually <strong>start two to five days</strong> after <strong>infection</strong> and <strong>last about one week</strong>.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Entamoeba histolytica: Invasive intestinal parasitic infection</strong> can result in symptoms of <strong>fulminant dysentery</strong>, such as <strong>fever, chills, bloody</strong> or <strong>mucous diarrhea</strong>, and <strong>abdominal discomfort</strong>.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Shigella: Shigellosis </strong>usually start experiencing <strong>symptoms 1 to 2 days</strong> after <strong>contact</strong> with <strong>the germ</strong>. These symptoms include:&nbsp;<strong>Diarrhea </strong>that can be <strong>bloody or prolonged</strong>&nbsp;(lasting <strong>more than 3 days</strong>).</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Causes of acute gastroenteritis with blood in stool:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Bacteria</strong>- Shigellosis, enterohemorrhagic E coli, C. jejuni, Salmonella spp, Yersinia enterocolitica</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Protozoa-</strong> Entamoeba histolytica, Balantidium coli</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Helminths</strong>- Massive trichuris infection, Schistosoma mansoni, S.japonicum</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Rota virus</strong>, <strong>Noro virus&nbsp;</strong>is the <strong>least</strong> likely cause of <strong>bloody diarrhea.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Causes of <strong>acute gastroenteritis</strong> with <strong>blood in stool</strong> -&nbsp;<strong>Shigellosis,</strong> <strong>enterohemorrhagic E coli, C. jejuni</strong>, <strong>Salmonella spp, Yersinia enterocolitica,&nbsp;Entamoeba histolytica, Balantidium coli,&nbsp;Massive trichuris infection, Schistosoma mansoni, S.japonicum</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Textbook of Community Medicine- Rajvir Bhalwar- 4<sup>th</sup> edition (page 661)</strong></span></p>",
    "correct_choice_id": 8095,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 2027,
    "choices": [
      {
        "id": 8101,
        "text": "<p><span style=\"font-size:12pt;\">1 mg</span></p>"
      },
      {
        "id": 8102,
        "text": "<p><span style=\"font-size:12pt;\">5 mg</span></p>"
      },
      {
        "id": 8103,
        "text": "<p><span style=\"font-size:12pt;\">10 mg</span></p>"
      },
      {
        "id": 8104,
        "text": "<p><span style=\"font-size:12pt;\">20 mg</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">A pediatric resident is managing a 7-month-old child who presented to the clinic with acute diarrhea. As part of the treatment plan, the resident decides to include zinc supplementation, which is recommended for the management of acute diarrhea in children to reduce the duration and severity of the episode. The resident is aware that the dose of zinc supplementation varies based on the age of the child and is determining the appropriate dose for this 7-month-old patient. What is the recommended dose of zinc supplementation for a 7-month-old child with acute diarrhea, to be given for a duration of 14 days?</span></p>",
    "unique_key": "Q7161318",
    "question_audio": null,
    "question_video": null,
    "map_id": 34192,
    "difficulty_level": "difficult",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. D. 20 mg</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">When a <strong>zinc supplement</strong> is given during an episode of <strong>acute diarrhoea</strong>, it <strong>reduces</strong> the <strong>episode's duration and severity</strong>. In addition, <strong>zinc supplements</strong> given for <strong>10 to 14 days</strong> to <strong>lower</strong> the <strong>incidence of diarrhoea</strong> in the following <strong>2 to 3 months.</strong></span></p><p>&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>WHO and UNICEF</strong> therefore recommend daily - <strong>10 mg of zinc</strong> for <strong>infants</strong> under <strong>6 months of age</strong>, and <strong>20 mg</strong> for <strong>children older</strong> than <strong>6 months for 10-14 days.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Some important Pointers -&nbsp;</span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Micronutrient Zinc deficiency</strong> associated with <strong>rash and diarrhea</strong></span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Acrodermatitis enteropathica</strong> is due to <strong>Zinc deficiency</strong> (Clinical triad of <strong>acral dermatitis, alopecia and diarrhea</strong>)</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Zinc deficiency</strong>: <strong>Growth failure, Sexual infantilism</strong>, <strong>Loss of taste</strong>, Delayed <strong>wound healing</strong>, Loss of integrity of <strong>immune system</strong>, Spontaneous abortions, Congenital malformations, <strong>Low birth weight</strong>, IUGR, Preterm delivery, <strong>Skin lesions</strong>, <strong>Depressed appetite</strong>, Skeletal abnormalities</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Banana</strong> is <strong>not</strong> a <strong>good source</strong> of: Calcium, Iron (Due to <strong>presence</strong> of <strong>phytates</strong>) and&nbsp;Zinc.</span></p></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Zinc supplementation</strong>:</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>Infants &lt; 6 months</strong> age: <strong>10 mg/day \u00d7 10\u201314 days.</strong></span></li><li><span style=\"font-size:12pt;\"><strong>Children &gt; 6 months</strong> age: <strong>20 mg/day \u00d7 10\u201314 days.</strong></span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Park 26<sup>th</sup> edition (page 264)</strong></span></p>",
    "correct_choice_id": 8104,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 3592,
    "choices": [
      {
        "id": 14347,
        "text": "<p><span style=\"font-size:12pt;\">Bacillus cereus</span></p>"
      },
      {
        "id": 14348,
        "text": "<p><span style=\"font-size:12pt;\">Botulism</span></p>"
      },
      {
        "id": 14349,
        "text": "<p><span style=\"font-size:12pt;\">Clostridium Perfringens&nbsp;</span></p>"
      },
      {
        "id": 14350,
        "text": "<p><span style=\"font-size:12pt;\">Staphylococcus</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt;\">A medical resident is consulting on a case in the emergency department involving a group of individuals who presented with symptoms of food poisoning after attending a buffet. The resident is considering the various pathogens that could be responsible based on the type of onset and nature of the toxins involved. While some foodborne illnesses are caused by preformed toxins, others result from toxins produced in the body after consuming contaminated food. The resident needs to determine which pathogen in this scenario is least likely to be associated with preformed toxins in the context of food poisoning. In the case of the group presenting with food poisoning after a buffet, which pathogen is least likely to be associated with illness caused by preformed toxins?</span></p>",
    "unique_key": "Q5822898",
    "question_audio": null,
    "question_video": null,
    "map_id": 34193,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. C. Clostridium perfringens</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C.</strong></span></p><p>&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Clostridium perfringens</strong> food poisoning: Is&nbsp;<strong>acute gastroenteritis</strong> caused by <strong>ingestion of contaminated food</strong> (symptoms are due to <strong>protein enterotoxin</strong> produced during <strong>sporulation </strong>of the organism in the <strong>intestine</strong>). <strong>IP 6\u201324</strong> <strong>hours</strong>;&nbsp;Symptoms are <strong>watery diarrhoea</strong> and <strong>abdominal cramps</strong>. Diagnosis is by identifying <strong>C. perfringens</strong> in <strong>contaminated food</strong> or in <strong>stool</strong>. Treatment is supportive.&nbsp;Rapid recovery with <strong>no deaths</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u>&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. Bacillus cereus: Emetic type</strong> causes illness through the ingestion of <strong>preformed toxins</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Botulism:</strong> &nbsp;Is caused by the ingestion of a <strong>preformed toxin</strong> in <strong>contaminated food</strong>. The toxin is produced when the <strong>bacteria grow in food</strong> that has been <strong>improperly preserved</strong>, or <strong>stored under anaerobic conditions</strong>.<strong>&nbsp;</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option D. Staphylococcus </strong>-&nbsp;<strong>Mechanism </strong>of<strong> </strong>food poisoning: <strong>Intra-dietetic toxins</strong> (ingestion of toxins pre-formed in food, in which <strong>bacteria</strong> have <strong>grown</strong>).&nbsp;Incubation period (<strong>1\u20136 hours</strong>) is <strong>short</strong> because of <strong>\u2018preformed</strong> <strong>toxin</strong>\u2019.&nbsp;Toxins are <strong>relatively heat stable</strong> and <strong>resist </strong>boiling for <strong>30 min</strong> or more.&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Clostridium botulinum, Staphylococcus aureus, and Bacillus cereus</strong> (<strong>emetic type</strong>) cause<strong> illness</strong> through the <strong>ingestion</strong> of <strong>preformed toxins</strong> present in the <strong>food</strong>.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref:</u> Park 26<sup>th</sup> edition (page 276)</strong></span></p>",
    "correct_choice_id": 14349,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "InvestigationBased"
    ]
  },
  {
    "id": 3596,
    "choices": [
      {
        "id": 14363,
        "text": "<p><span style=\"font-size:12pt;\">Chronic carrier</span></p>"
      },
      {
        "id": 14364,
        "text": "<p><span style=\"font-size:12pt;\">Contact carrier</span></p>"
      },
      {
        "id": 14365,
        "text": "<p><span style=\"font-size:12pt;\">Convalescent carrier</span></p>"
      },
      {
        "id": 14366,
        "text": "<p><span style=\"font-size:12pt;\">Incubatory carrier</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt;\">A public health physician is managing a recent outbreak of cholera in a coastal community. One of the patients, a 40-year-old man, has recently recovered from a severe case of cholera. Despite clinical recovery, follow-up testing reveals that he is still excreting Vibrio cholerae in his stool. This information is critical for the public health team in understanding the dynamics of disease transmission post-recovery. The physician needs to categorize this patient correctly in terms of carrier status to inform further public health actions. In the context of a cholera outbreak, how should the public health physician categorize a patient who continues to excrete Vibrio cholerae in his stool 2 to 3 weeks after clinical recovery?</span></p>",
    "unique_key": "Q9544783",
    "question_audio": null,
    "question_video": null,
    "map_id": 34198,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. &nbsp;C. Convalescent carrier</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C.</strong></span></p><p>&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>CONVALESCENT CARRIER</strong>: The patient who has <strong>recovered </strong>from an <strong>attack of</strong> <strong>cholera </strong>may continue to <strong>excrete vibrios</strong>, during his <strong>convalescence for 2-3 weeks.</strong> A convalescent state has been <strong>found to occur</strong> in patients who have <strong>not</strong> received effective <strong>antibiotic treatment</strong>. The convalescent carriers <strong>can</strong> often become <strong>chronic or long-term carriers</strong>. Example - <strong>Typhoid, Bacillary Dysentery,</strong> <strong>Amoebic Dysentery, Cholera, Diphtheria &amp; Pertussis</strong> (Clinical recovery does not coincide with bacteriological recovery)</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u>&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. Chronic carrier:&nbsp; Excretes infectious agents</strong> for <strong>indefinite periods</strong> (&gt; 6 months).&nbsp;Example - Typhoid, Hepatitis-B, Dysentery, Meningococcal Meningitis, Malaria, Gonorrhoea, etc.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Contact&nbsp;carrier: </strong>Carrier who gets <strong>infected from a case.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Incubatory&nbsp;carrier: Shed infectious agent</strong> during <strong>incubation period</strong> of disease.&nbsp;Example - <strong>Measles, Mumps, Polio, Pertussis, Influenza, Diphtheria, Hepatitis-B</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Convalescent Carriers</strong>: Shed the <strong>disease agent</strong> during the <strong>period</strong> of <strong>Convalescence</strong>, e.g. <strong>Typhoid, Bacillary Dysentery, Amoebic Dysentery, Cholera, Diphtheria &amp; Pertussis</strong> (Clinical recovery does not coincide with bacteriological recovery)</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Different types of carriers of a disease</strong></span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-122809.png\" alt=\"\" width=\"1000\" height=\"583\"></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Reference: Park 26<sup>th</sup> edition (page 267)</strong></span></p>",
    "correct_choice_id": 14365,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "InvestigationBased"
    ]
  },
  {
    "id": 1567,
    "choices": [
      {
        "id": 6263,
        "text": "<p><span style=\"font-size:12pt;\">Pregnancy</span></p>"
      },
      {
        "id": 6264,
        "text": "<p><span style=\"font-size:12pt;\">HIV infection- asymptomatic</span></p>"
      },
      {
        "id": 6265,
        "text": "<p><span style=\"font-size:12pt;\">Respiratory infection</span></p>"
      },
      {
        "id": 6266,
        "text": "<p><span style=\"font-size:12pt;\">Malnutrition</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A medical resident is discussing the administration of the measles vaccine with a supervising physician. The conversation focuses on contraindications to vaccination, which are critical for ensuring patient safety. The resident is asked about definitive contraindications for administering the measles vaccine. Which of the following is considered a definitive contraindication for the measles vaccine?</span></p>",
    "unique_key": "Q1913368",
    "question_audio": null,
    "question_video": null,
    "map_id": 34186,
    "difficulty_level": "beginner",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A. Pregnancy</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A:</strong></span></p><p>&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Measles vaccine</strong> is <strong>contraindicated</strong> in <strong>pregnancy</strong>, as the measles vaccine is a <strong>live attenuated vaccine</strong>.&nbsp;</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Contraindications</strong> of <strong>measles</strong> vaccine -&nbsp;<strong>Allergy to measles virus, gelatin</strong> or <strong>neomycin</strong>, <strong>reduced immunity</strong> due to <strong>cancer</strong>, <strong>concurrent infection</strong>, or <strong>immunosuppressants</strong> or those taking <strong>monoclonal antibodies.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option&nbsp;B. HIV Infection - Asymptomatic: </strong>Can be <strong>administered to HIV-infected individuals</strong>, especially if they are <strong>asymptomatic</strong> or <strong>not severely immunocompromised</strong>. <strong>Vaccination</strong> should be <strong>considered</strong> after careful<strong> evaluation of the immune status.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option&nbsp;C. Respiratory Infection: Not</strong> a <strong>contraindication,</strong> if the <strong>illness is mild</strong> and <strong>without fever</strong>, vaccination can generally<strong> proceed</strong>.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option&nbsp;D. Malnutrition: </strong>Malnutrition<strong>,</strong> particularly in countries where <strong>measles is endemic</strong>, is <strong>not</strong> a <strong>contraindication</strong> to <strong>measles</strong> vaccination. In fact, <strong>vaccination</strong> is crucial in <strong>malnourished</strong> individuals due to their <strong>increased risk </strong>of <strong>severe measles</strong>.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Some important pointers regarding vaccine contraindications -&nbsp;</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Vaccines <strong>contraindicated</strong> in <strong>Pregnancy</strong>: All live vaccines <strong>EXCEPT Yellow fever vaccine</strong></span></li><li><span style=\"font-size:12pt;\">Vaccines <strong>contraindicated</strong> in <strong>HIV</strong>:</span><ul><li><span style=\"font-size:12pt;\">Asymptomatic HIV: NONE</span></li><li><span style=\"font-size:12pt;\"><strong>Symptomatic HIV</strong>: <strong>All live vaccines</strong> EXCEPT <strong>MMR, Varicella &amp; Zoster</strong> may be given if required</span></li></ul></li><li><span style=\"font-size:12pt;\">Vaccines contraindicated in Immuno-suppression: All live vaccines</span></li><li><span style=\"font-size:12pt;\">Vaccines contraindicated in Corticosteroid therapy: All live vaccines</span></li><li><span style=\"font-size:12pt;\">Vaccines<strong> contraindicated</strong> in <strong>fever</strong>: <strong>Typhoid vaccines</strong></span></li><li><span style=\"font-size:12pt;\">Vaccines contraindicated in ARTI/diarrhoea: NONE</span></li><li><span style=\"font-size:12pt;\">Vaccines contraindicated together: Yellow fever and Cholera vaccine</span></li><li><span style=\"font-size:12pt;\">Vaccine contraindicated in<strong> Preterm-premature baby</strong> with birth weight &lt; 2 kg: <strong>Hepatitis B</strong></span></li><li><span style=\"font-size:12pt;\">Vaccines contraindicated in age &lt; 1 year (infants):&nbsp;\u2013 Yellow fever vaccine,&nbsp;Meningococcal vaccine,&nbsp;Pneumococcal vaccine</span></li><li><span style=\"font-size:12pt;\">Vaccines contraindicated in age &lt; 2 year (infants):&nbsp;\u2013 Meningococcal vaccine,&nbsp;Pneumococcal vaccine,&nbsp;Typhoid vaccines</span></li><li><span style=\"font-size:12pt;\">Vaccine <strong>contraindicated</strong> in <strong>progressive neurological disease</strong>: <strong>Pertussis vaccine</strong> (Pertussis vaccine IS NOT CONTRAINDICATED IN epilepsy controlled on medications, Cerebral palsy)</span></li><li><span style=\"font-size:12pt;\">Only <strong>absolute contraindication</strong> to <strong>killed vaccines</strong>: Severe <strong>local or general reaction</strong> to a <strong>previous dose</strong></span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Measles vaccine</strong> is <strong>definitively</strong> <strong>contraindicated</strong> in <strong>pregnancy.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Textbook of Community Medicine- Rajvir Bhalwar- 4<sup>th</sup> edition (page 729)</strong></span></p>",
    "correct_choice_id": 6263,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 1652,
    "choices": [
      {
        "id": 6603,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">One tablet twice a day</span></span></p>"
      },
      {
        "id": 6604,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Two tablets twice a day</span></span></p>"
      },
      {
        "id": 6605,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Three tablets twice a day</span></span></p>"
      },
      {
        "id": 6606,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Four tablets twice a day</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A group of medical residents participating in a public health initiative are tasked with developing a protocol for the administration of cotrimoxazole in pediatric patients. They are focusing on standardizing treatment according to the Integrated Management of Neonatal and Childhood Illnesses (IMNCI) guidelines. The residents are reviewing the dosing guidelines for different age groups and weights. According to the IMNCI guidelines, what is the recommended dosage of pediatric cotrimoxazole tablets for children aged 1 to 5 years with a body weight of 10-19 kg?</span></span></p>",
    "unique_key": "Q8886897",
    "question_audio": null,
    "question_video": null,
    "map_id": 34184,
    "difficulty_level": "difficult",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. Three tablets twice a day</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">According to <strong>IMNCI guidelines</strong>, the recommended dosage of <strong>pediatric cotrimoxazole</strong> for children aged <strong>1 to 5 years</strong> weighing between <strong>10-19 kg</strong> is <strong>3 tablets twice</strong> a <strong>day.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. 1 tablet twice a day:</strong> <strong>Incorrect.</strong> This <strong>dosage</strong> is appropriate for <strong>infants &lt;2 months</strong>, weight <strong>3-5 kg.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. 2 tablets twice a day:</strong> <strong>Incorrect</strong>. This <strong>dosage</strong> is <strong>less </strong>than the recommended amount for an <strong>infant 2-12 months</strong>, <strong>weighing </strong>between <strong>6 and 9</strong> <strong>kg </strong>as per <strong>IMNCI guidelines</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. 4 tablets twice a day:</strong> <strong>Incorrect</strong>. This <strong>dosage exceeds</strong> the <strong>recommended</strong> amount for a <strong>child</strong> in the <strong>specified weight </strong>range according to <strong>IMNCI guidelines</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Pediatric Cotrimoxazole Dosage</strong> - (as per age and weight)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:14px\"><span style=\"font-family:Georgia,serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/12/picture20_RImCV8I.jpg\" style=\"height:832px; width:1000px\" /></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref:</u></strong><strong> Park 26<sup>th</sup> edition (page 187)</strong></span></span></p>",
    "correct_choice_id": 6605,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 1653,
    "choices": [
      {
        "id": 6607,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Reduce pneumonia mortality in under 5 children to &lt; 3 per 1000 live births</span></span></p>"
      },
      {
        "id": 6608,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Reduce diarrhoea mortality in under 5 children to &lt; 3 per 1000 live births<strong>&nbsp; </strong></span></span></p>"
      },
      {
        "id": 6609,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Reduce incidence of severe pneumonia by 75% as compared to 2010 levels</span></span></p>"
      },
      {
        "id": 6610,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Reduce incidence of severe diarrhoea by 75% as compared to 2010 levels</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A team of medical residents is participating in a global health challenge competition, where they are tasked with developing innovative strategies to achieve the targets set by the Integrated Global Plan for the Prevention and Control of Pneumonia and Diarrhoea by 2025. As part of the challenge, they are given a quiz to test their knowledge of the plan&#39;s objectives. The team needs to identify which of the following objectives for 2025 is not included in the plan. Which goal is NOT a part of the Integrated Global Plan for the Prevention and Control of Pneumonia and Diarrhoea?</span></span></p>",
    "unique_key": "Q1911940",
    "question_audio": null,
    "question_video": null,
    "map_id": 34185,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. B. Reduce diarrhoea mortality in under 5 children to &lt; 3 per 1000 live births</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>correct Goal</strong> is -&nbsp;<strong>Reduce Diarrhoea mortality</strong> in <strong>Infants &lt; 1 per 1000 LB</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Integrated Global Action Plan</strong> for <strong>Prevention and Control</strong> of&nbsp;<strong>Pneumonia</strong> &amp; <strong>Diarrhoea (GAPPD)</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Specific Goals for 2025:</span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Reduce Pneumonia mortality</strong> <strong>in Under-five &lt; 3 per 1000 LB</strong>, <strong>Reduce Diarrhoea mortality</strong> in Infants <strong>&lt; 1 per 1000 LB</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. Reduce Incidence of Severe Pneumonia in Under- </strong>fives by <strong>75%</strong> (2010 baseline)</span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Reduce Incidence of Severe Diarrhoea in Under</strong>-fives by <strong>75% </strong>(2010 baseline)</span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Reduce</strong> Global no. of <strong>Stunted Under-fives</strong> by <strong>40%</strong> (2010 baseline)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">&bull; Coverage targets:</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-125739.png\" style=\"height:543px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Integrated Global Action Plan</strong> for <strong>Prevention</strong> and <strong>Control of&nbsp;Pneumonia</strong> &amp; <strong>Diarrhoea </strong>(GAPPD)&nbsp;Specific Goals for <strong>2025</strong> are&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Reduce <strong>Pneumonia</strong> mortality in Under-five <strong>&lt; 3 per 1000 LB</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Reduce <strong>Diarrhoea </strong>mortality in Infants <strong>&lt; 1 per 1000 LB</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Reduce Incidence of <strong>Severe Diarrhoea</strong> in Under-fives by <strong>75%</strong> (2010 baseline)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Reduce Incidence of <strong>Severe Pneumonia</strong> in Under-fives by <strong>75%</strong> (2010 baseline)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Reduce <strong>Global no. of Stunted</strong> Under-fives by <strong>40% </strong>(2010 baseline)</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 189)</strong></span></span></p>",
    "correct_choice_id": 6608,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InvestigationBased"
    ]
  },
  {
    "id": 1696,
    "choices": [
      {
        "id": 6779,
        "text": "<p><span style=\"font-size:12pt;\">Replacement of tOPV with bOPV.</span></p>"
      },
      {
        "id": 6780,
        "text": "<p><span style=\"font-size:12pt;\">Replacement of OPV with IPV.</span></p>"
      },
      {
        "id": 6781,
        "text": "<p><span style=\"font-size:12pt;\">Both</span></p>"
      },
      {
        "id": 6782,
        "text": "<p><span style=\"font-size:12pt;\">None of the above</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">In a postgraduate teaching seminar focused on infectious diseases, a junior resident is presenting on the various strategies employed in the global initiative to eradicate polio. A significant portion of the presentation is dedicated to discussing 'the switch' \u2013 a pivotal moment in the history of polio eradication efforts. This strategy has played an essential role in the worldwide campaign to halt the transmission of all poliovirus types. The resident aims to explain the specifics of 'the switch' to the attendees, emphasizing its impact on the global fight against polio.&nbsp;In the global efforts to eradicate polio, what specifically does 'the switch' refer to?</span></p>",
    "unique_key": "Q2221629",
    "question_audio": null,
    "question_video": null,
    "map_id": 34181,
    "difficulty_level": "beginner",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A. Replacement of tOPV with bOPV.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">The <strong>first stage of OPV</strong> <strong>withdrawal </strong>involved a <strong>global synchronized cessation</strong> of <strong>tOPV </strong>use between <strong>18th April and 1st May 2016</strong>, <strong>replacing tOPV with bOPV</strong> containing only <strong>type 1 and 3 polioviruses</strong> and <strong>withdrawing OPV type 2</strong> from <strong>all immunization</strong> activities called \u201c<strong>the Switch</strong>\u201d. <strong>Once switch</strong> is made, <strong>tOPV</strong> will <strong>no </strong>longer be <strong>used </strong>anywhere in the <strong>world</strong> and <strong>manufacturers</strong> will <strong>no</strong> <strong>longer</strong> supply <strong>tOPV.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:14px;\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</span></p><p><span style=\"font-size:14px;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/12/picture23.jpg\" alt=\"\" width=\"300\" height=\"315\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>\u201cSWITCH\u201d</strong> - <strong>Replacing Trivalent OPV</strong> with <strong>Bivalent OPV.</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Concept: An important transition in the <strong>vaccines</strong> used to <strong>eradicate polio</strong> requires removal of <strong>all OPVs</strong> in the <strong>long\u2011term</strong> to <strong>eliminate rare risks</strong> of <strong>VAPP </strong>and <strong>cVDPV</strong></span></li><li><span style=\"font-size:12pt;\">Strategy:&nbsp;</span><ul><li><span style=\"font-size:12pt;\"><strong>Withdrawal</strong> of <strong>OPVs</strong> must occur in a <strong>globally synchronized</strong> manner, <strong>starting </strong>in <strong>April 2016</strong> with a <strong>switch from trivalent OPV</strong> (tOPV) to <strong>bivalent OPV</strong> (bOPV), <strong>removing</strong> the <strong>type 2</strong> component (OPV2) <strong>from immunization</strong> programs of countries.</span></li><li><span style=\"font-size:12pt;\">Preparation for the <strong>removal of OPVs</strong> also includes the <strong>introduction </strong>of at least <strong>one dose of IPV</strong> in <strong>routine immunization programs</strong> in <strong>all countries</strong> by end of <strong>2015.</strong></span></li></ul></li><li><span style=\"font-size:12pt;\">Indian \u201cSwitch\u201d:</span><ul><li><span style=\"font-size:12pt;\"><strong>National Switch Date</strong>: <strong>April 25, 2016</strong></span></li><li><span style=\"font-size:12pt;\"><strong>National Validation Day</strong>: <strong>May 09, 2016</strong> (India to be declared free of tOPV)</span></li><li><span style=\"font-size:12pt;\"><strong>Destroy</strong> all <strong>tOPV</strong> on/after <strong>25th April 2016</strong></span></li><li><span style=\"font-size:12pt;\"><strong>IPV </strong>in 6 states (UP, Bihar, Madhya Pradesh, Gujarat, Punjab, Assam): <strong>One Intramuscular</strong> dose given along <strong>with 3rd dose</strong> of <strong>DTP at 14 weeks</strong></span></li><li><span style=\"font-size:12pt;\"><strong>&nbsp;IPV</strong> in other states (Orissa, Andhra Pradesh, Telangana, Tamil Nadu, Kerala, Karnataka, Maharashtra, Puducherry): <strong>Fractional dose</strong> (<strong>0.1 mL</strong> instead of 0.5 mL) <strong>by intradermal</strong> route <strong>at 6 and 14 weeks</strong> from <strong>April, 2016</strong> <strong>(Right deltoid upper arm)</strong></span></li></ul></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">A critical step in <strong>eradication of Polio</strong>, is <strong>\u2018the switch\u2019</strong> which refers to -&nbsp;<strong>Replacement of tOPV</strong> with <strong>bOPV.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Park 26<sup>th</sup> edition (page 236)</strong></span></p>",
    "correct_choice_id": 6779,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 1705,
    "choices": [
      {
        "id": 6815,
        "text": "<p><span style=\"font-size:12pt;\">Intramuscular</span></p>"
      },
      {
        "id": 6816,
        "text": "<p><span style=\"font-size:12pt;\">\u200b Intradermal</span></p>"
      },
      {
        "id": 6817,
        "text": "<p><span style=\"font-size:12pt;\">Subcutaneous</span></p>"
      },
      {
        "id": 6818,
        "text": "<p><span style=\"font-size:12pt;\">Oral</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">In an immunization clinic, a junior resident in community medicine is preparing for a training session with interns. The focus is on educating them about the National Immunisation Schedule, specifically the correct administration routes and techniques for various vaccines. An important part of this session is the fractional Inactivated Polio Vaccine (fIPV), a key vaccine in polio eradication efforts. The resident needs to ensure that the interns understand the specific route of administration for fIPV as per the National Immunisation Schedule, as this knowledge is crucial for effective vaccine delivery and patient care. According to the NIS, what is the recommended route of administration for fractional Inactivated Polio Vaccine (fIPV)?</span></p>",
    "unique_key": "Q2703012",
    "question_audio": null,
    "question_video": null,
    "map_id": 34182,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. B. Intradermal</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">IPV Vs Fractionated IPV (fIPV)</span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-124535.png\" alt=\"\" width=\"1000\" height=\"641\"></p><p><span style=\"font-size:14px;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</span></p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Fractionated inactivated Polio Vaccine</strong> (fIPV) is administered <strong>intradermally </strong>according to the <strong>National Immunisation Schedule.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">NEW National Immunization Schedule (NIS) 2023-24</span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-125017.png\" alt=\"\" width=\"1000\" height=\"1129\"></p><p>&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Note - <strong>Age Limits</strong> for <strong>Delayed Immunization</strong> in <strong>NIS, India</strong> for <strong>fIPV is 1 year.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>fIPV</strong> is <strong>fractionated intradermal</strong> at <strong>6 weeks, 14 weeks &amp; 9 months</strong> (<strong>3 doses</strong>).</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Park 26<sup>th</sup> edition (page 237)</strong></span></p>",
    "correct_choice_id": 6816,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "InvestigationBased"
    ]
  },
  {
    "id": 1712,
    "choices": [
      {
        "id": 6841,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Classical signs of cholera is absent</span></span></p>"
      },
      {
        "id": 6842,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Higher rates of carriers</span></span></p>"
      },
      {
        "id": 6843,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">More number of secondary cases</span></span></p>"
      },
      {
        "id": 6844,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Chick erythrocyte agglutination is positive</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A medical resident specializing in infectious diseases is preparing a presentation on cholera, focusing on the differences between the El Tor and classical biotypes of Vibrio cholerae. Understanding these differences is important for epidemiology, clinical presentation, and public health response. The resident aims to clarify common misconceptions and highlight key characteristics that are similar or different between these two biotypes. Which of the following characteristics is NOT a difference between cases of cholera caused by the El Tor biotype and the classical biotype of Vibrio cholerae?</span></span></p>",
    "unique_key": "Q3228967",
    "question_audio": null,
    "question_video": null,
    "map_id": 34183,
    "difficulty_level": "difficult",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. More number of secondary cases</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">In <strong>El tor</strong> type:</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Higher incidence</strong> of <strong>mild and asymptomatic infections.</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Classical</strong> picture <strong>of cholera</strong> may <strong>not</strong> be seen often.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Fewer </strong>secondary cases in <strong>affected families.</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Chronic carriers</strong> are <strong>common.</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>More resistant</strong> than classical cholera.</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Some important Pointers related to Cholera -</span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;</span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Cholera</strong> is an <strong>acute diarrhoel disease</strong> caused by <strong>Vibrio cholera.</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Vibrio cholerae</strong>: &lsquo;<strong>Gram-negative bacterium&rsquo;</strong> that produces <strong>cholera toxin</strong> (enterotoxin), which act on <strong>c-AMP system</strong> of <strong>mucosal cells</strong> of epithelium lining of the <strong>small intestine</strong> (to cause <strong>massive diarrhea -</strong>&nbsp;<strong>Rice-watery diarrhoea</strong>)</span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Classical biotype</strong></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>El Tor biotype</strong> [Serotypes: <strong>Ogawa</strong> (Earlier MC in <strong>India</strong>), <strong>Inaba</strong> and <strong>Hikojima</strong>]</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Recently <strong>El Tor Hybrid</strong> subtype has become <strong>MC in India</strong></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Incubation period: <strong>1&ndash;2 days</strong> (Few hours&ndash;5 days)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Reservoir: <strong>Human beings only</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Essentials for <strong>treatment of cholera</strong>: <strong>Water and electrolyte replacement</strong> (<strong>ORS</strong>)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Father of Public Health: Cholera</strong> (although some regard John Snow as the same)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Most susceptible <strong>blood group to cholera</strong>: <strong>Blood group O</strong> (&gt;B &gt; A &gt; AB)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>History of cholera</strong>: &ndash; <strong>John Snow</strong> (1813-1858): Found the <strong>link</strong> between <strong>cholera and contaminated drinking water</strong> (1854 using Spot maps)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Robert Koch</strong> identified <strong>V. cholerae</strong> with a <strong>microscope</strong> as the <strong>bacillus</strong> causing the <strong>disease</strong> (<strong>1885</strong>).</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;<strong>Cholera morbus</strong>: Used in <strong>19th</strong> and <strong>early 20th centuries</strong> for both <strong>non-epidemic cholera</strong> and other <strong>gastrointestinal diseases</strong> (sometimes epidemic) that <strong>resembled cholera.</strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Important Pointers related to El tor type Cholera</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Higher incidence</strong> of <strong>mild and asymptomatic infections.</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Classical picture of cholera</strong> may <strong>not</strong> be seen often.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Fewer secondary cases</strong> in <strong>affected families</strong>.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Chronic carriers</strong> are <strong>common.</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>More resistant</strong> than classical cholera.</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Textbook of Community Medicine- Rajvir Bhalwar- 4<sup>th</sup> edition (page 680)</strong></span></span></p>",
    "correct_choice_id": 6843,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InvestigationBased"
    ]
  },
  {
    "id": 1659,
    "choices": [
      {
        "id": 6631,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">11 February 2020</span></span></p>"
      },
      {
        "id": 6632,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">21 February 2020</span></span></p>"
      },
      {
        "id": 6633,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">11 March 2020</span></span></p>"
      },
      {
        "id": 6634,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">21 March 2020</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">During a global health seminar, a medical student is learning about the timeline of significant events in the COVID-19 pandemic. One of the key moments in the pandemic was when the World Health Organization (WHO) officially declared COVID-19 as a pandemic. This declaration had substantial implications for public health responses worldwide. The student is asked to recall the specific date on which WHO made this declaration. On what date did the World Health Organization (WHO) declare COVID-19 as a pandemic?</span></span></p>",
    "unique_key": "Q1406785",
    "question_audio": null,
    "question_video": null,
    "map_id": 34206,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. 11 March 2020</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>COVID-19</strong> since its <strong>first detection</strong> in <strong>China,</strong> spread to over <strong>200 countries</strong>/territories. COVID-19.&nbsp;The <strong>World Health Organization</strong> (WHO) declared <strong>COVID-19</strong> as a <strong>pandemic</strong> on <strong>March 11, 2020.</strong> This declaration was a response to the <strong>rapid global spread</strong> and severe impact of the virus<strong>, signaling</strong> a <strong>heightened level</strong> of <strong>concern</strong> and the need for countries <strong>worldwide</strong> to <strong>take urgent and aggressive action</strong> to <strong>control the spread of the virus</strong>.</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>January 30, 2020</strong> - <strong>WHO</strong> declared <strong>COVID-19</strong> a <strong>Public Health Emergency</strong> of <strong>International Concern</strong>, not a pandemic. </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>February 11, 2020</strong> - The disease caused by the <strong>novel coronavirus</strong> was officially named <strong>COVID-19</strong> by <strong>WHO.</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>December 08, 2020</strong>: <strong>First dose</strong> of <strong>Covid vaccine</strong> administered <strong>globally</strong> (in United Kingdom)</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Indian</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>30 January 2020</strong>: India reports its <strong>First cases of COVID-19</strong> from <strong>Thrissur, Kerala</strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>25 March 2020</strong>: <strong>Nation-wide lockdown</strong> imposed</span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>16 January 2021</strong>: <strong>First </strong>dose of <strong>Covid vaccine</strong> administered in <strong>India</strong>; <strong>India </strong>begins one of the <strong>world&rsquo;s biggest COVID-19 vaccination</strong> programs</span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>December 2021</strong>: DGCI approves <strong>Covaxin </strong>for use in <strong>12-18 years old children</strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>December 2021</strong>: <strong>Booster drive</strong>, <strong>15-18 years old children</strong> vaccination drive announced</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">According to CDC (<strong>Centre for Disease Control</strong>) &ldquo;<strong>Pandemic </strong>is an <strong>epidemic spread</strong> over <strong>several countries</strong> or <strong>continents</strong>, usually <strong>affecting</strong> a <strong>large number of people</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>World Health Organization</strong> (WHO) declared <strong>COVID-19</strong> as <strong>a pandemic</strong> on <strong>March 11, 2020. </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 191)</strong></span></span></p>",
    "correct_choice_id": 6633,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 1661,
    "choices": [
      {
        "id": 6639,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Rota virus</span></span></p>"
      },
      {
        "id": 6640,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Rubella</span></span></p>"
      },
      {
        "id": 6641,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Meningococcal meningitis</span></span></p>"
      },
      {
        "id": 6642,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Hepatitis B</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A medical student, studying for a public health exam, is reviewing the National Immunisation Schedule. While familiarizing themselves with the various vaccines included in the schedule, the student is also trying to identify vaccines that are not typically part of this standard schedule but may be recommended in certain specific situations or risk groups. Understanding what is and isn&#39;t included in the national schedule is essential for future clinical practice, especially in pediatrics and family medicine. Which of the following vaccines is NOT typically included in the National Immunisation Schedule?</span></span></p>",
    "unique_key": "Q3059042",
    "question_audio": null,
    "question_video": null,
    "map_id": 34208,
    "difficulty_level": "beginner",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. Meningococcal meningitis</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Vaccination</strong> for <strong>Meningococcal meningitis</strong> is <strong>not</strong> included in <strong>National Immunisation schedule (NIS)</strong> of <strong>India.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Rota virus:</strong> &nbsp;<strong>3 doses</strong> at <strong>6, 10 and 14 weeks</strong> under NIS.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Rubella</strong>: (<strong>MR</strong> vaccine) <strong>2 doses</strong> at <strong>9 months</strong> and <strong>16-24 months</strong> under NIS.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Hepatitis B</strong>: <strong>4 doses</strong> at <strong>Birth, 6, 10 and 14 weeks</strong> under NIS.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">NEW National Immunization Schedule (NIS) 2023-24</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:14px\"><span style=\"font-family:Georgia,serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-125017_3PDctN8.png\" style=\"height:1129px; width:1000px\" /></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>JE vaccine</strong> only in <strong>Endemic districts.</strong></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>HiB Vaccine</strong> introduced as <strong>Pentavalent vaccine</strong> &ndash; DPT + HepB + HiB vaccine in 16 states</span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>fIPV</strong> is <strong>fractionated intradermal</strong> at <strong>6 weeks &amp; 14 weeks</strong> or <strong>IPV Intramuscular</strong> only at <strong>14 weeks.</strong></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Rotaviral vaccine</strong> introduced in <strong>9 States</strong> &ndash; Andhra Pradesh, Haryana, Himachal Pradesh, Odisha, Madhya Pradesh, Assam, Rajasthan, Tamil Nadu and Tripura.</span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Measles-Rubella</strong> (MR) vaccine started from 5 States/UTs - Karnataka, Tamil Nadu, Goa, Lakshadweep and Puducherry.</span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Pneumococcal conjugate vaccine</strong> PCV introduced in all 12 districts of Himachal Pradesh, 6 districts of Uttar Pradesh and 17 districts of Bihar.</span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Adult JE Vaccine</strong> introduced in <strong>31 high burden districts</strong> from Assam, Uttar Pradesh and West Bengal for <strong>adult JE vaccination</strong> in the age-group of <strong>15-65 years.</strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:14px\"><span style=\"font-family:Georgia,serif\"><strong><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Textbook of Community Medicine- Rajvir Bhalwar (4<sup>th</sup> edition) (page 756)</strong></span></span></strong></span></span></p>",
    "correct_choice_id": 6641,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 1663,
    "choices": [
      {
        "id": 6647,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">North Kerelia project</span></span></p>"
      },
      {
        "id": 6648,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">MONICA</span></span></p>"
      },
      {
        "id": 6649,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Oslow</span></span></p>"
      },
      {
        "id": 6650,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">MRFIT</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A medical resident, specializing in cardiology, is attending a seminar on the changing trends in coronary heart disease (CHD) over the years. The seminar highlights how shifts in socio-economic status and advancements in science and technology have impacted the patterns and prevalence of CHD globally. One of the key points of discussion is a significant project carried out by the World Health Organization (WHO) to study these changing trends in CHD. The resident is interested in knowing the specific project initiated by WHO for this purpose. Which project was carried out by the World Health Organization (WHO) to elucidate the changing trends in coronary heart disease (CHD) in light of evolving socio-economic conditions and technological advancements?</span></span></p>",
    "unique_key": "Q3559387",
    "question_audio": null,
    "question_video": null,
    "map_id": 34209,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. B. MONICA</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Multinational Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA)</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>WHO MONICA</strong> Project is designed to <strong>measure</strong> the trends in <strong>mortality</strong> and <strong>morbidity</strong> from <strong>Coronary heart disease</strong> (CHD) and <strong>stroke</strong>, and to <strong>assess</strong> the <strong>extent</strong> to which they are related to changes in <strong>known risk factors</strong> in <strong>different</strong> <strong>populations</strong> in <strong>27 countries</strong> (10 years period).</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>reasons</strong> for the <strong>changing trends</strong> in <strong>CHD</strong> are <strong>not precisely known</strong>.&nbsp;</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. North Kerelia project:</strong> <strong>Risk factor</strong> <strong>intervention</strong> trial aimed to <strong>reduce cardiovascular risk</strong> factor levels and to <strong>promote early diagnosis, treatment</strong> and <strong>rehabilitation of patients</strong>. The result showed the <strong>reduction of CHD deaths</strong> in <strong>10 years.</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. Oslow</strong>: <strong>Oslow diet/smoking intervention</strong> study aimed to <strong>determine</strong> if <strong>serum lipids lowering</strong> and <strong>smoking-cessation</strong> would <strong>reduce incidence</strong> of first attack of <strong>CHD</strong> in <strong>40-50 yrs males</strong>. The result showed that there is <strong>reduction</strong> of <strong>MI by 47%.</strong>&nbsp;With this study, <strong>primary prevention of CHD</strong> entered <strong>practical field</strong> of <strong>preventive medicine</strong> in an <strong>impressive manner.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. MRFIT: </strong>&nbsp;<strong>Multiple risk factor intervention trial</strong>, The <strong>study aim</strong> was to <strong>reduce cardiovascular risk factor levels</strong> (<strong>smoking, high BP,</strong> <strong>hypercholesterolemia</strong>). The study showed the <strong>non-significant reduction</strong>&nbsp;seen in <strong>CHD</strong> <strong>deaths</strong> in <strong>10</strong> <strong>years.</strong>&nbsp;<br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;&ndash; <strong>Interpretation</strong>: Control group was <strong>not</strong> properly chosen (<strong>changed habits</strong> and <strong>lifestyle</strong> to an extent <strong>not anticipated</strong> by <strong>designers of trial</strong>)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Project</strong> that was <strong>carried </strong>out by the <strong>World Health Organization (WHO)</strong> to <strong>elucidate</strong> the changing trends in <strong>coronary heart disease (CHD)</strong> in light of evolving <strong>socio-economic conditions</strong> and <strong>technological advancements</strong> - <strong>MONICA</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> ed pg 413.</strong></span></span></p>",
    "correct_choice_id": 6648,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 1680,
    "choices": [
      {
        "id": 6715,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">27 January 2014</span></span></p>"
      },
      {
        "id": 6716,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">27 February 2014</span></span></p>"
      },
      {
        "id": 6717,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">27 March 2014</span></span></p>"
      },
      {
        "id": 6718,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">27 April 2014</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A medical student, preparing for a presentation on public health achievements, is researching significant milestones in the eradication of infectious diseases. One of the notable successes discussed is India&#39;s achievement in polio eradication. The student needs to pinpoint the year when India was officially certified as polio-free, which represents a major public health triumph. In which year was India officially certified as polio-free?</span></span></p>",
    "unique_key": "Q5089316",
    "question_audio": null,
    "question_video": null,
    "map_id": 34205,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. 27 March 2014</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>India</strong> was declared &lsquo;<strong>POLIO-FREE&rsquo;</strong> on <strong>27 March 2014</strong> by <strong>WHO</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Poliomyelitis 2023</strong>&nbsp;[No case has been reported in India from 13 January 2011 onwards] -&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">No. of Polio cases: ZERO</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">No. of Vaccine derived Polio virus (VDPV) cases: Zero</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">No. of AFP cases: 9150</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Non-polio AFP rate: 5.79</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Some Important Pointers related to Poliomyelitis &ndash;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><em>Causative agent</em></strong><em>: </em><strong>Poliovirus</strong> (serotypes 1, 2 and 3)</span></span>\r\n\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>P1</strong> is <strong>MCC</strong> of <strong>epidemics</strong></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>P2</strong> is <strong>most antigenic</strong> and most <strong>easily eradicable</strong></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>P3</strong> is <strong>MCC</strong> of <strong>VAPP</strong> (Vaccine associated paralytic poliomyelitis) &ndash; <strong>1 per 2.7 million chance</strong></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><em>Reservoir: </em>Man</strong> (<strong>No chronic carriers</strong>)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">MC clinical occurrence: <strong>Subclinical cases&nbsp;</strong></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">For every <strong>1 clinical case</strong> of <strong>polio</strong>: there are <strong>1000 subclinical cases</strong> in <strong>children</strong> and <strong>75 subclinical </strong>cases in <strong>adults</strong></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><em>Infectious material</em></strong><em>: </em><strong>Faeces and oro-pharyngeal secretions</strong> </span></span></li>\r\n</ul>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">(Polio diagnosis<strong>: Isolation</strong> of <strong>wild poliovirus</strong> from <strong>stool</strong> is the recommended method). <strong>Virus</strong> usually can be <strong>found</strong> in the <strong>feces</strong> from <strong>onset to up to &lt; 8 weeks</strong> after <strong>paralysis</strong>, with the <strong>highest probability</strong>&nbsp;of detection during the <strong>first 2 weeks</strong> from <strong>onset of Paralysis</strong>.</span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><em>Period of <strong>communicability: </strong></em><strong>7-10 days before and after</strong> onset of symptoms</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><em>Risk factors for <strong>precipitation </strong>of an attack:</em></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Fatigue</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Trauma</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Intramuscular injections</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Operative procedures (<strong>Tonsillectomy</strong>) esp. in <strong>epidemics of polio</strong></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Administration of <strong>Alum </strong>containing <strong>DPT vaccine</strong></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><em>Incubation period</em></strong><em>: </em><strong>3 &ndash; 35 days</strong> (usually<strong> 7 &ndash; 14 days</strong>)</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>India</strong> was declared <strong>&lsquo;POLIO-FREE&rsquo;</strong> on <strong>27 March 2014 </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 236)</strong></span></span></p>",
    "correct_choice_id": 6717,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 1692,
    "choices": [
      {
        "id": 6763,
        "text": "<p><span style=\"font-size:12pt;\">1 AFP case for every 100000 children under 15 years of age.</span></p>"
      },
      {
        "id": 6764,
        "text": "<p><span style=\"font-size:12pt;\">1 AFP case for every 1000 children under 15 years of age.</span></p>"
      },
      {
        "id": 6765,
        "text": "<p><span style=\"font-size:12pt;\">1 AFP case for every 200000 children under 15 years of age.</span></p>"
      },
      {
        "id": 6766,
        "text": "<p><span style=\"font-size:12pt;\">1 AFP case for every 10000 children under 15 years of age.</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt;\">A medical consultant working with a non-governmental organization (NGO) is involved in a project focused on assessing the surveillance capacity for poliomyelitis (polio) in various regions. A critical aspect of this project is the analysis of the reporting rate of acute flaccid paralysis (AFP) cases, which serves as a key surveillance indicator for polio. Accurate detection and reporting of AFP cases are essential for monitoring potential polio outbreaks and guiding eradication efforts. The consultant is tasked with reviewing and understanding the established guidelines for AFP case detection to ensure the efficacy of the surveillance program. What are the established guidelines for detecting AFP cases as part of polio surveillance?</span></p>",
    "unique_key": "Q9853079",
    "question_audio": null,
    "question_video": null,
    "map_id": 34207,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A. 1 AFP case for every 100000 children under 15 years of age.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">The number of <strong>AFP cases</strong> reported <strong>each year</strong> is used as an <strong>indicator</strong> of a <strong>country's ability</strong> to <strong>detect polio</strong> - even in countries where the <strong>disease no longer occurs</strong>. A <strong>country's surveillance system</strong> needs to be <strong>sensitive</strong> enough to <strong>detect at least</strong> <strong>one </strong>case of <strong>AFP</strong> for every <strong>100,000 children</strong> under <strong>15,</strong> even in the absence of <strong>polio.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Surveillance Indicators -&nbsp;</strong></span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-113435.png\" alt=\"\" width=\"1000\" height=\"1252\"></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Acute Flaccid Paralysis (AFP) Surveillance</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Nationwide AFP</strong> (acute flaccid paralysis) surveillance is the <strong>gold standard</strong> for detecting cases of <strong>poliomyelitis</strong>. The <strong>four steps</strong> of surveillance are:</span></p><p>&nbsp;</p><ol><li><span style=\"font-size:12pt;\"><strong>Finding and reporting children</strong> with <strong>acute flaccid paralysis (AFP)</strong></span></li><li><span style=\"font-size:12pt;\">Transporting <strong>stool samples</strong> for <strong>analysis</strong></span></li><li><span style=\"font-size:12pt;\"><strong>Isolating and identifying</strong> <strong>poliovirus</strong> in the <strong>laboratory</strong></span></li><li><span style=\"font-size:12pt;\"><strong>Mapping </strong>the virus to determine the origin of the <strong>virus strain.</strong></span></li></ol><p>&nbsp;</p><p><span style=\"font-size:12pt;\">(All reported cases of <strong>AFP </strong>should be investigated by <strong>DIO </strong>\u2018within <strong>48 hours\u2019</strong> after <strong>notification</strong>)</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Available <strong>diagnostic</strong> <strong>tests</strong> for <strong>Poliomyelitis </strong>\u2013</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Stool examination (recommended in every case of AFP)</span></li><li><span style=\"font-size:12pt;\">CSF examination</span></li><li><span style=\"font-size:12pt;\">Throat examination</span></li><li><span style=\"font-size:12pt;\">Blood examination</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Acute Flaccid Paralysis</strong> (AFP): <strong>Acute onset</strong> (<strong>&lt; 4 weeks</strong>) in a child aged <strong>&lt;15 years</strong>, or any case of <strong>paralytic illness</strong> in a person of any age when <strong>polio is suspected.</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>Acute</strong>: <strong>rapid progression</strong> of from <strong>onset to maximum paralysis.</strong></span></li><li><span style=\"font-size:12pt;\"><strong>Flaccid</strong>: <strong>loss of muscle tone</strong>, \u2018<strong>floppy\u2019</strong> as opposed to <strong>spastic or rigid.</strong></span></li><li><span style=\"font-size:12pt;\"><strong>Paralysis</strong>: <strong>weakness</strong>, <strong>loss of voluntary movement.</strong></span></li><li><span style=\"font-size:12pt;\"><strong>Differential diagnosis</strong> of AFP:<strong> Descending</strong> <strong>asymmetric flaccid LMN paralysis</strong></span><ul><li><span style=\"font-size:12pt;\"><strong>Guillain Barre Syndrome</strong> (Cytologico-albuminic dissociation).</span></li><li><span style=\"font-size:12pt;\"><strong>Transverse myelitis</strong> (Normal CSF, sensory loss +, bladder dysfunction +).</span></li><li><span style=\"font-size:12pt;\"><strong>Traumatic neuritis</strong> (any age, only one leg involved).</span></li><li><span style=\"font-size:12pt;\">Other<strong> Non-polio enteric viruses</strong>: <strong>Coxsackie-B</strong>, <strong>ECHO, Enterovirus type 70 and 71, Mumps.</strong></span></li></ul></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">A <strong>country's surveillance</strong> system needs to be <strong>sensitive</strong> enough to <strong>detect</strong> at <strong>least</strong> <strong>one case of AFP</strong> for every <strong>100,000 children</strong> under <strong>15</strong>, even in the <strong>absence</strong> of <strong>polio</strong>.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Park 26<sup>th</sup> edition (page 237)</strong></span></p>",
    "correct_choice_id": 6763,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "InvestigationBased"
    ]
  },
  {
    "id": 2017,
    "choices": [
      {
        "id": 8061,
        "text": "<p><span style=\"color:black;font-size:12pt;\">Chloride \u2013 65 mmol/ litre</span></p>"
      },
      {
        "id": 8062,
        "text": "<p><span style=\"font-size:12pt;\">Citrate \u2013 10 mmol/ litre</span></p>"
      },
      {
        "id": 8063,
        "text": "<p><span style=\"font-size:12pt;\">Potassium \u2013 10 mmol/ litre</span></p>"
      },
      {
        "id": 8064,
        "text": "<p><span style=\"font-size:12pt;\">Sodium \u2013 75 mmol/ litre</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">A medical intern is conducting a session for healthcare workers on the management of dehydration in diarrheal diseases, emphasizing the use of Oral Rehydration Solutions (ORS). The session includes a discussion on the composition of reduced osmolarity ORS, which is designed to be more effective and have fewer side effects than standard ORS formulations. The intern is aware of some common misconceptions about the composition of reduced osmolarity ORS and aims to address these during the session. Which of the following statements about the composition of reduced osmolarity ORS is NOT correct?</span></p>",
    "unique_key": "Q1827420",
    "question_audio": null,
    "question_video": null,
    "map_id": 34204,
    "difficulty_level": "intermediate",
    "subjects_id": [
      7
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. C. Potassium \u2013 10 mmol/litre</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The correct answer is <strong>Potassium \u2013 20 mmol/ litre&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u>&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. Chloride \u2013 65 mmol/ litre. Correct&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Citrate \u2013 10 mmol/ litre. Correct&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Sodium \u2013 75 mmol/ litre. Correct&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Reduced osmolarity ORS:&nbsp;Total osmolarity - 245 mmol/ litre</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Comparison of different types of ORS solutions<strong> -</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:14px;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/12/picture32_SCVUL8k.jpg\" alt=\"\" width=\"1000\" height=\"752\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>WHO</strong> <strong>Reduced Osmolarity ORS</strong> contains (in mmol/L) - <strong>Sodium 75,</strong> <strong>Potassium 20</strong>, <strong>Chloride 65</strong>, <strong>Citrate 10</strong>,<strong>Glucose 75;</strong> <strong>Total Osmolar</strong> <strong>concentration </strong>is <strong>245 mmol/L.</strong></span></li><li><span style=\"font-size:12pt;\"><strong>Ratio of Sodium</strong>: <strong>Glucose</strong> in <strong>WHO</strong> Reduced Osmolarity ORS - <strong>1 : 1</strong></span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Park 26<sup>th</sup> edition (page 261)</strong></span></p>",
    "correct_choice_id": 8063,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  }
];
        let quizName = 'Communicable Diseases';
        let hierarchy = ["Cerebellum", "qBank", "PSM"];
        
        // Handle Custom Quiz Loading
        if (window.location.pathname.endsWith('custom_quiz.html')) {
            const customData = JSON.parse(localStorage.getItem('customQuizData'));
            if (customData) {
                questionsData = customData.questions;
                quizName = customData.name;
                hierarchy = customData.hierarchy;
                document.title = quizName + ' - Brain And Scalpel';
                document.getElementById('totalQuestions').textContent = questionsData.length;
                document.getElementById('quizHierarchy').textContent = hierarchy.join(' > ');
            }
        }

        let currentQuestionIndex = 0;
        let selectedOption = null;
        let currentMode = 'study';
        let timer = null;
        let timeRemaining = 0;
        let questionStartTime = Date.now();
        let quizStartTime = Date.now();
        let isQuizCompleted = false;
        
        let questionStates = new Array(questionsData.length).fill(null).map(() => ({
            status: 'not_attempted',
            bookmarked: false,
            markedForReview: false,
            selectedAnswer: null,
            timeSpent: 0
        }));
        
        let stats = {
            correctAnswers: 0,
            incorrectAnswers: 0,
            totalAttempted: 0,
            totalTime: 0,
            notAttempted: questionsData.length
        };

        const urlParams = new URLSearchParams(window.location.search);
        currentQuestionIndex = Math.min(parseInt(urlParams.get('startAt')) || 0, questionsData.length - 1);

        function goBack() {
            if (isQuizCompleted || confirm('Are you sure you want to leave the quiz? Your progress will be lost.')) {
                window.history.back();
            }
        }

        function selectMode(mode) {
            currentMode = mode;
            document.getElementById('modeModal').style.display = 'none';
            initializeQuiz();
        }

        function initializeQuiz() {
            quizStartTime = Date.now();
            
            const bookmarkBtn = document.getElementById('bookmarkBtn');
            const markReviewBtn = document.getElementById('markReviewBtn');
            const testModeReviewLegend = document.getElementById('testModeReviewLegend');
            const isTestMode = currentMode === 'test' || currentMode === 'timed_exam';
            
            document.getElementById('statsBar').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('studyModeLegend').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('testModeLegend').style.display = isTestMode ? 'block' : 'none';
            document.getElementById('submitSection').style.display = isTestMode ? 'block' : 'none';
            bookmarkBtn.style.display = isTestMode ? 'none' : 'flex';
            markReviewBtn.style.display = isTestMode ? 'flex' : 'none';
            testModeReviewLegend.style.display = isTestMode ? 'flex' : 'none';
            
            if (currentMode === 'timed_study' || currentMode === 'timed_exam') {
                document.getElementById('timerContainer').classList.remove('hidden');
            }
            
            loadBookmarkedQuestions();
            generateQuestionNav();
            updateStats();
            displayQuestion();
        }

        function generateQuestionNav() {
            const nav = document.getElementById('questionNav');
            nav.innerHTML = '';
            
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.createElement('button');
                btn.textContent = i + 1;
                btn.className = 'w-8 h-8 text-sm font-medium rounded transition-all duration-200';
                btn.onclick = () => jumpToQuestion(i);
                btn.id = `navBtn_${i}`;
                nav.appendChild(btn);
            }
            
            updateQuestionNav();
        }

        function updateQuestionNav() {
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.getElementById(`navBtn_${i}`);
                const state = questionStates[i];
                let className = '';
                
                if (i === currentQuestionIndex) {
                    className = 'nav-btn-current';
                } else if (state.bookmarked) {
                    className = 'nav-btn-bookmarked';
                } else if (state.markedForReview) {
                    className = 'nav-btn-marked-review';
                } else if (currentMode === 'study' || currentMode === 'timed_study') {
                    if (state.status === 'correct') className = 'nav-btn-correct';
                    else if (state.status === 'incorrect') className = 'nav-btn-incorrect';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                } else {
                    if (state.selectedAnswer !== null) className = 'nav-btn-answered';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                }
                btn.className = `w-8 h-8 text-sm font-medium rounded ${className}`;
            }
        }

        function jumpToQuestion(index) {
            if (index >= 0 && index < questionsData.length) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex = index;
                displayQuestion();
            }
        }

        function updateStats() {
            if (currentMode === 'study' || currentMode === 'timed_study') {
                document.getElementById('correctCount').textContent = stats.correctAnswers;
                document.getElementById('incorrectCount').textContent = stats.incorrectAnswers;
                document.getElementById('totalAttempted').textContent = stats.totalAttempted;
                
                const accuracy = stats.totalAttempted > 0 
                    ? Math.round((stats.correctAnswers / stats.totalAttempted) * 100)
                    : 0;
                document.getElementById('accuracy').textContent = accuracy + '%';
                
                stats.totalTime = questionStates.reduce((acc, state) => acc + state.timeSpent, 0);
                const timeSpent = Math.floor(stats.totalTime / 1000);
                const minutes = Math.floor(timeSpent / 60);
                const seconds = timeSpent % 60;
                document.getElementById('timeSpent').textContent = 
                    minutes + ':' + seconds.toString().padStart(2, '0');
            }
        }

        function setupVideo(videoElement, url) {
            if (Hls.isSupported()) {
                const hls = new Hls();
                hls.loadSource(url);
                hls.attachMedia(videoElement);
            } else if (videoElement.canPlayType('application/vnd.apple.mpegurl')) {
                videoElement.src = url;
            }
        }

        function displayQuestion() {
            if (!questionsData || questionsData.length === 0) {
                document.getElementById('questionText').innerHTML = 'No questions available for this quiz.';
                return;
            };
            
            const question = questionsData[currentQuestionIndex];
            questionStartTime = Date.now();
            
            selectedOption = questionStates[currentQuestionIndex].selectedAnswer;
            
            const progress = ((currentQuestionIndex + 1) / questionsData.length) * 100;
            document.getElementById('progressBar').style.width = progress + '%';
            document.getElementById('currentQuestion').textContent = currentQuestionIndex + 1;
            updateQuestionNav();
            
            document.getElementById('prevBtn').disabled = currentQuestionIndex === 0;
            
            document.getElementById('solutionContainer').classList.add('hidden');
            
            document.getElementById('questionText').innerHTML = question.text || 'No question text available';
            
            let mediaHtml = '';
            if (question.question_audio) mediaHtml += `<div class="glass-light p-4 mb-4"><audio src="${question.question_audio}" controls class="w-full"></audio></div>`;
            if (question.question_video) mediaHtml += `<div class="glass-light p-4 mb-4"><video src="${question.question_video}" controls class="w-full rounded-lg"></video></div>`;
            if (question.question_images) {
                question.question_images.forEach(imgSrc => {
                    if (imgSrc) mediaHtml += `<div class="glass-light p-4 mb-4"><img src="${imgSrc}" alt="Question Image" class="w-full rounded-lg"></div>`;
                });
            }
            document.getElementById('questionMedia').innerHTML = mediaHtml;
            
            const optionsContainer = document.getElementById('optionsContainer');
            optionsContainer.innerHTML = '';
            optionsContainer.classList.remove('answered');
            
            if (question.choices && Array.isArray(question.choices)) {
                question.choices.forEach((choice, index) => {
                    const optionLetter = String.fromCharCode(65 + index);
                    const isSelected = selectedOption === index;
                    
                    const optionDiv = document.createElement('div');
                    optionDiv.innerHTML = `
                        <button type="button" class="option-button ${isSelected ? 'selected' : ''}" data-option-index="${index}">
                            <div class="option-letter">${optionLetter}</div>
                            <div class="option-text">${choice.text || 'Option ' + (index + 1)}</div>
                        </button>
                    `;
                    optionsContainer.appendChild(optionDiv);
                });
                
                optionsContainer.addEventListener('click', function(e) {
                    const optionButton = e.target.closest('.option-button');
                    if (optionButton) {
                        const optionIndex = parseInt(optionButton.getAttribute('data-option-index'));
                        selectOption(optionIndex);
                    }
                });
            }
            
            updateBookmarkButton();
            updateMarkReviewButton();

            if ((currentMode === 'timed_study' || currentMode === 'timed_exam') && !isQuizCompleted) {
                startTimer();
            }
        }

        function selectOption(index) {
            const optionsContainer = document.getElementById('optionsContainer');
            if (optionsContainer.classList.contains('answered')) return;

            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                questionStartTime = Date.now();
            }
            
            selectedOption = index;
            questionStates[currentQuestionIndex].selectedAnswer = index;
            
            document.querySelectorAll('.option-button').forEach((btn, i) => {
                btn.classList.toggle('selected', i === index);
            });
            
            if (currentMode === 'study' || currentMode === 'timed_study') {
                setTimeout(processAnswer, 300);
            } else {
                if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                    questionStates[currentQuestionIndex].status = 'answered';
                    stats.totalAttempted++;
                    stats.notAttempted--;
                }
                updateQuestionNav();
            }
        }

        function processAnswer() {
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            
            if(selectedOption === null) return;

            const selectedChoice = question.choices[selectedOption];
            const isCorrect = selectedChoice.id === correctChoiceId;
            
            if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                stats.totalAttempted++;
                stats.notAttempted--;
                if(isCorrect) stats.correctAnswers++; else stats.incorrectAnswers++;
            }
            questionStates[currentQuestionIndex].status = isCorrect ? 'correct' : 'incorrect';
            
            updateStats();
            showInlineFeedback(isCorrect);
            updateQuestionNav();
        }

        function showInlineFeedback(isCorrect) {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;

            const optionsContainer = document.getElementById('optionsContainer');
            const optionButtons = optionsContainer.querySelectorAll('.option-button');
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            let correctOptionIndex = question.choices.findIndex(c => c.id === correctChoiceId);

            optionsContainer.classList.add('answered');

            optionButtons.forEach((btn, index) => {
                btn.classList.remove('selected');
                if (index === correctOptionIndex) btn.classList.add('correct');
                else if (index === selectedOption && !isCorrect) btn.classList.add('incorrect');
            });

            setTimeout(showSolution, 1500);
        }


        function showSolution() {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;
            
            const question = questionsData[currentQuestionIndex];
            document.getElementById('solutionText').innerHTML = question.solution || 'No solution provided';
            
            const videoContainer = document.getElementById('solutionVideo');
            const videoPlayer = document.getElementById('explanationVideoPlayer');
            const explanationVideo = question.explanation_video;
            
            if (explanationVideo) {
                videoContainer.classList.remove('hidden');
                if (explanationVideo.includes('.m3u8')) setupVideo(videoPlayer, explanationVideo);
                else videoPlayer.src = explanationVideo;
            } else {
                videoContainer.classList.add('hidden');
            }
            
            document.getElementById('solutionContainer').classList.remove('hidden');
        }

        function submitQuiz() {
            if (timer) clearInterval(timer);
            if (!confirm('Are you sure you want to submit the quiz?')) return;
            
            isQuizCompleted = true;
            let correct = 0, incorrect = 0;
            const totalTime = Date.now() - quizStartTime;
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                if (state.selectedAnswer !== null) {
                    if (question.choices[state.selectedAnswer].id === question.correct_choice_id) {
                        correct++;
                        state.status = 'correct';
                    } else {
                        incorrect++;
                        state.status = 'incorrect';
                    }
                }
            });
            
            // Save performance data
            const performanceData = JSON.parse(localStorage.getItem('quizPerformanceData')) || [];
            performanceData.push({
                quizName: quizName,
                hierarchy: hierarchy,
                timestamp: Date.now(),
                totalTime: totalTime,
                stats: {
                    correct: correct,
                    incorrect: incorrect,
                    notAttempted: questionsData.length - (correct + incorrect)
                }
            });
            localStorage.setItem('quizPerformanceData', JSON.stringify(performanceData));

            showPerformanceAnalysis(correct, incorrect, questionsData.length - (correct + incorrect), totalTime);
        }

        function showPerformanceAnalysis(correct, incorrect, notAttempted, totalTime) {
            const modal = document.getElementById('performanceModal');
            const accuracy = (correct + incorrect) > 0 ? Math.round((correct / (correct + incorrect)) * 100) : 0;
            
            const circumference = 2 * Math.PI * 65;
            const scoreCircle = document.getElementById('scoreCircle');
            scoreCircle.style.strokeDasharray = `${circumference} ${circumference}`;
            scoreCircle.style.strokeDashoffset = circumference - (accuracy / 100) * circumference;
            
            document.getElementById('accuracyScore').textContent = `${accuracy}%`;
            document.getElementById('totalQuestionsResult').textContent = questionsData.length;
            document.getElementById('correctResult').textContent = correct;
            document.getElementById('incorrectResult').textContent = incorrect;
            document.getElementById('notAttemptedResult').textContent = notAttempted;
            
            const totalMinutes = Math.floor(totalTime / 60000);
            const totalSeconds = Math.floor((totalTime % 60000) / 1000);
            document.getElementById('totalTimeResult').textContent = `${totalMinutes}:${totalSeconds.toString().padStart(2, '0')}`;
            
            const avgTime = totalTime / questionsData.length;
            const avgMinutes = Math.floor(avgTime / 60000);
            const avgSeconds = Math.floor((avgTime % 60000) / 1000);
            document.getElementById('avgTimeResult').textContent = `${avgMinutes}:${avgSeconds.toString().padStart(2, '0')}`;
            
            modal.classList.remove('hidden');
        }

        function closePerformanceModal() { document.getElementById('performanceModal').classList.add('hidden'); }

        function reviewQuestions() {
            document.getElementById('questionReviewSection').classList.remove('hidden');
            const container = document.getElementById('reviewQuestionsContainer');
            container.innerHTML = '';
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                const correctChoiceId = question.correct_choice_id;
                
                let statusClass = 'not-attempted', statusText = 'Not Attempted';
                if (state.selectedAnswer !== null) {
                    const selectedChoice = question.choices[state.selectedAnswer];
                    if (selectedChoice.id === correctChoiceId) { statusClass = 'correct'; statusText = 'Correct'; }
                     else { statusClass = 'incorrect'; statusText = 'Incorrect'; }
                }
                
                const reviewDiv = document.createElement('div');
                reviewDiv.className = `review-question ${statusClass}`;
                
                let optionsHtml = (question.choices || []).map((choice, choiceIndex) => {
                    const isSelected = state.selectedAnswer === choiceIndex;
                    const isCorrect = choice.id === correctChoiceId;
                    let borderClass = 'border-gray-600';
                    if(isCorrect) borderClass = 'border-green-500';
                    else if(isSelected) borderClass = 'border-red-500';
                    
                    return `<div class="p-3 rounded-lg border ${borderClass}"><span class="font-bold mr-3">${String.fromCharCode(65 + choiceIndex)}</span><span>${choice.text}</span></div>`;
                }).join('');

                const videoHtml = question.explanation_video ? `<div class="mt-4"><video id="review-video-${index}" data-src="${question.explanation_video}" class="w-full rounded-lg" controls></video></div>` : '';

                reviewDiv.innerHTML = `
                    <div class="mb-4">
                        <div class="flex justify-between items-center mb-3">
                            <h4 class="text-lg font-bold text-white">Question ${index + 1}</h4>
                            <span class="text-sm px-3 py-1 rounded-full bg-${statusClass === 'correct' ? 'green' : statusClass === 'incorrect' ? 'red' : 'gray'}-600 text-white">${statusText}</span>
                        </div>
                        <div class="text-white mb-4">${question.text}</div>
                    </div>
                    <div class="space-y-2 mb-4">${optionsHtml}</div>
                    <div class="bg-green-900 bg-opacity-20 p-4 rounded-lg border border-green-700">
                        <h5 class="text-green-400 font-bold mb-2">Explanation:</h5>
                        <div class="text-white text-opacity-90">${question.solution || 'No solution available.'}</div>
                        ${videoHtml}
                    </div>`;
                container.appendChild(reviewDiv);
            });
            initializeReviewVideos();
        }

        function initializeReviewVideos() {
            document.querySelectorAll('video[data-src]').forEach(videoEl => {
                const src = videoEl.dataset.src;
                if (src && src.includes('.m3u8')) {
                    setupVideo(videoEl, src);
                } else if (src) {
                    videoEl.src = src;
                }
            });
        }

        function retakeQuiz() {
            if (confirm('Are you sure you want to retake the quiz? This will reset all your answers.')) {
                if (window.location.pathname.endsWith('custom_quiz.html')) {
                    localStorage.removeItem('customQuizData');
                }
                location.reload();
            }
        }

        function loadBookmarkedQuestions() {
            const bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            bookmarks.forEach(bookmark => {
                if (bookmark.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-'))) {
                    if (bookmark.questionIndex < questionsData.length) {
                        questionStates[bookmark.questionIndex].bookmarked = true;
                    }
                }
            });
        }

        function toggleBookmark() {
            const isBookmarked = !questionStates[currentQuestionIndex].bookmarked;
            questionStates[currentQuestionIndex].bookmarked = isBookmarked;
            
            let bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            
            if (isBookmarked) {
                const bookmarkData = {
                    quizName: quizName,
                    quizFile: window.location.pathname.split('/').pop(),
                    questionIndex: currentQuestionIndex,
                    question: questionsData[currentQuestionIndex],
                    hierarchy: hierarchy,
                    timestamp: Date.now()
                };
                bookmarks.push(bookmarkData);
            } else {
                bookmarks = bookmarks.filter(b => 
                    !(b.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-')) && b.questionIndex === currentQuestionIndex)
                );
            }
            
            localStorage.setItem('bookmarkedQuestions', JSON.stringify(bookmarks));
            updateBookmarkButton();
            updateQuestionNav();
        }

        function updateBookmarkButton() {
            const btn = document.getElementById('bookmarkBtn');
            const text = document.getElementById('bookmarkText');
            const isBookmarked = questionStates[currentQuestionIndex].bookmarked;
            
            btn.className = isBookmarked ? 'gradient-yellow px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isBookmarked ? 'Bookmarked' : 'Bookmark';
        }
        
        function toggleMarkForReview() {
            questionStates[currentQuestionIndex].markedForReview = !questionStates[currentQuestionIndex].markedForReview;
            updateMarkReviewButton();
            updateQuestionNav();
        }

        function updateMarkReviewButton() {
            const btn = document.getElementById('markReviewBtn');
            const text = document.getElementById('markReviewText');
            const isMarked = questionStates[currentQuestionIndex].markedForReview;
            
            btn.className = isMarked ? 'gradient-purple px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isMarked ? 'Marked' : 'Mark for Review';
        }

        function previousQuestion() {
            if (currentQuestionIndex > 0) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex--;
                displayQuestion();
            }
        }

        function nextQuestion() {
            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
            }
            
            if (currentQuestionIndex < questionsData.length - 1) {
                currentQuestionIndex++;
                displayQuestion();
            } else {
                if (currentMode === 'test' || currentMode === 'timed_exam') {
                    if (confirm('You have reached the end of the quiz. Would you like to submit your answers now?')) {
                        submitQuiz();
                    }
                } else {
                    if (confirm('You have completed all questions. Would you like to review from the beginning?')) {
                        currentQuestionIndex = 0;
                        displayQuestion();
                    }
                }
            }
        }

        function startTimer() {
            if (timer) clearInterval(timer);
            timeRemaining = 120; // 2 minutes per question
            updateTimerDisplay();
            
            timer = setInterval(() => {
                timeRemaining--;
                updateTimerDisplay();
                
                if (timeRemaining <= 0) {
                    clearInterval(timer);
                    if (currentMode === 'timed_exam') {
                        submitQuiz();
                    } else {
                        nextQuestion();
                    }
                }
            }, 1000);
        }

        function updateTimerDisplay() {
            const minutes = Math.floor(timeRemaining / 60);
            const seconds = timeRemaining % 60;
            document.getElementById('timeDisplay').textContent = 
                minutes + ':' + seconds.toString().padStart(2, '0');
        }

        document.addEventListener('DOMContentLoaded', () => {
             if (!window.location.pathname.endsWith('custom_quiz.html')) {
                document.getElementById('modeModal').style.display = 'flex';
             } else {
                initializeQuiz();
             }
        });
        
        document.addEventListener('keydown', function(e) {
            if (document.getElementById('modeModal').style.display !== 'none') return;
            if (document.getElementById('performanceModal').classList.contains('hidden') === false) return;
            
            if (e.key >= '1' && e.key <= '4') {
                const optionIndex = parseInt(e.key) - 1;
                const options = document.querySelectorAll('.option-button');
                if (optionIndex < options.length) selectOption(optionIndex);
            } else if (e.key === 'ArrowLeft') {
                previousQuestion();
            } else if (e.key === 'ArrowRight' || e.key === ' ') {
                e.preventDefault();
                nextQuestion();
            } else if (e.key.toLowerCase() === 'b' && (currentMode === 'study' || currentMode === 'timed_study')) {
                toggleBookmark();
            } else if (e.key.toLowerCase() === 'm' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                toggleMarkForReview();
            } else if (e.key.toLowerCase() === 's' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                submitQuiz();
            }
        });
    </script>
</body>
</html>